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DUAL PHASE ENGINEERED TISSUE FOR ENHANCED BONE FORMATION 
 
Chair: Dr. Jan Phillip Stegemann 
 
Large bone defects are a significant clinical problem in the United States and worldwide. “Non-
unions” are fractures that fail to heal due to a lack of blood supply to the defect site. In our 
approach to bone regeneration, we create modular engineered tissues (“microbeads”) designed to 
form bone, and combine them with a surrounding vascularizing tissue to generate a dual-phase 
injectable matrix for enhanced bone formation. In the first Aim, human bone marrow 
mesenchymal stem cells (bmMSC) or human adipose stem cells (AdSC) were embedded in 
collagen/fibrin (COL/FIB) or collagen/fibrin/hydroxyapatite (COL/FIB/HA) microbeads. Both 
cell types mineralized microbeads, indicating differentiation towards the osteogenic lineage. The 
second Aim used a co-culture model of bmMSC and human umbilical vein endothelial cells in 
COL/FIB composite hydrogels to create a vasculogenic matrix. Cell ratio and matrix 
composition were varied in a systematic manner. Vascular network formation increased in vitro 
with increasing fibrin content in composite materials, although the 40/60 COL/FIB and pure 
fibrin materials exhibited similar responses. Hydroxyapatite (HA) was found to recover 
endothelial network formation in unconstrained hydrogels. Over 7 days of dorsal subcutaneous 
implantation in nude mice, these matrices exhibited increasing neovascularization, though there 
was no significant effect of HA. The final Aim combined osteogenic microbeads with a 
surrounding vasculogenic matrix to evaluate the effect of this dual-phase tissue in vivo. Both 
vasculogenesis and osteogenesis were examined in a subcutaneous bone formation model in the 
mouse at 4 and 8 weeks. Blood flow measured by Doppler imaging was not significantly 
different between any conditions at any time point, except at 8 weeks where the vasculogenic 
matrix alone was lower than all other groups. Micro-computed tomography of ectopic bone 
demonstrated significantly higher bone volume in the osteogenic microbead condition at 4 weeks 
and both the blank and osteogenic microbead conditions at 8 weeks, compared to the dual 
osteogenic/vasculogenic condition. These data suggest an inhibitory effect of the vasculogenic 
component on bone formation in the non-ischemic model. Dual-phase implants may be more 
effective in ischemic orthotopic bone regeneration models, and these results demonstrate that 








1.1 – Background of the Thesis 
 Large bone defects are a significant clinical problem in the United States and worldwide. 
According to 2006 data from the U.S. Health and Cost and Utilization Project (HCUP), there are 
approximately one million hospital admissions related to appendicular skeletal-tissue injuries 
each year in the United States [1]. Bone injuries and fractures require over 500,000 grafting 
procedures and account for over $26 billion of healthcare costs in the U.S. annually, and skull 
and facial fractures contribute an additional $1.3 billion to the annual health care cost. 
Importantly, approximately 10% of the total fractures in the U.S. are complicated by impaired 
healing, non-unions or delayed unions. “Non-unions” are defined as broken bones that fail to 
heal while “delayed unions” are fractures that take longer than usual to heal. A main cause of 
delayed and non-union is tissue instability and lack of nutrient supply around the defect site, 
since both stability and vascularization are required for the normal bone healing process. Some 
bones, such as the head of the femur and the wristbones, have limited vasculature to provide 
necessary proteins, vitamins, and calcium required for healing [2], and these bones therefore tend 
to be more susceptible to non-unions.  
 Although the natural healing response can lead to physiological bone remodeling, non-
unions and large-scale traumatic bone injuries require surgical intervention. Autografts, 
allografts, and xenografts are currently used as treatment options, but these are associated with 
complications including donor site morbidity, disease transmission, and immunological rejection. 
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The current gold standard for large bone defect repair therefore uses a tissue autograft from the 
patient [3]. These grafts contain the proper cell types, matrix, and vasculature necessary for 
proper bone regrowth in the injured area. However, autografts require a secondary operative 
procedure that can lead to complications such as pain and donor-site morbidity. Allografts using 
tissue from human donors are also commonly used but are associated with an increased risk of 
disease transmission and failure rate over long-term use, relative to autografts [4]. Xenografts 
involve the transplantation of bone tissue from species other than humans; however, they also 
present the risk of disease transmission after implantation. Futher, xenografts must undergo 
sterilization processes that cause the loss of osteoinductive factors within the grafting material. 
One major drawback of both allografts and xenografts is the potential for immune rejection after 
implantation. 
Medullary rods and internal fixation using metallic devices is sometimes an option to 
enhance bone healing. However, these approaches require permanent implants that are not 
remodeled by the patient and are susceptible to fatigue fracture over long-term use [5]. Bonding 
of such metallic devices to adjacent bone is challenging. Attempts to modify the surfaces of 
implants with bioceramics and mineralized coatings have shown some success, but these surface 
conditioning techniques can lead to decreased durability of the device [5]. Local stress shielding 
caused by metallic implants can also lead to a reduction in bone density and can require revision 
surgeries [6]. Vascularization of regions supported by metallic implants is also limited [5].        
 The problems associated with transplanted grafts and stabilization strategies have resulted 
in an increasing interest in improved bone graft substitutes and bone tissue engineering solutions. 
Current osteobiologic approaches provide a scaffold material that is designed to allow growth 
and proliferation of host cells. Many approaches also include osteogenic growth factors, and in 
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particular the bone morphogenetic proteins (BMPs), to enhance bone formation in large defects 
[7]. The commercially available Medtronic INFUSE® Bone Graft combines recombinant human 
BMP-2 with an absorbable collagen sponge, and has been used widely in the clinic [8]. The 
product is currently approved for selected spinal fusion, intramedullary fixation, and sinus 
augmentation procedures, and it has had a dramatic effect on treatment of particularly difficult 
bone healing indications. However, concerns have been raised about the degree of control of 
BMP-2 release from the product and potentially serious reactions when the product is used off-
label such as ectopic bone formation, nerve damage, edema and inflammation [9-11]. Most 
recently, the possibility that BMP is cancer promoting has further clouded the view of how these 
products are best used [12-14]. The limitations and potential complications associated with these 
early osteobiologic treatments has driven development of even more biologically-based 
approaches, which included living cells to provide more refined control over bone formation. 
Bone tissue engineering aims to mimic and recreate native tissue through the combination 
of cells, scaffolds, and inductive factors [15]. Numerous studies have employed osteoconductive 
matrices to transplant both osteoprogenitor cells and osteoinductive factors to enhance healing in 
bone defect sites. Modular tissue engineering embraces advances in material science and biology 
to create individual cellular microenvironments and assemble them in desired geometries to 
create functional tissues [16]. Although limited to non-load bearing applications, injectable 
scaffolds provide beneficial properties to large bone injuries such as the ability to serve as shape-
filling matrices, biodegradability, and in situ formation. Therefore, injectable modular tissue 
engineering can be employed for a minimally invasive bone regeneration therapy that allows for 
bone regeneration and restoration of proper function. 
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Combinatorial tissue engineering therapies using osteogenic and vasculogenic 
components have been previously investigated with mixed results. Patel et. al combined vascular 
endothelial growth factor (VEGF) and BMP-2 recombinant delivery at fixed concentrations (12 
µg/scaffold and 2 µg/scaffold, respectively) in a rat cranial defect model [17]. The combination 
of both growth factors did not achieve a significant increase in bone formation at 12 weeks 
compared to the BMP-2 alone condition. Furthermore, Young et. al varied doses of VEGF and 
BMP-2 at decreased concentrations compared to Patel et al., but achieved similar results [18]. 
Finally, Schonmeyr et. al showed co-delivery of VEGF and BMP-2 inhibited bone formation of 
rat bone marrow-derived mesenchymal stem cells (bmMSCs) as VEGF inhibited any osteogenic 
effects of BMP-2 in their system [19]. Taken together, these studies indicate that growth factor 
delivery may not be a suitable method of treating critical sized bone defects.  
 
1.2 - Cell-Seeded Hydrogel Microbeads  
 In contrast to traditional tissue engineering techniques in which cells are seeded onto a 
scaffold, modular tissue engineering aims to fabricate engineered tissues through the assembly of 
cell-seeded biomimetic structures [20]. Tissue subunits, or “modules,” are utilized to generate 
larger tissue structures that have been employed for orthopedic, vascular, and numerous other 
applications. Methods such as micro-fabrication of cell-laden hydrogels [21, 22], cell printing 
[23, 24], or the creation of cell sheets [25, 26] have been employed in modular tissue engineering 
applications. Current work in the formation of cell-seeded hydrogels includes creating collagen 
microspheres in small droplets and through water-in-oil emulsion techniques [27, 28]. Cheng et. 
al utilized two different types of microspheres fabricated in this method to assemble larger tissue 
structures with compartmentalized cell phenotypes [29]. 
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 Cell-seeded hydrogel microenvironments have been previously utilized as cell delivery 
vehicles for orthopedic applications. There is a need for better bone repair strategies for healing 
of complex fractures, non-unions, tumor resected sites, and periodontal defects, which together 
constitute over 4 million procedures per year worldwide [30]. Kim et. al developed biomimetic 
collagen-apatite microspheres through a water-in-oil emulsion technique that served as 
microcarriers for rat bone marrow derived stem cells [28]. Although these structures did not 
encapsulate cells directly, they demonstrated favorable adhesion properties for cells and 
upregulation of alkaline phosphatase activity, an osteogenic marker, as well as gene expression 
for osteogenic genes such as osteocalcin. Other work has utilized RGD-modified alginate 
microspheres to deliver a co-culture of human bone marrow stromal cells with endothelial cells 
into mouse femoral defect model [31]. The implantation of these hydrogel microspheres 
demonstrated bone regeneration and promoted mineralization of delivered cells.  
  
1.3  - Vasculature  
Capillaries 
 Microcirculation exists within each organ and tissue as vessel structures called capillaries 
[32]. Compared to arteries, arterioles, veins, and venules, capillaries have the smallest diameter; 
on the order of 5 – 10 µm. Capillaries form vascular networks that allow fluids to exchange 
gasses, metabolites, and waste products to and from tissues. Capillaries are composed of a single 
layer of endothelial cells and these cells form a narrow tube that allows for the passage of red 
blood cells one at a time. Blood flow through capillaries can be controlled by local and systemic 
signals such as nitric oxide.  
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 Three types of capillaries exist: continuous, fenestrated, and discontinuous. Continuous 
capillaries are found in the muscle, lung, and central nervous system and are held together by 
tight, or occluding, junctions. These capillaries only allow the passage of relatively small 
molecules between adjacent endothelial cells. Fenestrated capillaries have small pores across 
their walls that allow small molecular weight proteins to diffuse through their pores. These types 
of capillaries can be found in endocrine glands and in the kidney. Finally, discontinuous 
capillaries, which are found in the liver, spleen, and bone marrow, tend to have larger diameters 
than other capillary types and are more irregularly shaped. These vessels have a discontinuous 
basal lamina and utilize gaps between cells to allow for the movement of cells and proteins.   
 
Pericytes 
 Pericytes are relatively undifferentiated cells that surround continuous capillaries that 
function to provide vascular support and stability. Through physical and chemical signaling from 
endothelial cells, pericytes can contract to regulate blood flow through the capillary. Pericytes 
are characterized by their expression of smooth muscle actin and vimentin, a protein found in the 
cytoskeleton. Bone marrow derived mesenchymal stem cells can act as pericytes when co-
cultured with endothelial cells and can also differentiate towards pericytes if exogenous 
transforming growth factor-beta (TGF-β) is added to the culture media [33, 34]. 
 
Angio- and vasculogenesis 
 Neovascularization can be classified into two general categories: vasculogenesis and 
angiogenesis. Vasculogenesis is the creation of new vessels in situ with the assembly of 
endothelial cells. Angiogenesis, on the other hand, involves the sprouting of new capillaries from 
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existing vasculature. Both processes are critical during the wound healing response and have 
been implicated for bone tissue engineering applications. In either case, vessel development 
involves formation, stabilization, branching, remodeling, and pruning [35]. 
 During the formation of a nascent vascular network, VEGF plays a critical role in 
regulating initial vessel formation. Endothelial cells combine and form tubular-like structures 
under the influence of VEGF. These newly created vessels are formed in a hypoxic environment 
which induces further angiogenesis. Mural cells such as fibroblasts and mesenchymal stem cells 
are then recruited to the nascent vessels and stabilize their structures by depositing extracellular 
matrix (ECM). Numerous factors such as platelet-derived growth factor (PDGF) [36], Tie 
receptors [37], and TGF-β1 [38] are involved in stabilizing newly formed vessels and in 
differentiating mesenchymal stem cells towards the pericytic lineage. Vessels then continue to 
elongate, branch, anastomose with other vascular networks, and remodel into specialized 
segments. Various ECM components and signaling pathways are involved in the continued 
proliferation and differentiation of endothelial cells and mural cells. Proteases such as matrix 
metalloproteinases-2, 3, and 9 and proangiogeneic growth factors such as VEGF and fibroblast 
growth factor (FGF) have also been demonstrated to be involved with these functions in vessel 
maturation [35].   
 
1.4  - Overarching Hypothesis 
We hypothesized that the use of a dual-phase injectable matrix consisting of osteogenic 
and vasculogenic components will prove to be superior to either component alone in the ability 





1.5 – Specific Aims 
Aim 1: Formation of osteogenic microbeads 
Modular tissue engineering approaches will be applied to generate three-dimensional hydrogel 
cell microenvironments composed of collagen/fibrin or collagen/fibrin/hydroxyapatite and will 
be seeded with either human adipose-derived stem cells or human bone marrow-derived 
mesenchymal stem cells and differentiated towards the osteogenic lineage. The goal will be to 
Figure 1.1 – Dual-Phase Engineered Tissue for Enhanced Bone Formation.






















In vitroIn vitroIn vitro
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compare and contrast the osteogenic ability of bone-marrow derived mesenchymal stem cells and 
adipose derived stem cells in our composite protein-ceramic microbeads. 
 
Aim 2: Generation of a vasculogenic matrix 
Subaim 2.1: Co-culture system in composite collagen/fibrin hydrogels - Human mesenchymal 
stem cells and human umbilical vein endothelial cells will be co-cultured in collagen/fibrin 
composite gels to create a vasculogenic matrix upon implantation. The relationship between 
matrix stiffness and network formation will be investigated.  
Subaim 2.2: Addition of hydroxyapatite into the vasculogenic matrix – Hydroxyapatite will be 
systematically added into composite collagen/fibrin hydrogels to prevent cell-mediated 
compaction and provide proangiogenic cues in an attempt to maintain endothelial network 
formation in unconstrained culture. In vitro and in vivo studies will be conducted to investigate 
the effect of hydroxyapatite on vasculogenesis.  
 
Aim 3: Dual-Phase Engineered Tissue for Enhanced Bone Formation 
Osteogenic microbeads will be dispersed throughout the vasculogenic matrix and the resulting in 
vitro model will be utilized to show endothelial network formation by human umbilical vein 
endothelial cells around osteogenic microbeads. This dual-phase engineered tissue will then be 
implanted into a mouse subcutaneous model to investigate whether the combination of 
osteogenic and vasculogenic components demonstrate enhanced bone formation over either 





1.6 – Translational Potential 
 Recalcitrant bone defects are of significant clinical concern as large bone defects fail to 
heal. Numerous bone void fillers are currently available on the market to combat these 
deficiencies; however, they lack the ability to completely regenerate tissue that is similar to 
native bone in terms of function and structure. This project utilizes Food and Drug 
Administration (FDA)-approved biomaterials and cells types with translational potential (Figure 
1.2). A further discussion and the clinical indications are shown below. 
  
Biomaterials  
 The ideal scaffolding material for use in bone tissue engineering would be 
osteoconductive, osteoinductive, biocompatible, and biodegradable and would only serve as a 
template for bone regeneration [39]. Osteoconductivity refers to a material’s ability to support 













cell attachment and migration on and through the scaffold. This feature is important in not only 
creating a bone-bonding interface with host bone and implant but in also allowing host cells to 
infiltrate, interact with, and remodel the implant. Osteoinductivity describes a material’s ability 
to induce undifferentiated stem cells towards the osteogenic lineage. The chosen biomaterial 
should elicit an appropriate immune response and the host should be able to interact and remodel 
implanted matrices. Natural biomaterials provide beneficial properties for bone tissue 
engineering applications in their ability to be osteoconductive and osteoinductive as well as 
biodegradable.    
 Collagen type I (COL) is the most abundant protein in the human body and constitutes 
the majority of the ECM in tissues such as bone, tendon, skin, and cornea [40]. Collagen 
molecules are composed of a triple-helical structure and its subunits are organized with – 
(glycine-X-Y) - repeats where X and Y can be proline, hydroxyproline, lysine, hydroxylysine or 
other amino acids. 30% of collagen is composed of glycine, the smallest amino acid.  Its small 
structure allows collagen fibrils to wind into α-helices by minimizing steric hindrance. Collagen 
quaternary structure involves the self-assembly of tropocollagen into an entropically favorable 
form of collagen fibrils.  
 Collagen is widely used as a biomaterial as it supports cell attachment and proliferation 
and contains favorable mechanical properties. Recent studies have illustrated the osteoinductive 
potential of collagen towards human bone marrow mesenchymal stem cells [41, 42]. Moreover, 
collagen exhibits favorable mechanical properties that allow it to be handled and formed into 
desired geometries [40]. Collagen has FDA-approved indications as skin filler (CosmoDerm, 
Evolence) [43, 44], eye filler to treat glaucoma (AquaFlow) [45], wound dressing (Oasis, Integra, 
E-Z-Derm) [46], and bone (Infuse) [9-12]. 
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 Fibrinogen, the precursor of fibrin (FIB), is a 340 kDa protein that regularly circulates in 
the bloodstream and is one of the proteins involved in the wound healing cascade [47, 48]. Under 
normal physiological conditions, fibrinogen remains soluble and aggregation is prevented by the 
α and β subunits. Following vessel injury, numerous reactions take place allowing for the release 
of the enzyme thrombin, which cleaves the two subunits. Thrombin also activates factor XIII 
which crosslinks adjacent fibrin structures. Fibrin monomers then polymerize to form a network 
of fibers allowing for the stabilization of a clot. 
 Fibrin hydrogels have been fabricated for numerous tissue engineering applications [49]. 
Cells can be added directly into the fibrinogen precursor and the mixture can form a hydrogel 
without appreciable cell death. Fibrin concentrations and gel structure can be modified to direct 
cell phenotype and stem cell differentiation [50]. Owing to its intrinsic properties in the wound 
healing cascade, fibrin can be utilized in angiogenic and vasculogenic applications [51, 52]. 
Matrix metalloproteinases, cell-secreted proteinases, have been shown to be critical in the 
remodeling of fibrin to successfully create stable vessels. Fibrin was first approved for clinical 
use in the U.S. in 1998 and there are currently 7 commercially available fibrin products with 
indications as hemostats, sealants, and adhesives [49, 53].   
 Hydroxyapatite (HA) is the mineral component of bone and is present in a crystalline 
form throughout the collagen structure [32]. HA can provide an osteoconductive and 
osteoinductive environment for stem cell differentiation while increasing the mechanical 
properties of the underlying substrate [54, 55]. These changes in material properties can be 
achieved through creating a scaffold derived of HA or by incorporating synthetic particles 
throughout another material.   HA has clinical indications in bone (Bonesource, Interpore, Pro 




Cell Types  
 The cell types utilized in this dissertation have direct clinical potential as they can 
potentially be obtained from both autologous and allogeneic sources. Mesenchymal stem cells 
(MSC) are a multipotent cell type found in numerous tissues of the body and are characterized by 
their ability to proliferate in an undifferentiated state and their potential to differentiate into 
various cell types [60, 61]. MSCs can be isolated from bone marrow (bmMSC), adipose tissue 
(AdSC), muscle, peripheral blood, cord blood, and the placenta. These different tissues yield 
MSC that have different proliferative and multipotency profiles. Furthermore, age and disease 
stage are critical factors that can affect MSC function. Both autologous and allogenic MSC are 
currently being investigated for their use in clinical applications.  
 Endothelial cells are present within every blood vessel in the human body. These cells 
can self-assemble into vascular tubes when cultured in materials such as collagen and fibrin. 
Vessel formation can also occur under the guidance of pro-angiogenic factors such as VEGF and 
FGF. Endothelial cells can be extracted from numerous tissue sources such as umbilical cords, 
dermal tissue, and from the saphenous vein [62]. Human umbilical vascular endothelial cells 
(HUVEC) can be extracted from umbilical cords through a collagenase digestion and 
macrovascular endothelial cells can be isolated. HUVEC can form capillary-like structures when 
co-cultured with stromal cells such as fibroblasts or mesenchymal stem cells. Secreted factors 
from the MSC such as VEGF and MMPs allow migration of HUVEC through matrices allowing 
them to combine and form tubule structures.  





1.7 – Preview of the Thesis 
 Chapter 2 provides an in-depth review of cell-based approaches to vascularized bone 
tissue engineering. Basic bone biology, osteogenic and endothelial cell types, in vitro co-culture 
models, and in vivo bone formation and bone regeneration models are discussed throughout the 
review. Chapter 3 (Aim 1) describes the creation of collagen/fibrin composite three-dimensional 
cell-seeded hydrogel microenvironments that support the osteogenic differentiation of 
mesenchymal stem cells. The differentiation potential of adipose-derived stem cells and bone 
marrow mesenchymal stem cells are compared in both collagen/fibrin and 
collagen/fibrin/hydroxyapatite microbeads. Chapter 4 (Aim 2.1) presents the formation of a 
vasculogenic matrix composed of collagen and fibrin that supports endothelial network 
formation of human umbilical vein endothelial cells that are co-cultured with bone marrow 
mesenchymal stem cells.  Cell ratio and matrix composition are varied and matrix stiffness is 
investigated as a potential cause behind the obtained results. Both in vitro and in vivo studies are 
conducted in Chapter 5 (Aim 2.2) to study the addition of hydroxyapatite and its effect on 
endothelial network formation and cell-mediated compaction within the vasculogenic matrix 
previously developed. The osteogenic microbeads and the vasculogenic matrix are then 
combined in Chapter 6 (Aim 3). An in vitro model is utilized to demonstrate endothelial network 
formation around the microbeads. The dual-phase engineered tissue is then implanted into an in 
vivo mouse subcutaneous model and ectopic bone formation is studied over a period of 8 weeks. 
The results and key findings are then summarized in Chapter 7 and the broader impacts of this 
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Cell-Based Approaches to the 
Engineering of Vascularized Bone Tissue 
 
2.1 The Physiology of Bone 
Composition and Architecture at the Micro- and Macro-scale 
Bone is one of the main connective tissues in the human body. It is characterized by a 
collagenous extracellular matrix (ECM) that is extensively mineralized with hydroxyapatite 
(Ca10(PO4)6(OH)2) [1], which is found as plate-like structures 20-80 nm in length [2]. 
Hydroxyapatite contributes to the high density and strength of bone which in turns provides both 
support and protection to the other tissues and organs of the body. The mineral component of 
bone is both reactive and soluble, allowing turnover and remodeling within the bone structure. 
Bone tissue also contains a variety of other ionic species such as carbonate and magnesium, 
which are liberated to the systemic circulation as bone remodels. Bone therefore serves as an 
important storage depot for ions, including calcium and phosphate, which play roles in 
homeostatic regulation and metabolic function.  
 The proteinaceous ECM of bone is composed primarily of collagen type I, with lesser 
amounts of collagen type V and a variety of noncollagenous proteins [3]. Proteoglycans found in 
bone include chondroitin sulfate and keratin sulfate, which consist of a core protein surrounded 
by glycosaminoglycans and are found throughout the bone structure. Several key bone-
associated proteins such as osteonectin, osteopontin, bone sialoprotein I and II, and osteocalcin 
play regulatory roles in bone formation and cellular attachment. In addition, the bone tissue 
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environment includes potent growth factors and cytokines, including insulin-like growth factors 
(IGF), tumor necrosis factor alpha (TNF-α), transforming growth factor-beta (TGF-β), and bone 
morphogenetic proteins, which direct cell differentiation and proliferation. The 
microenvironment in bone therefore is comprised of a complex combination of physical and 
chemical cues that orchestrate tissue function in both health and disease. 
 There are two main types of bone structure: cortical (also called compact) and trabecular 
(also called cancellous or spongy) [4]. Cortical bone is stiffer and more organized than trabecular 
bone and forms a compact, dense layer that surrounds the trabecular tissue in the long bones. 
Cortical bone consists of highly organized concentric structures called osteons that serve as the 
tissue’s anatomical and functional unit. Osteons are supplied with blood form the marrow 
through Haversian canals, whereas Volkmann’s canals move blood between osteons. Trabecular 
tissue is found in the interior of bones and is also highly vascular. Trabecular bone is less dense 
and stiff compared to compact bone, due to the large marrow cavities it contains. The red 
marrow within trabecular bone contains hematopoietic progenitor cells that are responsible for 
the production of the cells of the blood, as well as a small population of stem cells that can give 
rise to mesenchymal tissues, including new bone. The marrow itself is also highly vascularized 
and provides nutrients to the surrounding bone. 
 There are four primary cell types in bone tissue: osteoprogenitor cells, osteoblasts, 
osteocytes, and osteoclasts [3]. Osteoprogenitor cells reside in the marrow, periosteum, and bone 
canals. When environmental signals initiate the processes that require bone formation, such as 
tissue growth or repair, these progenitors migrate, proliferate, and differentiate into osteoblasts. 
The primary function of osteoblasts is to secrete the protein ECM of bone, which subsequently 
becomes mineralized to form new bone tissue. Found on the outer lining of bone, these cells can 
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either remain inactive on the surface of bones or become osteocytes. Alkaline phosphatase (ALP) 
activity serves as a marker of their action. BMPs play an important role in the regulation of 
osteoblast differentiation and activity. As bone is formed, osteoblasts become trapped in the 
matrix, and they alter their phenotype to become osteocytes, which account for the majority of 
the cells in bone. These cells fill spaces called lacunae in the osteons and communicate to one 
another through channels called canaliculi, maintaining the bone under homeostasis. Osteoclasts 
are bone-resorbing cells that are activated during bone injury and remodeling, and their function 
is to digest bone. The balance of growth, remodeling, and repair that is important in maintaining 
skeletal function is maintained by the orchestrated action of these cell types. 
 
The Vascular Supply to Bone 
Bone is a highly metabolic tissue requiring an abundant vascular supply throughout its 
structure for homeostasis, growth and remodeling. It is estimated that bone tissue uses 
approximately 10 to 20% of resting cardiac output [5]. A dual blood supply exists in both flat 
and long bones, through major arteries surrounding the bones [6]. Long bones have a nutrient 
foramen in both the diaphysis (midsection of bone) and epiphysis (end of long bone), which are 
openings in the hard tissue to allow blood vessels to pass through and reach the marrow cavities. 
Smaller epiphyseal and metaphyseal arteries arising from surroundings joints connect with 
capillaries throughout the diaphysis. In the outer areas of cortical bone, capillaries that run 
through the Volkmann’s canals split into smaller arterioles that enter Haversian canals and in 
turn connect with surrounding skeletal muscle. Blood and waste drainage through the venous 
supply closely follows the nutrient arteries through bone. As flat bones do not contain diaphyses, 
metaphyses, or epiphyses, the dual blood supply runs adjacent to the plates of flat bones 
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providing areas for nutrient and waste exchange along the bone structure. The highly 
vascularized structure of bone allows the high demand of nutrient, waste, and ion transfer to be 
satisfied throughout the tissue and maintains normal development, growth, and remodeling of 
bone.  
 
The Bone Healing Process 
Injury to bone results in a cascade of events that allows the tissue to regenerate in a 
manner in which functionally developed tissue is recreated. These processes are triggered when 
skeletal integrity and local vasculature are disrupted at the defect site. Tissue damage initiates the 
bone healing response, which encompasses an initial inflammatory response, followed by 
intramembranous bone formation, endochondral bone formation, and finally bone remodeling 
(Figure 2.1). 
 
Angiogenesis is the formation of new blood vessels and is a critical component of the 
bone healing process, as it is required for the transport of nutrients, wastes, and cells to and from 
the injured site. Lack of angiogenesis has been cited as one of the primary causes of delayed- and 
non-unions. The capillary networks formed during the inflammatory phase of healing are 
typically transient in nature and are incapable of forming the functional vasculature required to 
heal non-unions. Evidence of this observation has been provided in a rat distraction osteogenesis 
Figure 2.1 – Schematic of the process of bone fracture healing, showing the major cell and matrix types



























model where administration of anti-angiogenic drugs during osteogenesis caused fibrous tissue 
formation and resulted in non-union [7]. 
Immediately after a bone fracture, ruptured blood vessels in the injured area constrict and 
a clot is formed to prevent further bleeding [3]. The resulting lack of blood supply causes a local 
hypoxic environment. Fibroblasts migrate towards the injured site to deposit initial extracellular 
matrix and generate granulation tissue. The lack of oxygen acts as a signal for local endothelial 
cells to proliferate and chondroblasts to differentiate from bone marrow stem cells, forming a 
bridge of hyaline cartilage between the ends of the injury site. The chondroblasts subsequently 
become hypertrophic and express pro-angiogenic factors, including vascular endothelial growth 
factors (VEGF) and fibroblast growth factors (FGF), causing blood vessels to further extend into 
the cartilaginous matrix. The presence of new blood vessels allows osteoprogenitor and 
hematopoietic cells to be transported to the wounded area, where they differentiate in the 
ossification center to form bone and bone marrow, respectively. In the final stages of healing, the 
local osteoprogenitor cells differentiate into osteoblasts to produce functional bone. 
2.2 Cell Types used in Engineering of Vascularized Bone Tissue  
The general approach to creating vascularized bone tissue is to combine an osteogenic 
cell type with an endothelial cell type, as shown schematically in Figure 2.2. For regeneration of 
defects, 3D hydrogel- or solid scaffold-based approaches are often used, though 2D co-culture 
models have been used to study the healing process. There are now a range of possible 
osteogenic cell sources, including bone marrow-derived mesenchymal stem cells, adipose-
derived stem cells, or mature osteoblasts. Similarly, a variety of endothelial cell types or their 





Osteogenic Cell Types 
Mesenchymal stem cells (MSC) are a multipotent cell type found in numerous tissues of 
the body. They are characterized as stem cells based on their ability to proliferate in an 
undifferentiated state and their potential to differentiate into various mesenchymal cell lineages 
[8, 9]. MSC are commonly isolated from bone marrow (bmMSC) and adipose tissue (AdSC), 
though they have also been extracted from a variety of other tissues, including umbilical cord, 
placental tissue, cord blood, amniotic fluid, and the periosteum [10-12]. These different tissues 
yield MSC that have different proliferative and multipotency profiles. Furthermore, age and 
disease stage are critical factors that can affect MSC function and potential. 
 MSC differentiation can be controlled by exogenous factors including hormones, growth 
factors, and extracellular matrix molecules. In vitro, bmMSC have been shown to differentiate 
towards bone, cartilage, muscle, adipose tissue, and tendon [13]. In particular, osteogenesis of 
bmMSC is commonly induced in vitro by adding dexamethasone, beta-glyocerophosphate (β-
Figure 2.2 – Schematic of cell-based approaches to engineering vascularized bone tissue. Cells and scaffolds






























GP), and ascorbic acid to the culture media [14-17]. Dexamethasone, a glucocorticoid, induces 
transcription of osteogenic factors such as bone sialoprotein [18] and the α5 integrin, an activator 
of Runx-2, ALP, and collagen I mRNA expression [19]. Ascorbic acid is an important cofactor 
in collagen formation, the most abundant protein in the ECM of bone, and increases ALP 
expression. Typically, ascorbic-2-phosphate is used in osteogenic studies as it is more stable in 
cell culture (pH = 7.4, 37ºC, and 5% CO2) conditions [20].  Cell-secreted ALP hydrolyzes 
supplemented β-GP to form the inorganic phosphate that aids in matrix mineralization [21]. 
Furthermore, growth factors such as TGF-β1, TGF-β2, TGF-β3, and BMPs can be exogenously 
applied in specific concentrations to differentiate bmMSC towards both the osteogenic and 
chondrogenic lineages. MSC differentiation can also be directed through matrix identity, matrix 
stiffness mechanical stimulation, substrate stiffness and nanotopographical cues [22-26]. The 
ability to control the phenotype of these progenitor cells makes them a valuable resource for 
tissue engineering approaches to bone regeneration. 
 Autologous bmMSC have advantages when designing cell-based therapies, because they 
avoid issues of immune rejection and can be harvested from patients using relatively simple 
surgical procedures. Clinical studies have been performed in which autologous bmMSC were 
purified from bone marrow aspirates, followed by ex vivo expansion and subsequent re-
implantation as therapies for graft-versus-host-disease, liver disease, bone fractures, heart failure, 
and multiple sclerosis [27]. Biopsy from the iliac crest is the most widely used procedure for 
obtaining bone marrow from which bmMSC can be purified. However, this method is associated 
with donor site pain and other types of morbidity. Furthermore, bone marrow aspirates contain 
bmMSC at a frequency of only 0.001-0.01% of total marrow cells, and therefore yield a 
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relatively low number of bmMSC after isolation. For these reasons, other sources of MSC have 
been examined and developed for cell-based therapies. 
 Allogeneic cells and tissues typically elicit a host immune reaction upon implantation. 
This response can be managed through pharmacological immune suppression, but may also 
cause an array of undesired side effects. Interestingly, it has been suggested that bmMSC are 
hypoimmunogenic relative to other cell types, and therefore that they may be useful for 
therapeutic purposes even in the absence of immune modulation [28, 29]. Studies have shown 
that bmMSC can inhibit T-cell proliferation through the secretion of soluble factors such as 
hepatocyte growth factor (HGF), TGF-β1, and interleukin-10 (IL-10) [30-32]. It is thought that 
these growth factors and cytokines create an immunosuppressive environment around bmMSC, 
resulting in a delayed and attenuated immune response. Allogeneic bmMSC offer the great 
advantage that they could be produced in large quantities for therapeutic use, allowing more 
comprehensive quality control of both safety and function. The possibility of using these cells 
without immunosuppression makes them very attractive for cell-based therapies.  
 Adipose-derived stem cells (AdSC) are a subtype of MSC that are derived from fat tissue. 
They are considered separately here because of the great interest in their use, engendered by the 
ease of isolating them from adipose tissue and their associated translational potential [33]. These 
cells can be isolated from liposuction aspirates or other biopsies [34, 35], and have been shown 
to differentiate into a variety of mesenchymal cell lineages including bone [36, 37], fat [38, 39], 
and cartilage [40-42]. Similar to bmMSC, AdSC have been shown to possess 
immunomodulatory properties allowing for inhibition of inflammatory cytokines [43, 44]. 
 Osteoblasts are the secretory cells that form the collagen matrix present within the bone 
structure. These cells also secrete non-collageneous proteins such as osteocalcin, osteopontin, 
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and osteonectin, which participate in the mineralization process required to create mature bone. 
Osteoblasts also play a primary role in fracture healing. They are recruited towards fracture sites 
and deposit matrix to achieve the appropriate geometry required to fill the defect. In tissue 
engineering applications, primary osteoblasts [45, 46], osteoblast cell lines [47, 48], and pre-
osteoblast cell lines [49-51] have typically been used to demonstrate efficacy in up-regulating 
osteogenic genes in vitro and bone formation in vivo. The use of primary osteoblasts in bone 
regeneration has the advantage that cell differentiation is not required, but an autologous source 
would be required. However, these cells have limited proliferative capacity in vitro and therefore 
present challenges in obtaining a sufficient quantity of cells to achieve a therapeutic effect [52]. 
 
Endothelial Cell (EC) Types  
 Endothelial cells (EC) line the blood vessels and are present throughout the vasculature in 
the human body [53, 54]. These cells have the ability to self-assemble into vascular tubes when 
isolated and then cultured in protein materials such as collagen and fibrin [55, 56]. Vessel 
formation can also occur under the guidance of pro-angiogenic factors such as VEGF, FGF, 
HGF, and platelet-derived growth factor (PDGF) [57, 58].  
 Endothelial cells can be extracted from numerous tissue sources, including umbilical 
cords, dermal tissue, and the saphenous vein [54]. A commonly used macrovascular cell type is 
human umbilical vascular endothelial cells (HUVEC), which can be isolated from discarded 
umbilical cords through a facile collagenase digestion procedure. HUVEC can form capillary-
like structures when co-cultured in 3D matrices with stromal cells, including fibroblasts [59], 
MSC [56, 60], and AdSC [61]. Secreted factors from the MSC, such as VEGF and MMPs, allow 
migration of HUVEC through matrices, thereby enabling the cells to combine and form tubular 
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structures. Human dermal microvascular endothelial cells (HMVEC) are an alternate endothelial 
cell source for the engineering of vascularized tissue that can be isolated from neonatal foreskin 
[62] or adult skin capillaries [63]. HMVEC have been shown to create vessel-like structures in 
vitro when co-cultured with stromal cell types such as fibroblasts [64], and have yielded perfused 
vessels in vivo [65]. An advantage of HMVEC is that they potentially represent an autologous 
cell source for therapeutic neovascularization.  
 Endothelial progenitor cells (EPC) have also been studied for their ability to form 
capillary-like structures in vivo when co-cultured with stromal cells [66]. EPC are a somewhat 
heterogeneous cell type that can be derived from a number of sources including from adult bone 
marrow, adult peripheral blood, and umbilical cords. There are two types of EPC which can be 
obtained from peripheral blood: late outgrowth and early outgrowth, which differ in their culture 
times, proliferative potential, and gene expression [67]. Au et al. [68] showed that EPC derived 
from umbilical cord blood and EPC derived from adult peripheral blood can both form vessels in 
vivo when co-cultured with fibroblasts, but the stability and density of the vessels differed. EPC 
can be obtained from adult humans, and therefore they offer the potential of an autologous stem 
cell use in engineered tissues.  
Other sources of EC such as those isolated directly from the bone marrow (bmEC) [69] 
and EC derived from an original progenitor cell source such as AdSC [70] or bmMSC [71] are 
being explored, including as sourced in vascularized bone tissue engineering applications. While 
these cell types are less commonly used, they have potential advantages in terms of ease of 
procurement and use as an allogeneic cell source. However, the methods for consistently 
isolating these cells are still being developed, and the full functional characterization of these 
sources as vasculogenic EC are not yet complete.  
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2.3 In Vitro Co-Culture Models of Vascularized Bone Formation 
 A variety of two-dimensional (2D) experimental models have been employed to study the 
mechanisms of both osteogenesis and angio/vasculogenesis, with the aim of understanding the 
relationships and interactions between various cell types in vitro. Early co-culture studies 
established a synergistic relationship between endothelial cell types and osteoblastic cell types. 
Co-culturing these cell types together caused an upregulation of the activity of the osteogenic 
marker ALP in bmMSC, AdSCs, and osteoblasts [72-75]. Increased ALP expression requires 
direct contact between the two cell types, allowing for gap junctional communication between 
HUVEC and osteoblasts [75]. It has also been suggested that ALP mRNA is stabilized by p38 
mitogen-activated protein kinase expressed by EC in the system [76]. However the contribution 
of EC to osteogenesis is complex, and other 2D co-culture models have shown downregulation 
of osteogenic factors such as Runx2 and osteocalcin [77, 78]. 
 Other work has demonstrated a positive effect of EC on both bmMSC and osteoblast 
proliferation [79], putatively through inactivation of the proapoptotic protein BAD [80]. 
Conversely, MSC and osteoblasts secrete pro-angiogenic factors such as VEGF [81], causing 
upregulation of the VEGF receptor in EC, which in turn increases ALP expression in bmMSC 
and osteoblasts [82]. The sonic hedgehog pathway is implicated as one of the main signaling 
pathways that control both angiogenesis and osteogenesis in these co-culture models [83]. The 
secretion of proangiogenic factors from bmMSC has also been suggested to be differentiation-
state dependent, such that osteogenically induced bmMSC show reduced secretion of VEGF and 
FGF-2, leading to a decrease in EPC chemotaxis [84]. Other studies have investigated the effects 
of modulating cell ratio, cell type, and culture medium in order to optimize both osteogenic and 
angiogenic conditions of the two cell types [85-89].      
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 Three-dimensional (3D) co-culture systems using a variety of natural and synthetic 
biomaterials have also been employed as systems to study concurrent angio-/vasculogenesis and 
osteogenesis. Three-dimensional spheroid co-culture of bmMSC and HUVEC was shown to 
produce well-organized 3D vascular structures in vitro [90]. Further, the authors observed an 
increase in ALP expression in the bmMSC/HUVEC co-culture system compared to a control 
(bmMSC/fibroblast) co-culture system. These effects were attributed to enhanced activation of 
Wnt signaling as evidenced by β-catenin expression, as well as upregulation of BMP signaling 
through elevated pSmad 1/5/8 expression.  
 Similarly, 3D solid scaffold-based co-culture systems have been investigated. Santos et al 
cultured HMVEC with osteoblasts on fiber-mess scaffolds composed of a blend of corn starch 
and polycaprolactone (PCL) scaffolds and observed alignment of EC and expression of collagen 
IV, an endothelial basement membrane protein, after 21 days of culture [91]. Further gene 
expression analysis showed upregulation of key osteogenic and angiogenic genes such as 
collagen I, VEGF, ALP, and VCAM-1. Direct cell-cell contact between the two cell types 
promoted increased VEGF secretion and high expression of the gap junction protein connexin 43 
was detected at the osteoblast-HUVEC interface. These data suggest that heterotypic intercellular 
crosstalk between the two cell types impacts their respective gene expression profiles. Beta-
tricalcium phosphate (β-TCP) scaffolds were assessed for their ability to support both HUVEC 
and bmMSC co-cultures as shown in Figure 2.3 [92]. In this study, the authors investigated the 
effects of mono- or co-cultured bmMSC and HUVEC at various ratios (bmMSC:HUVEC ratios 
of 5:1, 1:1, and 5:1). This system was permissive to both bmMSC and HUVEC proliferation, 
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vessel-like structure formation by the HUVEC, and upregulation of ALP.
 
Poly(lactide-co-glycolide) (PLGA) scaffolds have also been employed as scaffolds to support co-
cultures of bmMSC and EPC. Nukavarapu et. al observed increases in BMP-2 and VEGF gene 
expression as well as ALP expression on macro-porous scaffolds fabricated from PLGA 
microspheres [93]. Moreover, other scaffolding materials such as PCL [69] and polyester-




Figure 2.3 – In vitro co-culture models of vascularized bone formation. (A) Kang et al showed
endothelial network formation by HUVEC on β-tricalcium phosphate scaffolds after 14 days of co-
culture with bmMSC. CD31 is labeled red and cell nuclei are labeled blue. Scale bar = 10 µm. (B and
C) Both cell proliferation and alkaline phosphatase expression were modulated in co-culture





2.4 In Vivo Regeneration of Vascularized Bone Tissue 
 Combined osteogenic/angiogenic cell-based co-culture systems have been applied to 
generating vascularized bone tissue in both ectopic and orthotropic sites in vivo. After 
demonstrating that HMVEC increase osteogenic differentiation of bmMSC through the secretion 
of BMP-2, Kaigler et al investigated the co-transplantation of HMVEC and bmMSC on PLGA 
scaffolds into the dorsal region of SCID mice and monitored ectopic bone formation after 8 
weeks [95]. The authors observed no differences between total blood vessel content in the 
implants containing both cell types, compared to implants with bmMSC alone. However, there 
was a significant increase in bone formation in the HMVEC+bmMSC condition, compared to the 
bmMSC alone implants. In another study, examination of culture conditions of HUVEC and 
bmMSC in vitro suggested that vasculogenesis needed to be induced prior to osteogenesis [96]. 
The two cell types were then cultured for 6 weeks on decellularized bone grafts and implanted 
subcutaneously into nude mice, which resulted in bone formation. 
 Scaffold-less co-transplantation of bmMSC and HUVEC has also been investigated as a 
means of generating ectopic bone formation [97]. A dense cell sheet was constructed by seeding 
bmMSC in a monolayer and inducing the cells towards the osteogenic phenotype. HUVEC were 
then seeded on top of the bmMSC cell layer, which created a vessel-like network within the cell 
sheet. After transplantation of the co-cultured cell sheet into nude mice, immunohistochemical 
analysis demonstrated expression of the bone marker osteocalcin, and integration of transplanted 
HUVEC with host vasculature. Ectoptic osteogenesis has also been evaluated through the co-
transplantation of EPC and bmMSC on collagen fiber mesh scaffolds into nude mice 
subcutaneously [98]. Neovasculature and total bone area, as measured by capillary density and 
histological analysis, were both increased in the co-culture group compared to the bmMSC only 
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condition after 12 weeks of implantation. Ectopic bone formation has also been achieved in a 
large animal model. Geuze et al combined EPC and bmMSC on biphasic calcium phosphate 
scaffolds and implanted them intramuscularly into a goat model [99]. The authors observed 
significant increases in bone formation in the co-culture condition compared to acellular 
controls, however there was no significant difference in bone generation compared to the 
bmMSC alone group. Similar results were observed by Fedorovich et al using goat bmMSC and 




 An interesting approach to engineering vascularized bone grafts was demonstrated by 
Tsigkou et al [101]. Bone marrow MSC were first seeded onto porous PLGA scaffolds and 
predifferentiated toward the osteogenic lineage for one week of in vitro culture (Figure 2.4). The 
scaffolds were then seeded with a collagen-fibronectin hydrogel containing HUVEC and 
bmMSC, and were implanted subcutaneously into SCID mice. Seeded HUVEC were shown to 
Figure 2.4 - In vivo regeneration of vascularized bone tissue. (A) Tsikgou et al seeded bmMSC on
PLGA scaffolds and pre-differentiated them towards the osteogenic lineage prior to embedding the
scaffolds in a collagen-fibronectin hydrogel containing a bmMSC and HUVEC co-culture. (B) In vitro
formation of vessel- like structures after 21 days of culture. MSC (eGFP) and HUVEC (tdTomato)
were transduced with a lentivirus to fluorescently label the cells. Scale bar = 50 µm. (C) Von Kossa
staining after 8 weeks of subcutaneous implantation in immunodeficient mice. Calcium deposition
was observed on the pore surfaces of the implanted scaffold. Scale bar = 500 µm. (D) Osteocalcin, a
late marker of osteogenesis, was also present throughout the scaffold. Scale bar = 100 µm. All panels






connect with host vasculature, and ectopic bone formation and expression of osteocalcin was 
achieved after 8 weeks of implantation.  
Orthotopic models in animals have also demonstrated the potential of MSC and EC co-
cultures systems to regenerate bone, but the results have been mixed. Calvarial defects in rodents 
are a common orthotopic model. Early studies by Kaigler et al combined bmMSC and HMVEC 
on PLGA scaffolds to assess bone regeneration in a rat cranial defect model [102]. Bone mineral 
density of the bmMSC+HMVEC group was significantly higher after 6 weeks compared to the 
bmMSC alone condition, but was not statistically different after 12 weeks post-implantation. 
Conversely, bone volume was not statistically different after 6 weeks of implantation, but was 
significantly higher in the co-culture condition after 12 weeks. Koob et. al also used calvarial 
defects in SCID mice to study the effect of bmMSC+HUVEC co-cultures that were embedded in 
fibrin/Matrigel hydrogels and then seeded onto decalcified bone scaffolds [103]. Human EC 
were successfully transplanted into the mice, as demonstrated by positive human CD31 staining. 
However, the dual (MSC+HUVEC) group showed no significant increase in either capillary or 
bone formation in the implant site, relative to controls. This result was attributed to a lack of 
direct contact between implanted HUVEC and bmMSC as well as the contribution of 
endogenous angiogenesis from the host, which enabled comparable bone formation in controls. 
In a separate study, pre-differentiation of AdSC toward the bone lineage and co-transplantation 
with HUVEC on PCL/PLGA/TCP scaffolds yielded different results [104]. More rapid and more 
extensive bone regeneration was observed in the AdSC+HUVEC group compared to the AdSC 
alone condition, indicating a beneficial response to the addition of HUVEC. In a study using 
EPC+bmMSC co-cultures on PLGA scaffolds, no significant increase in neovascularization was 
observed compared to the bmMSC alone group [105]. Further, the dual group did not yield 
38 
 
improved bone regeneration compared to the bmMSC or EPC groups, which the authors 
attributed to low transplantation efficiency of EPC in vivo. 
 Femoral defects are another orthotopic model that has been used to study osteogenesis 
induced by bmMSC+EC co-cultures. In this model, co-transplantation of bmMSC and HUVEC 
embedded within alginate microspheres enhanced bone regeneration compared to the bmMSC 
alone condition, suggesting a synergistic response of HUVEC with transplanted bmMSC [106]. 
Co-transplantation of EPC and bmMSC on fibronectin-coated β-TCP scaffolds also showed 
promising results [107]. Both neovascularization and bone volume fraction were increased in the 
dual group compared to the cell types individually at the early time points of one and four weeks. 
Importantly, after 8 weeks, bone quality was significantly higher in the EPC+bmMSC group, as 
measured by ultimate load measurements, indicating a potential benefit of generating highly 
vascularized engineered bone.   
2.5 Summary and Conclusions 
 The healing of large bone defects remains a particular clinical challenge due to the need 
to establish vascularization in appropriate conjunction with bone regeneration. Approaches to 
this problem using growth factor and gene delivery have shown some promise, but results have 
been variable, and consistently robust regeneration has not been achieved. Only cells can create 
new bone and new vasculature, and therefore cell-based therapies are particularly promising for 
the treatment of large bone defects where the native cellular component may be absent. 
Numerous cell types in this application, including bone marrow mesenchymal stem cells, 
adipose-derived stem cells, osteoblasts, umbilical vein endothelial cells, dermal microvascular 
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endothelial cells, and endothelial progenitor cells. Each cell type presents its own advantages and 
disadvantages, particularly in their capacity to be used as an autologous or allogeneic source. 
 In vitro 2D co-cultures models have provided a deeper mechanistic understanding of the 
crosstalk between MSC and EC that is critical to regenerating mature and stable tissue. For 
example, expression of ALP, an osteogenic protein, by MSC is increased when they are co-
cultured with EC. At the same time MSC secrete VEGF, which induces local EC to form 
primitive tubular networks. Similarly, in vitro 3D co-cultures using various natural and synthetic 
biomaterials have provided proof-of-concept studies to demonstrate cell survival and 
maintenance of both osteogenic and angiogenic phenotypes. Furthermore, these scaffolds have 
served as materials to transplant cells in vivo in both ectopic bone formation and orthotopic bone 
regeneration models. The transplantation of MSC and EC co-cultures in vivo has shown 
promising results in generating vascularized bone and in regenerating higher quality bone faster 
compared to transplanting either cell type alone. 
 This review has endeavored to summarize the key cellular components and processes 
involved in regenerating vascularized bone tissue, and how biologists and bioengineers have 
attempted to mimic these processes in vitro and in vivo. It is clear that an interplay between 
osteogenic and vasculogenic cells is required to create vascularized bone, and the studies 
summarized above have provided insight into these interactions. The 2D and 3D studies that 
have been performed to date suggest that targeting of vasculogenesis concomitantly with 
osteogenesis can lead to more rapid, robust, and mature bone formation. However these early 
approaches need to be validated in pre-clinical large animal models, before they can be 
investigated in humans. The ability to generate well-vascularized bone tissue in vivo will 
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Osteogenic Differentiation of Adipose-derived and Marrow-derived 
 Mesenchymal Stem Cells in Modular Protein/Ceramic 
Microenvironments 
3.1 Introduction 
 Improved therapies for the regeneration of bone are needed to achieve full repair of 
recalcitrant and large fractures. Through the combination of cells, materials, and signaling 
molecules, tissue engineering aims to create biomimetic tissue constructs to both regenerate and 
replace damaged tissue [1].  Numerous sources of stem and progenitor cells [2] have been used in 
bone tissue engineering applications including embryonic [3], umbilical cord [4], and dental pulp 
[5].  However, bone marrow-derived mesenchymal stem cells (bmMSC) and adipose-derived 
stem cells (AdSC) [6] are the most commonly studied cell types for orthopaedic applications and 
both have demonstrated the ability to regenerate bone in vivo [7,8]. Further, both of these cell 
types has specific advantages in their use; bmMSC have been suggested to have 
immunomodulatory properties [9] and therefore can be used as an allogeneic source. AdSC have 
the advantage that they are an easily obtained autologous cell source [10]. A number of recent 
studies have directly compared the osteogenic potential of these two cell types, however the 
results are context-dependent and more work is needed to determine the utility of these cells in 
specific applications [11-15].     
50 
 
Natural biomaterials such as collagen [16-18], fibrin [19,20], and chitosan [21,22] have 
been proposed as osteoconductive materials for engineering and regenerating bone. Ceramics 
such as β-tricalcium phosphate [18], calcium carbonate [23], bioglass [24], or coatings created by 
simulated body fluid [25] have been combined with these materials to enhance the mechanical 
properties and osteoinductivity of the matrices. In particular, incorporation of hydroxyapatite 
(HA), the principal mineral component of native bone, has proven to be an effective strategy to 
provide stem cell-specific cues that aid in the formation of biomimetic composite structures for 
the engineering of bone [15, 27, 28].  
Modular tissue engineering has emerged as a scheme for applying a “bottom-up” 
approach to fabricate engineered tissues [29]. Cell-seeded, modular hydrogel microenvironments 
(“microbeads”) can be individually cultured, differentiated, and then later combined to create 
macroscopic tissue constructs with defined architecture. In bone tissue engineering, recent 
studies have used gelatin microcarriers to support osteogenic differentiation of human amniotic 
fluid mesenchymal stem cells which were then combined to create bone tissue constructs [30]. 
Other studies have used alginate microbeads to differentiate human embryonic stem cells 
towards the osteoblast lineage [31].  Previous work in our lab has used various natural 
biomaterials including chitosan, fibrin, collagen, and agarose to create cell-seeded 
microenvironments through a water-in-oil emulsion process [32-34]. Pure protein microbeads 
have been difficult to fabricate using this process because they are difficult to harvest and are 
fragile.  To circumvent this issue, the collagen matrix can be supplemented with agarose to 
generate composite microbeads for osteogenic differentiation of encapsulated bmMSC [35]. 
However, the inclusion of agarose, a polysaccharide not found in bone, limits the application of 
such microbeads in bone repair. 
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In this study, we generated pure protein microbeads by combining collagen (COL) and 
fibrin (FIB) for bone repair applications. Particulate HA was also added to the microbeads to 
increase the density of microbead preparations, thereby facilitating harvesting during the 
production process. Our primary goal was to directly compare the osteogenic differentiation of 
bmMSC and AdSC in COL/FIB and COL/FIB/HA microbeads. These modular cell-based 
hydrogel microenvironments could provide utility in generating natural biomaterial based 
approaches to bone regeneration. 
3.2 – Materials and Methods 
Collagen/Fibrin Microbead Fabrication 
 
Figure 3.1 – Schematic of microbead fabrication process. COL/FIB and COL/FIB/HA microbeads












 Microbeads composed of 50/50 (mass ratio) collagen/fibrin (COL/FIB) were generated 
through a water-in-oil emulsion technique as shown in Figure 3.1. Bovine Type I COL (MP 
Biomedicals, Solon, OH, USA) was dissolved in 0.02 N acetic acid at a concentration of 4.0 
mg/ml and bovine fibrinogen (Sigma Aldrich, St. Louis, MO USA) was dissolved at 4.0 mg/ml 
clottable protein in serum-free Dulbecco’s modified Eagle’s medium (DMEM; Thermo 
Scientific, Logan, UT, USA). COL (1.25 mg/ml) and FIB (1.25 mg/ml) were then added to a 
mixture containing 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY, USA), 
10% 5X-concentrated DMEM (starting concentration), 5% 0.1 N sodium hydroxide (NaOH), 2% 
bovine thrombin (1 UT/ml; Sigma), and 1 mM glyoxal (Sigma) at 4°C. The remaining volume 
For HA-containing microbeads, 2.5 mg/ml of HA in 1X DMEM was sonicated for 1 hour prior 
to incorporation to ensure homogenous distribution throughout the microbeads [36]. The HA was 
then added directly into the pre-gel mixture.  
The pre-gel mixture was then quickly pipetted into a pre-cooled bath of 100 cSt 
polydimethylsiloxane (PDMS; Xiameter, Dow Corning, Midland, MI) and stirred with a double-
bladed impeller set at 700 RPM. After 5 minutes of mixing at 0°C, the temperature was then 
raised to 37°C to initiate co-polymerization and gelation of the COL and FIB. Microbeads were 
collected from the oil phase by centrifuging the mixture at 200X g and washing three times for 
10 minutes per wash with phosphate buffered saline (PBS; Life Technologies) containing 
Pluronic L101 (BASF, Florham Park, NJ, USA) in order to separate the beads from the oil phase 
and remove excess oil.  
Microbead Imaging, Size and Size Distribution Quantification 
For light microscopy imaging, microbeads were stained with EZBlue Coomasie reagent 
overnight and imaged with an Olympus IX15 Microscope system (Olympus America, Center 
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Valley, PA, USA). Confocal reflectance microscopy using a laser scanning microscope 
(Olympus) was used to acquire images of the microbead architecture. Microbead diameter was 
analyzed using ImageJ software (National Institute of Health, Bethesda, MD, USA) and size and 
size distribution of the microbeads were quantified.  
 
Cell Culture  
 Human marrow-derived mesenchymal stem cells (bmMSC; Lonza Inc., Walkersville, 
MD, USA) and human adipose-derived stem cells (AdSC; Lonza) were grown in Minimum 
Essential Medium Alpha (αMEM) supplemented with 10% bmMSC-Qualified FBS and 1% 
penicillin/streptomyocin (Life Technologies). bmMSC were used at passage 6 and AdSC were 
used at passage 5, corresponding to two subculture periods after arrival. Cells were added 
directly into the pre-gel mix at a concentration of 1.0 X 106 cells/ml to promote even cell 
distribution throughout the beads. Microbeads were cultured statically in 15 ml centrifuge tubes 
(Corning Incorporated, Corning, NY, USA) with 3 ml of media.   
 
Cell Viability Studies 
Cell viability was assessed using a vital stain kit (Live/Dead®, Life Technologies). At 
days 1 and 7, cell-seeded microbeads were collected and washed three times in sterile PBS for 10 
min/wash. Microbeads were then incubated in a solution containing 4.0 µm calcein-AM and 4.0 
µm ethidium homodimer-1 in PBS at 37°C for 35 min. Microbeads were again washed three 
times in PBS, and then imaged using a laser scanning confocal microscope (Olympus). Percent 
viability was calculated by comparing the total green-stained cells (live) to the total red-stained 




Osteogenic Differentiation  
 For osteogenic studies, cell-seeded microbeads were cultured in either complete medium 
(growth) or osteogenic medium composed of complete medium supplemented with 10 mM β-
glycerophosphate (Sigma), 50 µg/ml ascorbic acid 2-phosphate (Sigma), and 100 nM 
dexamethasone (Sigma) for 14 days. Microbead samples were collected at days 1, 3, 7, and 14 
and flash-frozen in in liquid N2 and stored at -80°C. To analyze cell proliferation and alkaline 
phosphatase (ALP) activity, microbeads were dissolved overnight in 10 mM Tris-HCl (Sigma) 
containing 0.6 mg/ml collagenase Type I (MP Biomedicals), 0.2% IGEPAL (Sigma), and 2 mM 
phenylmethanesulfonylfluoride (Sigma). DNA content was then assessed using a commercially 
available DNA assay (PicoGreen®, Life Technologies). Alkaline phosphatase activity was 
quantified by adding 20 µl of the sample lysate to a 100 µl of 0.5 M 2-amino-2-methyl-1-
popanol (Sigma) with 5.0 mM p-nitrophenol phosphate substrate (Sigma) at a pH of 10.3 and 
read spectrophotometrically at 405 nm [22]. Total calcium secretion was analyzed using the 
OCPC method as described [36]. Briefly, microbead samples were dissolved overnight in 1.0 N 
acetic acid and 10 µl of the sample was incubated in 0.05 mg/ml of OCPC solution in 
ethanolamine, boric acid, and 8-hydroxyquinoline buffer (Sigma) for 10 min. Samples were read 
against a standard curve with known calcium values at 565 nm.  
 
Statistical Analysis 
 All values are represented as mean +/- standard deviation. N = 4 independent samples 
were used for the osteogenic differentiation studies. DNA content and calcium secretion data 
were normalized to day 1 values from within each condition. A one-way analysis of variance test 
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(ANOVA) and a two-way ANOVA with a Tukey’s post hoc analysis were used to determine 
significance between conditions and groups. A value of p < 0.05 was used to determine statistical 
significance.  
 
3.3 - Results 
Acellular Microbead Morphology, Size, and Size Distribution 
  Figure 3.2 depicts acellular COL/FIB microbeads directly after fabrication and shows 
their regular spheroidal morphology (panels A-D). Coomasie staining allowed for visualization 
of microbeads under light microscopy, and microbeads containing HA were dark due to the 
attenuation of light passing through the microbeads. Hydroxyapatite remained well-dispersed 
and homogeneous throughout the microbeads. Confocal reflectance imaging allowed for the 
visualization of the microbead architecture (panels E, F). COL/FIB microbeads exhibited a 
fibrillar structure whereas the COL/FIB/HA microbeads was observed to have homogenous 
distribution of hydroxyapatite throughout and within its fibrillar structure.  The addition of HA 
did not significantly affect the average size of the microbead populations, and both had an 
average diameter of approximately 130 +/- 25 µm, with a relatively narrow size distribution 




Figure 3.2 – Morphology and size distribution of acellular microbeads. Coomasie Blue staining
allowed for visualization of microbeads under light microscopy (A-D). Microbeads that formed
were spherical. Images of the matrix microarchitecture of microbeads obtained through confocal
reflectance microscopy (E,F). Confocal reflectance imaging demonstrated the fibrillar nature of
the COL/FIB microbeads and homogenous dispersion of the HA throughout the microbeads.
Histograms of the size distribution of microbeads (G,H). The size and size distribution did not
















 Cell viability of bmMSC or AdSC in COL/FIB or COL/FIB/HA beads was assessed at 
days 1 and 7, and vital staining of microbeads is shown in Figure 3.3. Viability remained high 
(>90%) at both time points in all conditions as seen by the abundant green staining and low red 
staining. By day 7, the morphology of the embedded cells began to change as they spread 
throughout both the matrix and mineral phases of the microbeads.  
 
Confocal Reflectance Imaging of Cell-Seeded Microbeads 
 Characterization of matrix architecture was performed using confocal reflectance 
microscopy, as shown in the representative imaged in Figure 3.4. Changes in matrix architecture 
in cell-seeded microbeads were tracked over a 7 day culture period. At day 1, individual fibers 
were visible within the collagen/fibrin microbeads. However, by day 7, both COL/FIB and 
COL/FIB/HA microbeads became denser and the fibrillar structure of the matrix was less 
evident. The mineral phase could be discerned in HA-containing microbeads, but did not change 












Figure 3.3 – Cell viability of bmMSC or AdSC in COL/FIB or COL/FIB/HA microbeads at days 1 and 7.
High viability (green staining) was observed in all conditions at all time points. bmMSC COL/FIB (A,B),










Osteogenic Differentiation  
 Figure 3.5 shows DNA, ALP, and calcium secretion data for both bmMSC and AdSC in 
COL/FIB and COL/FIB/HA microbeads after 14 days in either growth or osteogenic media. In 
Day 1 Day 7
50 μm
Figure 3.4 – Confocal reflectance imaging of bmMSC or AdSC in COL/FIB or COL/FIB/HA
microbeads at days 1 and 7. The fibrillar nature of the cell-seeded COL/FIB microbeads was visible
after 1 day of culture. COL/FIB microbeads aggregated and the fibrillar structure was less visible after
7 days in culture. HA remained evenly dispersed for 7 days in cell-seeded COL/FIB/HA microbeads.
bmMSC COL/FIB (A,B), AdSC COL/FIB (C,D), bmMSC COL/FIB/HA (E,F), AdSC COL/FIB/HA
















growth medium, there were no significant differences in DNA content at day 7; however, the 
bmMSC COL/FIB/HA group exhibited significantly higher DNA content compared to the other 
conditions at day 14. In osteogenic media, the AdSC COL/FIB group showed higher DNA 
content relative to the other conditions at day 7; however, there were no significant differences at 
day 14.   
 ALP activity in microbeads was significantly higher at day 3 in the bmMSC 
COL/FIB/HA formulation compared to the bmMSC COL/FIB microbeads. The bmMSC 
COL/FIB/HA microbeads showed significantly higher ALP activity when cultured in osteogenic 
media, as compared to growth media. Both AdSC COL/FIB and bmMSC COL/FIB/HA had 
statistically greater ALP activity than the bmMSC COL/FIB microbeads when cultured in 
osteogenic media.  
 Calcium deposition markedly increased at day 14 in both the bmMSC COL/FIB and 
AdSC COL/FIB microbeads in osteogenic media, relative to microbeads cultured in growth 
media. However, there were no significant differences in calcium deposition between any of the 
conditions in osteogenic media at day 14.   
 A full list of the statistical results generated from two-way ANOVA analyses is provided 
in the tables in Figure 3.6.   
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Figure 3.5 – Cell function and osteogegenic differentiation in microbeads. DNA Content in
growth Media (A) and osteogenic media (B), alkaline phosphatase activity in growth media (C)
and osteogenic media (D), and calcium secretion in growth media (E) and ostegenic media (F). (*)
denotes statistical significance against growth condition. (@) denotes statistical significance
against MSC COL/FIB. (#) denotes statistical significance against ASC COL/FIB. ($) denotes
statistical significance against MSC COL/FIB/HA. (^) denotes statistical significance against ASC
COL/FIB/HA. (&) denotes statistical significance against Day 1. (!) denotes statistical significance
against Day 7.
















3.4 - Discussion 
 This study has demonstrated that a simple water-in-oil emulsion process can be used to 
create modular microenvironments consisting of native extracellular matrix proteins 
supplemented with a ceramic phase. The addition of hydroxyapatite into the microbeads 
increased the yield that was harvested, but did not alter the size or size distribution of the 
microbeads. COL/FIB and COL/FIB/HA microbeads were spheroidal and approximately 130 µm 
+/- 25 µm in diameter. In this range of microbead sizes, a defined number of cells can be 
encapsulated within each bead, but cells can also spread and interact with the microbead matrix. 
Calcium Day 7 Day 14
Significant p value Significant p value
bmMSC vs. AdSC 0.962 0.710






bmMSC vs. AdSC 0.656




DNA Day 7 Day 14
Significant p value Significant p value
bmMSC vs. AdSC X 0.001 0.671




Figure 3.6 – Two-way Analysis of Variance (ANOVA) results. 
63 
 
Further, this size allows sufficient mass transfer through the microbead matrix to the embedded 
cells, since the maximum diffusion path for nutrients through tissues has been suggested to be 
only 150-200 µm [37]. Although not explored in this study, the microbead size and distribution 
can be controlled by modulating the impeller speed, oil viscosity and other fabrication process 
parameters [32,33].  
 Analysis of cell viability showed that both bmMSC and AdSC survived the embedding 
process and remained viable over at least a week in culture. Furthermore, after 7 days both 
bmMSC and AdSC exhibited a spread morphology indicating that they associated with the COL 
and FIB extracellular matrix components. Inclusion of HA in the microbeads did not alter either 
cell type’s viability or morphology. In addition, confocal reflectance microscopy allowed the 
microarchitecture of microbeads to be visualized. The fibrillar structure of the microbeads 
became denser over time, suggesting that the microbeads were compacted by the embedded 
cells, a phenomenon that is commonly observed when cells are seeded within natural 
biomaterials [38].  Taken together, these findings suggest that the microbead environment is 
conducive to maintenance of living cells and allows them to retain their active functions. 
 Comparison of bmMSC and AdSC osteogenic differentiation in COL/FIB and 
COL/FIB/HA microbeads suggested that theses cell types are mostly similar in their responses. 
Two-way ANOVA found no significant differences between AdSC and bmMSC in their DNA 
content, ALP activity, or calcium secretion over two weeks of culture in either growth or 
osteogenic media. Moreover, we did not observe any significant differences between the 
COL/FIB and COL/FIB/HA matrices in any of the assays, indicating that the addition of HA did 
not cause any detrimental effects to stem cell differentiation throughout the culture period. ALP 
activity, an early osteogenic marker, was somewhat elevated in the bmMSC COL/FIB/HA 
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group, suggesting potential osteoinductive effects of the COL/FIB microbeads. Calcium 
secretion, a late osteogenic marker, increased in both bmMSC and AdSC in COL/FIB 
microbeads in osteogenic media compared to growth media. There were no differences in 
calcium secretion of either bmMSC or AdSC in COL/FIB/HA microbeads in the two media 
types, presumably because these matrices already contained a large amount of exogenous 
mineral [39].  
 The modular microbead technology we have demonstrated is aimed at developing new 
minimally invasive techniques for bone repair. Fabrication of microbeads can be easily scaled up 
to create larger populations of microbeads in a controlled batch process. Cell-seeded microbeads 
can be pre-differentiated towards the osteogenic phenotype, collected, concentrated into a paste, 
and then injected into a defect site in a minimally invasive manner. The advantages of such a 
cell-based therapy are particularly important in treating recalcitrant bone wounds and non-
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Matrix Composition Regulates Three-Dimensional Network Formation 
by Endothelial Cells and Mesenchymal Stem Cells in Collagen/Fibrin 
Materials 
4.1 Introduction 
 Angiogenesis and vasculogenesis are biological processes that are vital to developing and 
regenerating tissues [1]. Vasculogenesis is the de novo formation of neovessels through the 
assembly of endothelial cells into a tube, followed by stabilization and maturation into a blood 
vessel. Angiogenesis creates new vessels via the sprouting of new capillaries from existing 
vasculature. When tissues are transplanted, these processes are critical in enabling the transport 
of nutrients and waste products and achieving integration of the transplanted tissue with the host 
vasculature [2, 3]. The field of tissue engineering has encountered a particular challenge in 
creating large tissue constructs that can be transplanted without subsequent loss of tissue 
viability, since the limit of effective diffusive transport has been suggested to be only 150-200 
µm [4]. The interior regions of large implanted tissues therefore become necrotic due to the lack 
of a functional vascular supply to provide convective transport [5]. Stimulating the rapid creation 
of a functional vascular supply by either vasculogenesis or angiogenesis is a key to maintaining 
tissue viability post-implantation [6]. 
 A number of experimental investigations have demonstrated that important aspects of 
vasculogenesis can be recapitulated in vitro [7-9]. Recent studies have focused on the 
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interactions of human umbilical vein endothelial cells (HUVEC) with stromal cells in generating 
vessel-like structures [10-12]. In such co-culture systems, stromal cells have been suggested to 
act as pericytes that provide paracrine factors to induce the formation of vessel structures and 
also stabilize neovessels by providing mechanical support [13, 14]. In vivo evidence suggests 
that the lack of a stromal cell component leads to pathological vessel formation characterized by 
hyperplasia and irregular HUVEC morphology [15, 16]. 
 Co-cultures of HUVEC and bone marrow-derived mesenchymal stem cells (bmMSC) 
have been used as a model of vasculogenesis and it has been shown that bmMSC can function as 
pericytes to promote vessel formation and maturation [17-19]. In this role, bmMSC secrete 
specific pro-angiogenic cytokines [20, 21] and control the permeability of neovessels through 
regulation of cell-cell adherens junctions [22, 23].  The ratio of HUVEC to bmMSC has been 
shown to affect cell function and capillary morphogenesis. Lower HUVEC:bmMSC ratios have 
been associated with higher cell metabolic activity in vitro, though higher ratios increase the 
proportion of CD31+ cells [24]. In vivo, lower ratios have been associated with an increased 
vasculogenic response [25], and functional prevascular networks have been observed in vivo at 
even very low (2:99) ratios [26]. Although the effect of HUVEC:bmMSC ratio is not yet clear, it 
is likely to be one of the contributing factors in determining the rate and degree of 
vasculogenesis. 
 Vasculogenesis has been studied in a variety of extracellular matrix systems in vitro. 
Collagen and fibrin are of particular interest in this context because of their prominent role as 
wound healing proteins [27, 28]. Studies in which collagen and fibrin were combined as 
composite matrices have suggested that collagen delays neovessel formation in a dose-dependent 
manner [29]. Previous work in our lab has shown that collagen/fibrin composite materials have 
71 
 
mechanical properties distinct from either of the pure components alone, even at equivalent total 
protein concentrations [30, 31]. The effects of matrix concentration and stiffness on capillary 
morphogenesis have recently been investigated using pure extracellular matrix components of 
different compositions and stiffness [32-34]. These studies have shown that the degree of 
vascularization can be modulated by the properties of the surrounding matrix, and have 
suggested an inverse relationship between matrix stiffness and the degree of neovessel 
formation.  
 In the present study, we systematically examined vasculogenesis by HUVEC-bmMSC 
co-cultures in vitro using well defined three-dimensional (3D) matrices made of collagen and 
fibrin. Our goal was to determine the relative role of cell ratio and matrix composition in a 
controlled environment that incorporated both pure and composite formulations of matrix 
proteins of relevance in wound healing. In particular, we varied the HUVEC:bmMSC ratio and 
the collagen/fibrin proportion of the surrounding matrix and quantified the degree of vessel-like 
structure formation. The mechanical properties of the extracellular matrices were assessed using 
rheometry to provide measures of the stiffness of the matrix. Our findings demonstrate that 
collagen/fibrin matrices supported vasculogenesis in vitro, but the degree of vessel-like structure 
formation was dependent on matrix composition. Further experiments in which matrix 
mechanical properties were varied revealed a clear correlation between matrix stiffness and the 
degree of vasculogenesis. These studies highlight key features of the extracellular milieu that 
regulate neovessel formation, which may provide insight into the biological process of 





4.2 – Materials and Methods 
Cell Culture 
 Human bone marrow-derived mesenchymal stem cells (bmMSC; Lonza Inc., 
Walkersville, MD) were cultured in Dulbecco’s modified Eagle’s medium (low glucose DMEM; 
Thermo Scientific; Logan, UT) supplemented with 10% bmMSC-qualified fetal bovine serum 
(FBS; Invitrogen, Carlsbad, CA) and 1% penicillin and streptomyocin (PS; Invitrogen). bmMSC 
were used between passages 6-8. Media was changed every other day. 
 Human umbilical vein endothelial cells (HUVEC) were isolated from harvested umbilical 
cords as previously described [20]. Briefly, umbilical veins were irrigated with sterile phosphate 
buffered saline (PBS) and then incubated with 0.1% collagenase (Type I, Worthington 
Biochemical, Lakewood, NJ) at 37°C for 20 min. The digestion product was collected, the vein 
was washed with PBS, and the resulting suspension was centrifuged. The cell pellet was re-
suspended in Endothelial Growth Medium-2 (EGM-2, Lonza) and plated into flasks. After 24 
hours, the cells were washed with PBS to remove residual erythrocytes. HUVEC were cultured 
in EGM-2 and used at passage 4. Culture medium was changed every other day.  
 
Fabrication of Three-Dimensional Collagen-Fibrin Gels 
 Collagen (COL) and fibrin (FIB) composite gels were fabricated as previously described 






Briefly, 4.0 mg/ml Type I COL (MP Biomedicals, Solon, OH) was dissolved in 0.02 N acetic 
acid and 4.0 mg/ml bovine fibrinogen (Sigma Aldrich, St. Louis, MO) was dissolved in DMEM. 
Cell-seeded COL/FIB composite gels were created by suspending HUVEC and bmMSC in a 
mixture with 10% FBS, 10% 5X-concentrated DMEM (starting concentration), 5% 0.1 N NaOH, 
2% bovine thrombin (0.1 UT/ml; Sigma), COL, and fibrinogen at 4°C. COL and fibrinogen 
volumes were varied to generate COL/FIB composite gels at mass ratios of 100/0 (pure COL), 
60/40, 50/50, 40/60, and 0/100 (pure FIB) at a constant total protein concentration of 2.5 mg/ml. 
1X-concentrated DMEM was used to fill the final volume to 100%. The suspension was then 
pipetted into a 24-well plate and allowed to gel at 37°C for 45 min. The resulting gels contained 
homogenously distributed HUVEC and bmMSC embedded directly within the protein matrix. 
Cells were embedded in the gels in all five COL/FIB concentrations at HUVEC:bmMSC ratios 
of 5:1, 3:2, 1:1, 2:3, and 1:5. The total cell concentration of all gels was kept constant at 6.0×105 
cells/ml. After fabrication cell-seeded gels were cultured for 7 days at 37 °C and 5% CO2. 
Figure 4.1 – Schematic of composite matrix fabrication and parameters varied in experimental design.
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 The first experimental series examined the effects of cell ratio and relative matrix 
composition using the parameter described above. In subsequent studies, a cell ratio of 1:1 
HUVEC-bmMSC and a matrix composition of 40/60 COL/FIB were used. The effect of total 
protein concentration on vasculogenesis was evaluated by creating COL/FIB gels with total 
protein concentrations of 1.25 mg/ml, 2.5 mg/ml, and 5.0 mg/ml using a stock collagen solution 
of 4.0 mg/ml and stock fibrinogen solutions of 4.0 and 20.0 mg/ml. To examine the effect of 
matrix stiffness independently from matrix concentration, the small dialdehyde glyoxal was used 
to crosslink 40/60 COL/FIB composite gels. Glyoxal was added at 1.0 mM directly to the pre-
gelled matrix solution containing 1:1 HUVEC:bmMSC and gelation was initiated by incubating 
the mixture at 37°C for 45 minutes. Gels were then washed three times for 10 minutes each in 
PBS to remove unreacted glyoxal and medium was added.  
 
Vasculogenesis Assay 
 HUVEC were labeled with a fluorescent protein (mCherry; Clontech, Mountain View, 
CA) as previously described to allow visualization and quantification of vessel-like networks 
[17]. A retroviral expression system (Orbigen Inc., San Diego, CA) was used to achieve stable 
expression of the mCherry gene by HUVEC. At days 1, 3, 5, and 7 post-fabrication, gels were 
imaged on a fluorescent microscope system (Olympus America Inc., Center Valley, PA). Five 
representative images of each sample were taken at each time point. The images were analyzed 
using the Angiogenesis Module in Metamorph Premier software (Molecular Devices Inc., 
Sunnyvale, CA) as previously described [20]. Minimum width, maximum width, and intensity 
over background were set to discriminate vessel-like structures within the images. The total 




Confocal Imaging of HUVEC, bmMSC, and Matrix Architecture 
To determine the relative positions of the different cell types in 3D composite matrices, 
bmMSC were retrovirally transduced to achieve expression of GFP, using the same methods as 
for mCherry transfection (Orbigen Inc., San Diego, CA), and were co-embedded with mCherry 
labeled HUVEC. Images were acquired using a laser scanning confocal microscope (Olympus 
America Inc., Center Valley, PA). Separate image scans were taken to identify the HUVEC and 
bmMSC, and these sections were combined to determine co-localization of the cell types. Image 
scans were captured in a horizontal plane containing vessel-like structures. Images of the matrix 
architecture were obtained using confocal reflectance microcopy at a wavelength of 488 nm. 
These images are included in the Supplementary Data 4.5. 
 
Cell Viability and Proliferation 
 Cell viability was assessed using a vital staining kit (Live/Dead®, Molecular Probes, 
Eugene, OR) as previously described [35]. Briefly, gels were washed three times in sterile PBS 
for 10 min and then incubated at 37°C for 45 min in a solution containing 4.0 µm calcein-AM 
and 4.0 µm ethidium homodimer-1 in PBS. After three subsequent PBS washes, gels were 
imaged using a laser scanning confocal microscope (Olympus). Viability was quantified using 
ImageJ software (National Institute of Health, Bethesda, MD). 
 To quantify cell proliferation during the culture period, the total DNA content of gels was 
determined and run against a standard curve. Gels were washed three times in phosphate 
buffered saline for 10 minutes per wash and were then extracted using 4.0 M guanidine 
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hydrochloride solution. DNA analysis was performed on samples at days 0, 1, 3, and 7 of culture 
using a commercially available DNA assay (PicoGreen®, Invitrogen Inc.). 
 
Gel Rheology 
 The mechanical properties of acellular COL/FIB composite gels were determined by gel 
rheometry (AR-G2, TA Instruments, New Castle, DE) [36]. Pre-mixed COL/FIB matrix 
solutions were loaded onto a Peltier stage precooled to 10 °C. A 20 mm steel parallel plate was 
used at a gap height of 1000 µm. A temperature ramp over 2 minutes was performed to raise the 
temperature of the system to 37°C. A time sweep was then conducted for 45 minutes at 37°C at 
1% strain and at an oscillation frequency of 1 radian/second to simulate the gelation conditions 
used in the vasculogenesis assay. Reported storage (G’) and loss (G’’) moduli were generated 
from the average of the last 5 minutes of the time sweeps. 
 
Statistical Analysis 
 All quantitative analyses were processed using a one-way Analysis of Variance using 
Tukey’s post-hoc analysis. Statistical significance was set at p < 0.05. Numerical values are 
presented as mean +/- standard deviation; n = 3 for HUVEC-bmMSC cell ratio vasculogenic 
assays, n = 4 for cell proliferation studies, n = 5 for all rheological data, n = 4 for protein 
concentration and glyoxal vasculogenic assays, and n = 4 for cell viability studies. 
4.3 - Results 
Effect of Matrix Composition 
 COL/FIB composite matrices were fabricated at COL/FIB compositions of 100/0, 60/40, 
50/50, 40/60, and 0/100. Figure 4.2 shows representative images of these materials seeded with 
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cells at a 1:5 HUVEC-bmMSC ratio (panels A-E) and examined after 7 days in culture. In 
general, the degree of vessel-like network formation clearly increased with increasing fibrin 
content in the composite gels. Figure 4.2F shows quantification of the total network length over 
time in culture. The trend for increased network development over time is evident and all five 
matrix compositions showed significantly higher values (p<0.05) of both total network length 
and the number of segments at day 7 compared to day 1. By day 7, the length for all composite 
matrix compositions were significantly higher than the pure collagen (100/0) group. At day 7 the 
pure fibrin (100/0) group had statistically higher values (p < 0.05) of network length compared to 
the 60/40, 50/50, and 0/100 matrix compositions. However, there was no statistical difference in 





 Figure 4.2G shows quantification of the number of network segments in each of the 
matrix compositions over time.  These data closely mirror the total network length data, 
indicating that the vessel-like networks grew through branching and joining, as opposed to 
simple elongation of existing vessel segments. This trend of network growth via branching and 
joining of segments was evident in all of the samples analyzed (see Supplementary Data Figures 
4.1-4.4). 
 
Effect of Cell Ratio 
 Figure 4.3A shows vasculogenesis data at day 7 for all five matrix compositions and all 
five HUVEC:bmMSC ratios investigated.  
500 µm
A) B) C) D) E)
F)
Figure 4.2 - Images of vessel- like structures in COL/FIB matrices of indicated composition at an
HUVEC:bmMSC ratio of 1:5. Vessel- like structure formation showed a positive correlation with
increasing fibrin content. (A-E) Representative images of vessel- like structures in COL/FIB matrices of
indicated composition at an HUVEC:bmMSC ratio of 1:5. (F) Quantification of total network length in
each of the matrix compositions over time in culture




The trend of increasing network formation with increasing fibrin content is evident in these data 
as well. Within each matrix composition, the 5:1 HUVEC:bmMSC ratio resulted in the lowest 
values for total network length relative to all other cell ratios. In the 100/0, 50/50, and 0/100 
compositions, the 3:2 HUVEC:bmMSC ratio resulted in significantly greater values of total 
network length, compared to the other cell ratios. In general, there was no marked difference in 
vessel-like structure formation between the 1:1, 2:3, and 1:5 HUVEC:bmMSC ratios. Figure 
4.3B shows the total network length as a function of matrix composition, using data pooled 
across all cell ratios, and indicates significant differences caused by altered protein content. 
A full panel of experiments was performed, which included each of the five matrix 
compositions seeded with each of the five cell ratios, and analyzed at each of the four time 
points.  Figures 4.2 and 4.3 summarize the trends that were observed across all samples, and the 
Figure 4.3 – Network length of all cell ratios and all matrix compositions. Total length
measurements positively correlated with increasing fibrin content. (A) Total network
length as a function of matrix composition at all five cell rations investigated at day 7










remainder of the full data set is presented in Supplemental Figures 4.1-4.4. In the 2:3, 1:1, and 
3:2 HUVEC-bmMSC samples, the trends of increasing vessel formation with time and with 
increasing fibrin content were maintained. However, in the 5:1 HUVEC-bmMSC samples the 
degree of vasculogenesis was markedly lower across all matrix compositions. Although vessel-
like structures formed rapidly at this cell ratio, the network did not continue to expand, but 
instead retracted over time. In general, the pure fibrin (0/100) matrices resulted in significantly 
more (p<0.05) vessel-like structure formation compared to the 100/0, 60/40, and 50/50 matrix 
compositions. However, the 0/100 and 40/60 were similar in their behavior. Overall, it was clear 
that time and matrix composition had a greater effect on vasculogenesis than HUVEC:bmMSC 
ratio. 
 These findings allowed us to narrow the set of matrix and cell formulations to be used in 
subsequent experiments. A COL/FIB composition of 40/60 was selected because it supported 
vasculogenesis to the same degree as pure fibrin, and both of these materials had the most robust 
response of the compositions tested. Similarly, an HUVEC:bmMSC ratio of 1:1 was selected 
because this cell ratio behaved similar to the other ratios in the 40/60 matrix. The selection of a 
single construct formulation facilitated the extension of our studies without requiring all 









Cell Interactions and Proliferation 
 
 Distinct labeling of HUVEC and bmMSC using different fluorescent labels allowed the 
examination of the spatial relationships between the cell types in 3D COL/FIB materials, as 
shown in Figure 4.4. Panel A shows extended HUVEC and panel b shows bmMSC clustering at 
day 7 in culture. Overlay of these images (panel C) shows very clear association of bmMSC with 





Figure 4.4 - Characterization of cell-seeded 40/60 COL/FIB constructs with 1:1
HUVEC-bmMSC ratio. Both cell types were co- localized after 7 days in culture
indicating a peri-endothelial interactions. Embedded cells proliferated during the
7 day culture period. (A-C) Co-localization of bmMSC and HUVEC. (D) Cell





 Figure 4.4D shows the total DNA extracted from cell-seeded composite matrices, which 
was used as a measure of cell number and proliferation over the 7 day culture period. The 
number of cells increased significantly day 0 (post-gelation) to day 1, and then plateaued from 
day 1 to 3. Significant cell proliferation was again evident between day 3 and day 6, and overall 
the cell content of the gels increased by about 70% over the 7 day period.  
 
Mechanical Properties of COL/FIB Materials 
 To evaluate the effect of material properties on vasculogenesis, the shear moduli (storage 
and loss modulus) of the COL/FIB composite gels were evaluated at all five matrix 
compositions. Representative time sweeps are shown in Figure 4.5A and revealed distinct 
gelation curves for the pure and composite materials. Pure collagen (100/0) gelled rapidly and 
the modulus rose sharply, followed by a gradual decrease in modulus over time until it plateaued. 
Pure fibrin (0/100) had a delayed gelation response and then gelled to reach a plateau modulus. 
The mixed composites had intermediate behavior, which depended on their composition. The 
average moduli of gelled materials are presented in Figure 4.5B, which shows that gel stiffness 
as represented by the storage modulus (G’) decreased with increasing fibrin content. The 100/0 
composition was significantly stiffer than the other materials. The 40/60 and the 100/0 
compositions exhibited very similar mechanical properties. Figures 4.5C shows the correlation 
between total network length and matrix stiffness, and suggests an inverse linear relationship 
between these parameters (R2 = 0.92). 
 The loss modulus (G”) was also calculated from the dynamic testing data, and generally 
followed the same trends as the storage modulus. This parameter provides a measure of the 
viscoelastic nature of the hydrogels, and reflects the amount of viscous energy dissipation under 
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dynamic conditions. We did not include this parameter in our interpretation of network formation 
in different materials, since the 3D gels were cultured under static conditions, in which viscous 







Figure 4.5 - Gel rheometry for COL/FIB matrices. Storage modulus measurements decreased
with increasing fibrin content. (A) Representative gel rheometry time sweeps for COL/FIB
matrices. (B) Average storage (G’) and loss (G’) moduli for COL/FIB matrices. (C, D)
Correlations between formation of vessel-like structures and material stiffness
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Effect of Protein Concentration 
 The observed relationship between matrix stiffness and extent of vessel-like structure 
formation led us to further investigate this effect. To this end 40/60 COL/FIB gels were created 
at total protein concentrations of 1.25 mg/ml, 2.50 mg/mL and 5.00 mg/ml, to alter overall 
matrix stiffness while keeping the COL/FIB ratio constant. The rheological properties and 
associated vasculogenesis data at 1:1 HUVEC:bmMSC for these materials are shown in Figure 
4.6. The gelling curves in panel a show that protein concentration affects the mechanical 
properties of these composites. The 1.25 mg/ml gels had a storage modulus of 11±4 Pa, which 
increased to 56±8 Pa (p<0.03) at 2.50 mg/ml, and to 222±37 Pa (p<0.001) at 5.00 mg/ml, and the 
loss moduli followed a similar trend. Representative images of vasculogenesis in these materials 
at day 7 are shown in Figures 4.6C-E and network length is quantified in Figures 4.6f. There was 
no statistical difference between the 1.25 mg/ml and the 2.50 mg/ml materials at any time point. 
However, the 5.00 mg/ml materials exhibited dramatically decreased formation of vessel-like 
structures, relative to the lower concentration matrices at all time points (p<0.05). We observed a 
significant increase in cell proliferation at day 7 in the 5.00 mg/ml COL/FIB group compared to 








1.25 mg/ml 2.5 mg/ml 5.0 mg/ml
F) G)
500 µm
Figure 4.6 - Effect of total protein concentration on vasculogenesis in 40/60 COL/FIB matrices.
Increasing total protein content from 2.5 mg/ml to 5 mg/ml significantly decreased network
formation during the 7 day culture period. (A) Representative gel rheometry time sweeps. (B)




Effect of Glyoxal Crosslinking 
 Another approach to changing the mechanical properties of protein gels without altering 
the overall composition is to crosslink the matrix. To this end we used glyoxal, a small 
dialdehyde that crosslinks free amine groups, to stiffen 40/60 COL/FIB composite gels. The 
rheological properties and associated vasculogenesis data for these materials seeded with 1:1 




Treatment with glyoxal altered the gelation dynamics (panel 4.7A) and resulted in an 
approximately 2-fold increase in the storage moduli (panel 4.7B) of gels with otherwise identical 
composition. Vessel-like structures formed in both untreated control and crosslinked gels (panels 
A) B)
Day 1 Day 7
Control 1.0 mMC) D) E) F)
500 µm
G) H)
Figure 4.7 Effect of glyoxal crosslinking on vasculogenesis in 40/60 COL/FIB matrices. Crosslinking
40/60 COL/FIB matrices with 1 mM glyoxal led to a decrease in network formation after 7 days in
culture. (A) Representative gel rheometry time sweeps. (B) Storage and loss moduli. (C-F)




4.7C-4.7F), but crosslinked materials exhibited significantly lower values of both total network 
length by day 7 (panels 4.7G). Cell viability was assessed in both control and crosslinked gels, as 
shown in Figure 4.8.  
  
Figure 4.8 - Cell viability in 3D constructs after glyoxal
treatment. The addition of 1 mM glyoxal to the COL/FIB
hydrogels did not alter cell viability after 1 or 7 days in culture.
(A-D) Representative images on days 1 and 7 of culture. (E)














Viability was high in all samples at both day 1 and day 7 (panels 4.8A-4.8D), and there was no 
significant difference in viability between treatments at either time point (panel 4.8E). There was 
a significant decrease in cell number of HUVEC and bmMSC co-cultures at day 1 between 
control and glyoxal-crosslinked gels, but there were not a significant difference in cell number at 
day 7 (Supplemental Figure 4.6B). HUVEC alone COL/FIB composite gels were investigated to 
further evaluate the effect of glyoxal crosslinking on HUVEC. There was a significant decrease 
in DNA content from day 0 in both the control and glyoxal conditions, but there were no 
differences between the two conditions at days 1,3, or 7 (Supplemental Figure 4.7C). Vessel-like 
structures were not formed in either the control or glyoxal condition indicating the importance of 
the stromal cell the co-culture system (Supplemental Figure 4.7A,B). 
  
4.4 - Discussion 
 This series of studies examined the effects of material composition, HUVEC:bmMSC 
ratio, and matrix stiffness on vasculogenesis in a well-defined, three-dimensional in vitro model. 
The relative amounts of collagen and fibrin in the matrices were shown to have a marked effect 
on the formation of vessel-like networks in COL/FIB materials. In particular, the degree of 
vasculogenesis clearly increased in a dose-dependent manner with increasing fibrin content. 
While it is well established that both the extracellular matrix and the presence of stromal cells 
can modulate vasculogenesis, the interaction between these factors and in particular the effects of 
matrix type and density on the vasculogenic response are not fully understood. Earlier studies 
that used collagen and fibrin in vasculogenesis assays showed that these proteins can affect 
neovessel formation [30, 15, 37], however the properties of the matrix that produce these effects 
are still being elucidated. The present study used compositionally defined 3D composite 
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materials to further contribute to our understanding of how these biologically active and 
structurally important wound healing proteins can regulate neovessel formation. 
 The communication between HUVEC and stromal cells is an area of increasing 
importance in a variety of fields [20, 24], and therefore we examined the effect of varying the 
HUVEC:bmMSC ratio on the degree of vasculogenesis. The chosen HUVEC:bmMSC fractions 
were varied from 1:5 to 5:1 to cover a relatively wide range of ratios, while the total cell 
concentration was kept constant. Interestingly, the group with the highest relative fraction of 
HUVEC (5:1) exhibited the lowest vasculogenic response over a week in culture in all five of the 
tested matrix compositions. Although this cell ratio supported rapid formation of vessel-like 
structures initially, the total length and number of vessel-like structures decreased over time in 
culture. This behavior contrasts with the other (lower) HUVEC:bmMSC ratios examined, which 
exhibited steadily increasing network length over time. These results highlight the importance of 
pericyte-like cells in promoting and stabilizing nascent structures. In addition, clear co-
localization of HUVEC and bmMSC was observed when both cell types were labeled and 
imaged, further suggesting peri-endothelial interaction between the two cell types. These 
associations between endothelial and stromal cells have been shown to be important for stable 
neovessel formation in other recent studies [14, 17].  
 The 40/60 COL/FIB material seeded with 1:1 HUVEC:bmMSC was selected for further 
study because it exhibited the highest degree of vasculogenesis. This composition was 
statistically the same as pure fibrin in this regard, however in some applications a composite 
matrix may have advantages over a pure material. For example, the use of composite matrices 
has become more common in tissue engineering applications in order to harness both the 
mechanical and biochemical properties of such materials [30, 38]. The 1:1 HUVEC:bmMSC 
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ratio was statistically similar to the other ratios that showed robust vasculogenesis. Assessment 
of DNA content in the composite materials over time showed that cell number increased initially, 
followed by a plateau phase, and a subsequent second phase of cell growth. Cell proliferation is 
important to the vascular extension and maturation process. In this study, we were not able to 
distinguish between DNA contributed by HUVEC and that contributed by bmMSC. However, 
the initial growth phase may reflect proliferation of HUVEC, which have been shown to be 
capable of rapid division in response to mitogen stimulation [39]. The later growth phase may 
reflect either continued HUVEC division to extend vessels or may be due to proliferation of 
bmMSC, which may grow more slowly as they establish pericyte function [40]. 
 Rheological analysis showed that the mechanical properties of the COL/FIB composite 
materials varied with composition. In particular, the pure collagen materials were the stiffest and 
the pure fibrin materials were the least stiff, with the stiffness of composite materials falling in 
between the pure materials. A clear inverse relationship existed between matrix stiffness and 
degree of vessel-like structure formation. These findings agree with those of other recent studies 
that have examined the role of matrix compliance in the formation of neovasculature in vitro and 
in vivo [33, 34], which have suggested that vasculogenesis is inhibited in stiffer matrices. In the 
present study, we further investigated the role of matrix stiffness in modulating vasculogenesis 
by performing studies on 40/60 COL/FIB materials fabricated at a range of total protein 
concentrations. The resulting materials varied in stiffness in direct relation to the total protein 
content. The stiffest materials (5.00 mg/ml) exhibited about a 4-fold increase in storage modulus 
relative to the standard 2.50 mg/ml materials, and showed a correspondingly decreased 
vasculogenic response. In contrast, the least stiff materials (1.25 mg/mL) exhibited a storage 
modulus only about one fifth of the standard 2.5 mg/ml materials, but showed no statistical 
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difference in the formation of vessel-like structures. These results provide further evidence that 
matrix stiffness may be involved in modulating vasculogenesis, but also suggest that there may 
be a minimum stiffness below which the effect is no longer evident. 
 Increasing the total protein concentration in gel matrices does not alter the stiffness 
independently of all other factors that may affect cell function, since increased protein content 
can also lead to changes in adhesive ligand density and porosity of the matrices. Analysis of 
matrix architecture using confocal reflectance microscopy verified that the matrix architecture 
varied with both changing matrix composition and concentration (see Supplemental Figure 4.5).  
In an attempt to further isolate the effects of stiffness the protein matrices were crosslinked with 
glyoxal, a small dialdehyde that we have used previously to increase the mechanical properties 
of protein matrices without adversely affecting the viability of embedded cells [35]. Glyoxal 
crosslinking induced a two-fold increase in storage modulus in the 40/60 COL/FIB matrix 
composition with a resulting decrease in total network length at day 7. However confocal 
reflectance imaging showed that the matrix structure was also changed by crosslinking, though 
the effect was relatively modest. Viability staining confirmed that the decrease in vasculogenic 
response was not due to cell death. Cell proliferation quantification also confirmed that the 
decrease in vasculogenic response was not due to cell death. These data further support the idea 
that increased matrix stiffness results in decreased vessel-like structure formation, though the 
effect of crosslinking on stiffness may not have been completely independent of matrix 
architecture. 
This study has demonstrated that matrix composition is a potent modulator of 
vasculogenic activity in 3D matrices containing embedded HUVEC and bmMSC. In particular, 
fibrin-containing matrices were permissive of a robust vasculogenic response, whereas matrices 
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with a high collagen Type I content resulted in decreased vessel-like structure formation. 
Importantly, composites could be created that maintained strong vasculogenic activity while also 
containing both collagen and fibrin, which may be beneficial in some applications. The ratio of 
HUVEC:bmMSC was not a strong modulator of the vasculogenic response, although high 
HUVEC:bmMSC ratios (5:1) resulted in unstable vessel formation. The clear correlation 
between matrix stiffness and the vasculogenic response suggested that mechanical properties 
may be important in modulating vessel formation, and follow-up experiments in which stiffness 
was varied provided supporting evidence for this idea. However, the experimental treatments 
used in this study also altered the matrix architecture, which may have lead to changes in mass 
transport, ligand density, or other parameters that could modulate vasculogenesis. Taken 
together, these results are relevant to the variety of in vitro systems that have been developed to 
study angiogenesis and vasculogenesis, and in particular those that rely on 3D protein matrices to 
simulate the tissue environment. In addition, these data are relevant to efforts to understand and 













4.5 – Supplemental Figures 
 
 
Supplemental Figure 4.1 - 2:3 HUVEC:bmMSC ratio. Vessel- like structure formation showed a
positive correlation with increasing fibrin content. (A-E) Representative images of formed vessel- like
structures on the five matrix compositions. (F,G) Quantification of the total length and number of











Supplemental Figure 4.2 - 1:1 HUVEC:bmMSC ratio. Vessel-like structure formation showed a 
positive correlation with increasing fibrin content. (A-E) Representative images of formed vessel-like 
structures on the five matrix compositions. (F,G) Quantification of the total length and number of 














Supplemental Figure 4.3 - 3:2 HUVEC:bmMSC ratio. Vessel-like structure formation showed a 
positive correlation with increasing fibrin content. (A-E) Representative images of formed vessel-like 
structures on the five matrix compositions. (F,G) Quantification of the total length and number of 











Supplemental Figure 4.4 - 5:1 HUVEC:bmMSC ratio. Vessel- like structure formation showed a
positive correlation with increasing fibrin content. (A-E) Representative images of formed vessel- like
structures on the five matrix compositions. (F,G) Quantification of the total length and number of











Supplemental Figure 4.5 – Confocal reflectance images of COL/FIB matrices. Qualitative analysis
showed alterations in the matrix architecture when the matrix composition, total protein content, and
crosslinking density were modulated. Representative confocal reflectance images of COL/FIB






Supplemental Figure 4.6 – Cell proliferation of HUVEC and bmMSC co-cultures in 40/60
COL/FIB matrices. Increasing the total protein content of the hydrogels to 5.00 mg/ml led to a
significant increase in total DNA. Crosslinking matrices with glyoxal did not alter DNA content. (A)
Effect of total protein concentration. (#) denotes statistical significance against 5.00 mg/ml. (B)
Effect of glyoxal crosslinking. (*) denotes statistical significance against control.
Supplemental Figure 4.7 – Effect of glyoxal crosslinking on cell proliferation of EC alone in 40/60
COL/FIB matrices. Cellular DNA decreased from day 0 and there were no significant changes
between the control of glyoxal conditions any time points. (A,B) Representative images on day 7 of
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Effects of Hydroxyapatite on Endothelial Network Formation 
in Collagen/Fibrin Composite Hydrogels In Vitro and In Vivo 
5.1 Introduction 
  Transplantation and engraftment of engineered tissues requires creation of a vascular 
supply, either through vasculogenesis, the de novo formation of blood vessels, or through 
angiogenesis, the creation of new vessels via sprouting from existing vasculature [1]. The 
diffusive limit for nutrient transport in most tissues has been suggested to be only a few hundred 
microns, and therefore a new vascular supply to implanted tissue must be created to provide 
convective transport to the region [2]. A variety of model systems have been created to study the 
process of vasculogenesis, including 3D systems using extracellular matrix proteins such as 
collagen, fibrin, and Matrigel® [3-6]. Previous work in our lab has shown composite 
collagen/fibrin (COL/FIB) matrices to be permissive to endothelial network formation in vitro 
when human umbilical vein endothelial cells (HUVEC) are co-cultured with bone marrow-
derived mesenchymal stem cells (bmMSC) [7]. The degree of vasculogenesis was shown to be 
dependent on HUVEC:bmMSC ratio and the composition of the matrix. 
In most studies of vasculogenesis in 3D hydrogels in vitro, volume reduction of the 
matrix is prevented by constraining the sample at its boundaries. This technique prevents 
remodeling and compaction of the matrix by the contractile forces exerted by embedded cells. 
Unconstrained gel compaction leads to increased matrix density and a concomitant increase in 
matrix stiffness [8, 9]. It is has been suggested that matrix mechanics play an important role in 
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regulating endothelial network formation. Increased stiffness has been shown to promote 
angiogenesis in some studies [10, 11], while other studies have shown an inverse relationship 
between increased matrix stiffness and neovessel growth, both in vitro and in vivo [3, 7, 12-15]. 
In addition, unconstrained gel compaction has been shown to result in the regression of 
endothelial networks in vitro [16, 17].  
Bioceramics have been included in vasculogenesis and angiogenesis models to promote 
neovessel growth both in vitro and in vivo for bone tissue engineering applications. Bioactive 
glasses are ceramics containing oxidized mineral that have been shown to be proangiogenic at 
low concentrations, presumably by increasing endothelial cell proliferation via dissolution into 
ionic components [18-22]. Similarly, hydroxyapatite (HA) is the mineral component of bone, 
and also has been examined for its ability to promote both vasculogenesis and angiogenesis. Low 
concentrations of HA have been shown to be compatible with HUVEC, and to maintain the 
prototypical morphology and biochemical markers associated with normal HUVEC function [23, 
24]. HA has also been incorporated into 3D silk scaffolds designed to promote angiogenesis [25], 
and it has been observed that production of vascular endothelial growth factor (VEGF) from 
bmMSC is increased on poly (lactide-co-glycolide)-HA composite scaffolds [26]. In addition to 
its proangiogenic biochemical effects, it has been suggested that HA can inhibit cell-mediated 
compaction of protein hydrogels by providing structural integrity to the extracellular matrix [27].    
 In the current study, we examined the addition of HA to COL/FIB composite hydrogels, 
as a means to modulate the degree of vasculogenesis by seeded HUVEC and bmMSC in both 
constrained and unconstrained model systems. Our motivation was the observation that 
vasculogenesis is inhibited in unconstrained 3D hydrogels due to matrix compaction, but that HA 
can have both proangiogenic effects and can reduce gel remodeling. We systematically added 
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HA to 3D composite hydrogels and examined vascular network formation in vitro. We also 
measured matrix compaction and the mechanical properties of the hydrogels in an effort to 
understand the relationship between construct morphology and vasculogenic response. Cell-
seeded COL/FIB/HA constructs were then implanted subcutaneously into mice to determine 
whether the effects of HA translated to changes in neovascularization in vivo. These studies 
demonstrate the use of HA in protein-based composite matrices, and contribute to our 
understanding of how vasculogenesis can be modulated in bone tissue engineering applications.  
 
5.2 Materials and Methods 
Cell Culture 
 Human umbilical vein endothelial cells (HUVEC) were harvested from umbilical cords 
as previously described [7]. Briefly, umbilical veins were irrigated with sterile phosphate 
buffered saline (PBS) and then incubated with 0.1% collagenase (Type I, Worthington 
Biochemical, Lakewood, NJ) at 37°C for 20 min. The digestion product was collected, the vein 
was washed with PBS, and the resulting suspension was centrifuged. The cell pellet was re-
suspended in Endothelial Growth Medium-2 (EGM-2, Lonza) and plated into flasks. After 24 
hours, the cells were washed with PBS to remove residual erythrocytes. HUVEC were cultured 
in Endothelial Growth Medium-2 (EGM-2; Lonza Inc., Walkersville, MD, USA) and used at 
passage 4. Human bone marrow-derived mesenchymal stem cells (bmMSC; Lonza) were 
cultured in Dulbecco’s modified Eagles medium – low glucose (DMEM; Thermo Scientific; 
Logan, UT, USA) with 10% fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and 1% 
penicillin and streptomyocin (Invitrogen) and used at passage 7. Media was changed every other 




Formation of Three-Dimensional Collagen/Fibrin/Hydroxyapatite Hydrogels 
 Collagen/fibrin (COL/FIB) composite hydrogels were created as previously described 
[7]. Briefly, bovine skin COL Type I (4.0 mg/ml; MP Biomedicals, Solon, OH, USA) was 
dissolved in 0.02 N acetic acid and bovine fibrinogen (4.0 mg/ml; Sigma Aldrich, St. Louis, MO, 
USA) was dissolved in EGM-2. Stock solutions of hydroxyapatite (HA; Sigma) were prepared at 
concentrations of 0, 12.5, 25, 50, 100, and 200 mg/ml HA in DMEM and sonicated for 1 hour 
prior to use to facilitate homogenous dispersion in hydrogels [28].  Hydrogels were formed by 
adding COL and FIB at a mass ratio of 40/60 (total protein concentration 2.5 mg/ml) to a mixture 
of 10% FBS, 10% 5X-concentrated DMEM, 5% 0.1 N NaOH, 2% thrombin (0.1 UT/ml; Sigma), 
and 10% HA in DMEM at 4ºC. The resulting final concentrations of HA in the hydrogels were 0, 
1.25, 2.5, 5, 10, and 20 mg/ml. Matrix mixtures were placed into a 24-well plate and gelled at 
37ºC for 45 minutes. Both HUVEC and bmMSC were added directly into the gel mixture at a 
ratio of 1:1 HUVEC:bmMSC and a total cell concentration of (2.4×105 cells/ml). For constrained 
culture studies, hydrogels were kept in the original 24-well plates and adhered to the walls of the 
wells. For unconstrained studies, constructs were freed from the well walls and were transferred 
to non-tissue culture treated 6-well plates. All hydrogels were cultured in EGM-2 for 7 days at 
37ºC and 5% CO2.  
 
Endothelial Network Formation Assay 
 Vessel-like structure formation was quantified as previously described [7]. Briefly, 
HUVEC were labeled through a retroviral expression system (Orbigen Inc., San Diego, CA, 
USA) to enable stable expression of a fluorescent protein (mCherry; Clontech, Mountain View, 
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CA, USA). Cell-seeded hydrogels were imaged at day 7 with a fluorescent microscope (Olympus 
America Inc., Center Valley, PA, USA). For both constrained and unconstrained hydrogels, five 
representative images were taken of each gel and analyzed using the Angiogenesis Tube Module 
in Metamorph Premier Software (Molecular Devices Inc., Sunnyvale, CA, USA). Total network 
length of vessel-like structures formed in vitro was calculated by setting a minimum width, 
maximum width, and intensity over background.  
 
Mechanical Properties Testing 
 Gel rheology was performed on acellular COL/FIB/HA hydrogels as previously 
described [7]. Briefly, pre-formed COL/FIB/HA solutions were loaded into a gel rheometer (AR-
G2, TA Instruments, New Castle, DE, USA) and a time sweep was conducted for 45 minutes at 
37ºC. The storage (G’) and loss (G’’) moduli were calculated from the final 5 minutes of the 
time sweep.  
Compressive testing was performed by placing hydrogels under uniaxial compression 
using a 1.5 mm hemispherical indenter mounted on a 50 g load cell in a Test Resources frame 
(Test Resources Inc., Shakopee, MN, USA). Samples were removed from buffer and mounted on 
a dry rubber block to prevent slipping. Each was compressed at a rate of 0.33 cm/s and force-
displacement curves were generated at a sample rate of 200 Hz. Force-displacement curves were 
truncated to less than 25% compression and the Young's Modulus (E) was determined from the 











E is the compressive Young's modulus 
F is the load measured by the load cell 
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r is the radius of the indenter 
ν is the Poisson's ratio (assumed to be 0.5)  
d is the depth of penetration measured by the linear encoder 
 
Measurement of Gel Compaction and 3-D Ultrasound Imaging 
Representative images of unconstrained hydrogels were taken using a standard CCD 
camera in manual mode with a constant exposure setting at days 0, 1, 3, 5, and 7 to qualitatively 
demonstrate gel compaction throughout the time course. Ultrasound imaging of the constructs 
was performed with a Vevo 770 (VisualSonics Inc., Toronto, Canada) using an RMV 707B 
imaging probe with a nominal 30 MHz center frequency, 15-45 MHz bandwidth (−6 dB), 12.7 
mm focal distance, and 2.2 mm depth of focus (−6 dB), as described previously [28]. For each 
gel, a 3D ultrasound image data containing a series of consecutive B-mode images with a spatial 
interval of 100 μm was collected. The interval between adjacent A-lines in a B-mode cross-
sectional image was 50 μm. Volumes of these gels were measured from the ultrasound images 
using a semi-automated segmentation procedure, in which an edge detection algorithm identified 
the contour of the gel in an ultrasound B-mode image. Subsequent contours in adjacent frames or 
images were drawn semi-automatically until the contours in all frames were drawn, thus 
providing the volume of the gel within the contoured region. 
 
Subcutaneous Implants  
 All animal studies were conducted in accordance with the National Institutes of Health 
Guidelines following a protocol approved by the University of Michigan Committee on Use and 
Care of Animals. Seven-week old male C.B.-17/SCID mice (Taconic Labs, Hudson, NY, USA) 
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were administered an anesthetic analgesic drug cocktail containing ketamine (95 mg/kg, Fort 
Dodge Animal Health, Fort Dodge, IA), xylazine (9.5 mg/kg, Lloyd Laboratories, Shenandoah, 
IA), and buprenorphine (0.059 mg/kg, Bedford Laboratories, Bedford, OH) via intraperitoneal 
injection. Each mouse was shaved and sterilized with Betadine®  (Thermo Fisher Scientific, 
Fremont, CA) on its dorsal surface and wiped with alcohol prior to injection. COL/FIB/HA 
constructs containing 0, 2.5, or 20 mg/ml HA and a total cell concentration of 10.0 × 106 cells/ml 
were used for the in vivo studies. Acellular constructs served as controls. Two implants per 
animal were created with gel solutions of 300 µl. After injection, animals were kept stationary 
for 5 minutes and then placed in fresh cages. 
 
Laser Doppler Perfusion Imaging 
 Mice were anesthetized as previously described and blood flow through the implant was 
imaged using laser Doppler Perfusion Imaging (LDPI; Perimed AB, Sweden) [30]. Mice were 
imaged in triplicate and a region of interest (ROI) was overlayed over the implant area to 
calculate mean perfusion through each implant. Results were calculated as fold change from 
perfusion values over the baseline (before implantation).  
 
Histology and Immunohistochemistry 
 Explants were retrieved at day 7 and then fixed in zinc-buffered formalin (Z-Fix; Anatech 
Ltd., Battle Creek, MI) overnight. Samples were sent to AML Laboratories (Baltimore, MD) for 
embedding in paraffin and sectioned into 5 µm sections. Sections were then demineralized in a 
solution of 10% ethylenediamine tetraacetic acid (EDTA; Sigma) and Z-Fix for 3 hours at 4ºC. 
Tissue sections were rehydrated, steamed in a vegetable steamer for 25 minutes in antigen 
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retrieval solution (Dako, Carpinteria, CA), and then equilibrated in Tris-buffered saline with 
Tween 20 (TBS-T; Sigma). Sections were then incubated at 4 ºC in human anti-mouse CD31 
(Dako) diluted 1:50 in TBS-T overnight and then treated with horse radish peroxidase-
conjugated anti-mouse secondary antibody. Hematoxylin and eosin (H&E) was used as a 
counterstain. 
 
Quantification of In Vivo Vessel Formation 
 Blood vessels found within the implants were quantified manually by three blinded 
observers. Ten random images per sample at 20X magnification were used to quantify the 
number of human CD-31 stained vessels (i.e. those that arose from implanted cells) as well as the 
total number of vessels within the implant region. All vessels were quantified if they displayed a 
lumen containing erythrocytes and human vessels were identified if they displayed a positive 
CD31 stain around the lumen.    
 
Statistical Analysis 
 All quantitative analyses were performed using a one-way analysis of variance test 
(ANOVA) with a protected Fisher’s Least Significant Difference post hoc test. Statistical 









Vasculogenesis in Constrained and Unconstrained COL/FIB/HA Hydrogels 
 Figure 5.1 shows representative images and quantification of endothelial network 
formation in constrained COL/FIB/HA materials after 7 days of culture. At low concentrations of 
HA (1.25 and 2.5 mg/ml), formation of vessel-like structures was similar to control constructs (0 
mg/ml HA). However, higher concentrations of HA (5, 10, 20 mg/mL) inhibited vascular 
network formation. Quantification of total network length in these samples showed no significant 
differences between the 0, 1.25, and 2.5 mg/ml conditions, but a statistically significant decrease 




Figure 5.1: Endothelial network formation in constrained COL/FIB/HA composite hydrogels at day
7. Network formation was similar in COL/FIB/HA hydrogels containing 1.25 and 2.5 mg/ml HA
compared to COL/FIB hydrogels. Upper panels show representative images of network structures in
COL/FIB matrices at indicated HA concentrations. Graph shows quantification of total network
length at each HA concentration. *Statistical significance (p<0.05) against 0 mg/ml (pure
collagen/fibrin).
500 µm
0 mg/ml 1.25 mg/ml 2.5 mg/ml










Figure 5.2: Endothelial network formation in unconstrained COL/FIB/HA composite
hydrogels at day 7. Network formation was recovered in COL/FIB/HA hydrogels
containing 1.25 and 2.5 mg/ml HA. Upper panels show representative images of network
structures in COL/FIB matrices at indicated HA concentrations (both entire construct and
magnified subsections are presented). Graph shows quantification of total network length





5 mg/ml 10 mg/ml 20 mg/ml
0 mg/ml 1.25 mg/ml 2.5 mg/ml
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 Endothelial network formation in unconstrained COL/FIB/HA hydrogels after 7 days in 
culture is presented in Figure 5.2. Images of entire constructs, as well as magnified regions of 
each construct type are shown in order to clearly show the extent of vasculogenesis in these 
compacted gels. Endothelial network formation was dramatically reduced in constructs without 
HA (0 mg/ml), but addition of low concentrations of HA (1.25 and 2.5 mg/ml) lead to a recovery 
of vascular networks. Similar to the constrained hydrogels, there was a marked decrease in 
endothelial network formation in the hydrogels containing high concentrations of HA (5, 10 and 
20 mg/ml). Quantification of total network length in these samples confirmed that the 1.25, and 
2.5 mg/ml conditions were statistically greater than controls, whereas the 5, 10, and 20 mg/ml 
HA groups were not statistically different from controls. Notably, the degree of vessel formation 




 Representative images of COL/FIB/HA hydrogels at day 0 (immediately after gelation) 
and at day 7 in unconstrained culture are shown in Figure 5.3. At the initial time point (day 0) all 
constructs are essentially the same size because cell-mediated compaction has not yet occurred. 
However, by day 7 the constructs have reduced their volume to varying degrees, depending on 




Figure 5.4 shows high resolution three-dimensional volume renderings and two-dimensional 
sections of constructs at day 7, obtained through non-invasive ultrasound imaging. Control 
constructs without HA (0 mg/ml) compacted strongly, and the degree of compaction generally 
decreased with increasing HA content. Quantification of construct volume from rendered 
ultrasound images showed that compaction in the 1.25, and 2.5 mg/ml conditions was not 
statistically different than controls, whereas the 5, 10, and 20 mg/ml HA groups compacted 
statistically significantly less than controls. 




Figure 5.3: Compaction of COL/FIB/HA hydrogels after 7 days of culture. Images of COL/FIB/HA constructs in




Mechanical Properties of COL/FIB/HA Hydrogels 
 Figure 5.5 shows mechanical properties data for COL/FIB/HA hydrogels, including the 
storage moduli at day 0 as determined by gel rheology, and the elastic moduli at day 7 as 
2D 
3D
Figure 5.4: Ultrasound imaging and volumetric analysis of compacted COL/FIB/HA matrices.
Images showing 2D sections (upper panels) and 3D volume renderings (lower panels) of
COL/FIB/HA constructs after 7 days of unconstrained culture. Graph shows quantification of
construct volume at each HA concentration. *Statistical significance (p<0.05) against 0 mg/ml (pure
collagen/fibrin). Scale bar = 1 mm.
0 mg/ml 1.25 mg/ml 2.5 mg/ml





determined by compressive testing. At the day 0 timepoint before the gels could compact, there 
was a statistically significant decrease in the storage modulus of the hydrogels when low 
concentrations of HA (1.25 and 2.5 mg/ml) were added, compared to the control 0 mg/ml 
condition. However, at higher HA concentrations (5, 10, 20 mg/ml), the mechanical properties at 
day 0 were statistically the same as control constructs. After gel compaction had occurred (day 
7), compressive testing revealed that hydrogels containing 5 and 10 mg/ml hydroxyapatite were 
significantly stiffer than the 0 mg/ml condition, though the other conditions were not statistically 
different from controls without HA.  
 
In Vivo Implantation of COL/FIB/HA Materials 
 Three HA concentrations, 0, 2.5, and 20 mg/ml, were chosen for implantation 
experiments to evaluate the effect of HA incorporation on vascularization in vivo. Laser Doppler 
perfusion imaging (LDPI) allowed for non-invasive quantification of blood perfusion throughout 
each implant at days 0 (immediately after implantation), 3, and 7, as shown in Figure 5.6. 
Perfusion to implants was increased significantly compared to baseline values in all conditions at 
Figure 5.5: Mechanical property measurements of COL/FIB/HA matrices. Left graph shows average storage
(G’) moduli measured at the time of gelation. Right graph shows average elastic moduli of compacted gels
measured after 7 days of unconstrained culture. *Statistical significance against 0 mg/ml HA (pure
collagen/fibrin).
Elastic Modulus at Day 7Storage Modulus at Day 0
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both days 3 and 7. However, there were no significant differences between the implants 
containing HA and those without. 
 
 Representative human CD31 and H&E stained sections from cellular implants are shown 
in Figure 5.7. In all samples, numerous capillaries containing erythrocytes were evident 
throughout the implant site. Mononuclear inflammatory cells were present in all three conditions 
suggesting a potential inflammatory reaction to the implanted materials. Further, free 
erythrocytes were located throughout the implant region, particularly in the lower HA containing 
hydrogels. There was also a rich supply of small, positively-stained human capillaries within all 
Before Implant
Figure 5.6: Laser Doppler perfusion imaging (LDPI) of implanted COL/FIB/HA materials. Blood
perfusion was above baseline and similar in all conditions at all time points.Images show LDPI heat
maps indicating degree of perfusion at day 7. Graph shows quantification of mean perfusion at
indicated HA concentrations. *Statistical significance against 0 mg/ml (pure collagen/fibrin);











of the HA conditions. Quantification of both the number of human vessels and the total number 
of vessels within the implant area yielded no significant differences between the three implanted 
conditions (0, 2.5, and 20 mg/ml). In contrast, acellular control constructs with the same amounts 
of HA demonstrated no capillary formation and therefore vessel number was not quantified 
(Supplemental Figure 5.1). 
 
0 mg/ml 2.5 mg/ml 20 mg/ml
20X
60X
Figure 5.7: Histological analysis of COL/FIB/HA materials after 7 days of subcutaneous implantation in
the mouse. There were no significant differences between the conditions after 7 days post- implantation.
Image panels show human CD31 and H&E staining at two magnifications. Arrows point to new vessels.






 COL/FIB materials are known to support vasculogenesis, and in this study we examined 
the effect of incorporating HA into the matrix on endothelial network formation. In vitro, we 
studied both constrained and unconstrained hydrogels. In constrained constructs, addition of less 
than 2.5 mg/ml HA resulted in similar levels of vasculogenesis as in COL/FIB hydrogels 
containing no HA. However, amounts of HA above 5 mg/ml were shown to be detrimental to 
vasculogenesis in constrained constructs. In unconstrained hydrogels containing no HA, vascular 
network formation was essentially abolished. Addition of low levels of HA was successful in 
rescuing the vasculogenic response, even though these hydrogels compacted to a similar degree. 
However higher HA levels were again detrimental to network formation in unconstrained 
hydrogels, in spite of diminished gel compaction. The beneficial effect of low levels of HA did 
not translate to in vivo implants, as all conditions resulted in similar degrees of both xenogeneic 
and host vasculature within the implant region.  
 The compaction of protein hydrogels is a well characterized phenomenon caused by cell 
contractile forces that result in remodeling of the extracellular matrix. This process has been 
shown to cause regression of endothelial tube assembly [16] and we observed similar anti-
vasculogenic effects in our unconstrained hydrogel studies. The addition of low concentrations 
of HA to unconstrained COL/FIB hydrogels rescued endothelial network formation to the point 
where it was statistically indistinguishable from control constrained gels without HA. The 
mechanism of action of this effect is not clear, but may be related to increased secretion of 
VEGF from bmMSC in response to the HA, increased adsorption of proangiogenic growth 
factors and cytokines to the HA, or modulation of matrix metalloproteinase activity. 
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 The relationship between the degree of vasculogenesis and the bulk mechanical 
properties of COL/FIB matrices has been previously investigated [7]. In the present study, matrix 
stiffness at day 0 was slightly reduced by the addition of low levels of HA, but these differences 
were abolished as the gel compacted. By day 7, the 5 and 10 mg/ml loading levels were more 
stiff than the control, but the other conditions were statistically the same as the control. In 
addition, quantitative assessment of construct volume using ultrasound imaging showed that low 
concentrations of HA yielded a similar degree of compaction as hydrogels without HA. 
Therefore the effect of HA does not seem to be mediated by mechanical properties or by changes 
in gel compaction, though it may have affected related factors such as matrix architecture, ligand 
binding density, mass transport, and matrix porosity.     
In vivo implantation of COL/FIB/HA composite gels showed no beneficial effect of the 
HA component on perfusion.  Perfusion values measured through LDPI increased over time in 
all implants, indicating increased blood flow relative to the pre-implant level. By day 7, human-
derived vasculature was evident in the implant site in all conditions, as indicated by vessels that 
stained positive for human CD31. Host vasculature also infiltrated the implants, suggesting 
possible pro-angiogenic properties of composite COL/FIB/HA matrices. It is interesting to note 
that while HA was not clearly beneficial to vascular network formation in vivo, neither was it 
detrimental. Even the relatively high 20 mg/ml HA level, which strongly inhibited 
vasculogenesis in vitro, showed good perfusion and neovascularization in vivo. The differences 
between in vitro and in vivo results may be due to the richer and more complex environment in 
native tissue. Resident and recruited cells such as monocytes, leukocytes, and macrophages may 
secrete cytokines and other factors that mask or overcome the effects of transplanted HA. 
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 This study has demonstrated that formation of endothelial networks in COL/FIB 
hydrogels is affected by the culture method, and in particular that unconstrained compaction of 
these matrices results in a loss of vasculogenesis. This response could be recovered in 
unconstrained matrices in vitro by the addition of relatively low concentrations of HA. However, 
the effect of HA did not translate to in vivo subcutaneous implants, which were unaffected by the 
presence of HA.  While the mechanism of HA-enhanced network formation in vitro is not clear, 
these findings have relevance to the development of biomaterials for bone tissue engineering. 
HA is used widely as an additive and as a scaffold for promoting bone regeneration. As larger 
bone defects are targeted, the concomitant creation of a vasculature as the bone heals has become 
a main goal of orthopaedic tissue engineers. Understanding the effect of HA in protein-based and 
other biomaterial systems will facilitate design of scaffolds that are effective in generating the 
desired physiological response. 
5.5 Supplemental Figures 
 
Acellular COL/FIB/HA Matrices
Supplemental Figure 5.1: Histological analysis of acellular COL/FIB/HA matrices after 7 days of
subcutaneous implantation in the mouse. No vessels were observed after 7 days post- implantation. Image
panels show human CD31 and H&E staining at two magnifications.
200 µm
50 µm
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Dual-Phase Osteogenic and Vasculogenic Engineered Tissue 
for Bone Formation 
6.1 Introduction 
 A main goal in orthopaedic tissue engineering is the regeneration of bone, and in particular to 
develop methods for improved healing of recalcitrant bone fractures and large defects. Many 
bone tissue engineering strategies aim to recapitulate the native structure of bone by combining 
cells, materials, and signaling molecules in defined architectures. The primary structural matrix 
of bone consists of a collagenous extracellular matrix mineralized by the hydroxyapatite (HA) 
[1]. Bone also contains a rich vascular supply within its structure, which is vital to maintaining 
its high metabolic demand [2]. Therefore both the osseous and the vascular components of bone 
are critical to forming functional tissue, and bone healing requires concomitant development of 
both components. This need for a blood supply to nourish newly forming bone has motivated a 
variety of approaches to engineering vascularized bone tissue. 
 Controlled delivery of multiple growth factors is one strategy to achieve regeneration of 
vascularized bone tissue, though the results have been mixed. Patel and coworkers co-delivered 
bone morphogenetic protein-2 (BMP-2) and vascular endothelial growth factor (VEGF) in an 
orthotopic rat critical size defect [3]. The dual (BMP-2 + VEGF) group exhibited significantly 
higher bone volume percentage as measured by micro-computed tomography at 4 weeks 
compared to the other conditions, but was not statistically different from the other groups at 12 
weeks. In later work by the same group, the doses of each of the growth factors were varied in an 
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attempt to reduce BMP-2 concentration while achieving comparable bone formation, however 
the co-delivery of BMP-2 and VEGF did not result in an increase in bone formation compared to 
BMP-2 alone [4]. In another study, Shah and coworkers evaluated the use of polyelectrolyte 
films to control delivery rates of BMP-2 and VEGF and demonstrated enhanced bone formation 
measured by micro-computed tomography in the dual delivery group, compared to BMP-2 alone 
at 9 weeks [5]. Similarly, genetic modification of bone marrow-derived mesenchymal stem cells 
(bmMSC) for the constitutive delivery of both BMP-2 and VEGF demonstrated enhanced 
healing in the dual group compared to either growth factor alone [6]. These studies have 
demonstrated the potential promise of dual growth factor release, but the approach is hampered 
by the complexity of controlling dosing and obtaining the needed temporal release profile [7-10]. 
 Cell-based approaches to vascularized bone tissue engineering also are being pursued [11, 
12]. Numerous studies have shown that co-culture of endothelial cells and osteogenic cells 
allows for the formation of both vascular networks and mineralized tissue post-implantation. 
Kaigler and coworkers implanted poly(lactide-co-glycolide) (PLGA) scaffolds containing a co-
culture of human microvascular endothelial cells (HMVEC) and bone-marrow derived 
mesenchymal stem cells (bmMSC) into immunodeficient mice and monitored ectopic bone 
formation over 8 weeks [13]. Total vasculature was similar in the implants containing both cell 
types (bmMSC+HMVEC) compared to the bmMSC alone, but bone formation was significantly 
higher in the dual cell condition compared to bmMSC alone. Usami and coworkers also 
demonstrated ectopic bone formation through the co-transplantation of endothelial progenitor 
cells (EPC) and bmMSC on collagen fiber meshes [14].  Both neovasculature and bone 
formation were significantly higher in the bmMSC+EPC group at 12 weeks post-implantation.  
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 Orthotopic models have also been used to demonstrate osteogenesis induced by transplant of 
multiple cell types. Grellier and coworkers delivered alginate microspheres seeded with human 
umbilical vein endothelial cells (HUVEC) and bmMSC into a femoral defect model in 
immunocompromised mice [15]. Enhanced bone regeneration was observed in the dual condition 
(bmMSC+HUVEC) compared to the bmMSC group alone. In an attempt to look at the effects of 
pre-differentiation, Tsigkou and coworkers first seeded bmMSC on PLGA scaffolds and then 
cultured the cell-seeded scaffolds for one week in osteogenic supplemented medium to induce 
differentiation [16]. The scaffold was then coated with a collagen/fibronectin hydrogel 
containing bmMSC and HUVEC and implanted subcutaneously into immunodeficient mice. 
Both perfused human vasculature and bone formation were observed after 8 weeks post-
implantation, suggesting an added benefit to pre-differentiating bmMSC prior to implantation in 




 The goal of the present study was to evaluate the effectiveness of a minimally invasive, 
injectable, dual-phase tissue engineering approach to the regeneration of vascularized bone, as 
shown schematically in Figure 6.1. Our laboratory has previously employed modular tissue 
engineering techniques to fabricate three-dimensional (3D) cell-seeded hydrogel “microbeads” 
comprised of physiologically relevant proteins and polysaccharides, and has shown that they can 
be used as microenvironments to support osteogenic differentiation of embedded bmMSC [17, 
18]. We have also shown that composite matrices formed from collagen and fibrin (COL/FIB) 
support the formation of vessel-like structures when seeded with a defined co-culture of bmMSC 
Figure 6.1 – Schematic of the design and fabrication of the dual-phase engineered tissue. Modular
bone marrow-derived mesenchymal stem cell (bmMSC) seeded within collagen/fibrin/hydroxyapatite
(COL/FIB/HA) microbeads were generated and cultured in osteogenic media for 14 days. These
microbeads were then combined within a COL/FIB matrix containing a co-culture of human umbilical
vein endothelial cells (HUVEC) and undifferentiated bmMSC. In vitro studies were performed to
investigate endothelial network formation around the osteogenic microbeads. In vivo work was
performed to monitor neovascularization and ectopic bone formation in a mouse subcutaneous model.




and HUVEC [19]. In the present work, we have combined osteogenically differentiated bmMSC-
seeded COL/FIB microbeads with a COL/FIB matrix containing both bmMSC and HUVEC. We 
performed in vitro studies to examine vessel network formation around the microbeads, and in 
vivo experiments to measure ectopic bone formation in a subcutaneous injection model in 
immunocompromised mice. The development of injectable methods to potentiate the formation 
of vascularized bone would be an important advance in tissue engineering, and would have an 
impact on a variety of clinical pathologies in which bone healing is delayed or incomplete. 
 
6.2 Materials and Methods 
Cell Culture 
 Human bone marrow-derived mesenchymal stem cells (bmMSC; Lonza Inc., Walkersville, 
MD) were cultured in Minimum Essential Media Alpha (α-MEM; Life Technologies, Grand 
Island, NY) supplemented with 10% bmMSC-qualified fetal bovine serum (FBS; Life 
Technologies) and 1% penicillin and streptomyocin (PS; Life Technologies). bmMSC were used 
between passages 6-8 with media changes every other day. Human umbilical vein endothelial 
cells (HUVEC) were isolated from umbilical cords as previously described [19]. HUVEC were 
cultured in Endothelial Growth Media-2 (EGM-2; Lonza) and used between passages 4-5. 
Culture medium was changed every other day.  
 
Formation of Osteogenic Microbeads 
 Collagen/fibrin/hydroxyapatite (COL/FIB/HA) composite microbeads were fabricated as 
previously described [18]. Briefly, bovine type I COL (MP Biomedicals, Solon, OH) was 
dissolved at a concentration of 4.0 mg/ml in 0.02 N acetic acid. Bovine fibrinogen (FIB; Sigma 
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Aldrich, St. Louis, MO) was dissolved in serum-free Dulbecco’s modified Eagle’s medium 
(DMEM; Thermo Scientific, Logan, UT) at 4.0 mg/ml clottable protein. COL and FIB were 
combined to yield a total protein concentration of 2.5 mg/ml (mass ratio 50/50) and added to a 
mixture containing 2% bovine thrombin (1 UT/ml; Sigma), 1 mM glyoxal (Sigma), 5% 0.1 N 
NaOH, 10% 5X-concentrated DMEM, 10% FBS, and 2.5 mg/ml of nano-hydroxyapatite (HA; 
Sigma) at  4°C. HA was sonicated for 1 hour prior to use to maintain homogenous distribution of 
the particles after microbead encapsulation [20]. Cells were added directly into the gel mixture to 
guarantee their uniform distribution within the microbeads. The mixture was then injected into a 
bath of 100 cSt polydimethylsiloxane (PDMS; Xiameter, Dow Corning) that was cooled to 0°C 
and stirred at 600 RPM for 5 minutes with a double-bladed impeller. The temperature was then 
increased to 37°C, inducing gelation of COL and FIB and formation of composite microbeads 
with embedded bmMSC. Collection of microbeads from the oil phase was performed by 
centrifuging the mixture at 200X g for 5 minutes and washing with phosphate buffered saline 
(PBS; Life Technologies) supplemented with Pluronic L101 (BASF, Florham Park, NJ). 
Microbeads were cultured and maintained in α-MEM supplemented with 2 mg/ml ε-amino 
caproic acid (ACA; Sigma) to prevent fibrinolysis. Media was changed every other day. 
Acellular microbeads were stained with EZBlue Coomasie reagent and visualized with a light 
microscope (Olympus America, Center Valley, PA) [18]. Acellular microbeads were also labeled 
with 5 µg/ml FITC-Fibrinogen (Life Technologies) at the time of microbead fabrication to 






Osteogenic Differentiation of Microbeads 
 Cell-seeded microbeads were induced to differentiate toward the osteogenic lineage by 
culturing the microbeads for 14 days in α-MEM supplemented with 2.0 mg/ml ACA, 50 µg/ml 
ascorbic acid 2-phosphate (Sigma), 10 mM β-glycerophosphate (Sigma), and 100 nM 
dexamethasone (Sigma). Microbeads were collected by centrifugation at 200X g for 5 minutes 
prior to the media change. 
 
Fabrication of Vasculogenic Matrix 
 Composite collagen/fibrin hydrogels were fabricated as previously described to serve as a 
vasculogenic surrounding matrix for the microbeads [19]. Both cell-seeded and acellular 
microbeads were encapsulated directly into the vasculogenic gel mixture at a ratio of 1:1 bead 
mixture:gel mixture by centrifuging the microbeads for 5 min at 200 x g and then removing the 
excess media. COL and FIB (total protein concentration of 2.5 mg/ml and a mass ratio of 40/60) 
were then added at 4°C to 2% bovine thrombin (1 UT/ml), 5% 0.1 N NaOH, 10% 5X-
concentrated DMEM, 10% FBS, and serum-free EGM-2 to bring the final volume to 100%. The 
mixture was then transferred into a 24-well plate and allowed to gel for 30 min. Four conditions 
were used throughout the study as listed in Table 6.1. For bmMSC-HUVEC co-culture 
conditions, both cell types were added into the gel mixture at 300,000 cells/ml (600,000 total 
cells/ml) at a 1:1 cell ratio. EGM-2 was added on top of the gels and cell-seeded gels were 
cultured at 37°C and 5% CO2. Media was changed every other day. A summary of the in vitro 





 At days 7 and 14, cell-seeded microbeads and hydrogels were washed twice in PBS for 5 
min/wash and then fixed in zinc-buffered formalin (Z-Fix; Anatech, Battle Creek, MI) for 10 min 
at 4°C. After two subsequent washes in PBS, embedded cells were permeabilized with 0.5% 
Triton X-100 (Sigma) in PBS for 20 min at room temperature. Gels were then washed again 
twice in PBS for 5 min/wash, and the appropriate stain was added at room temperature. Stains 
were added to 1% bovine serum albumin (BSA; Sigma) in PBS at the appropriate concentration: 
165 nM AlexaFluor 488 phalloidin (Life Technologies), 20 µg/ml rhodamine labeled Ulex 
Europaeus Agglutinin I (UEA-1; Vector Laboratories, Burlingame, CA), and 10 nM fluorescent 
DAPI (Life Technologies). Gels were then washed twice in PBS prior to imaging on a confocal 
microscope (Nikon Instruments Inc., Melville, NY).    
 
Implantation into Ectopic Model in the Mouse 
 All animal experiments were performed in accordance with the National Institutes of Health 
Guidelines and by following a protocol approved by the University of Michigan’s Committee on 
Use and Care of Animals. Male C.B.-17/SCID mice (Taconic Labs, Hudson, NY, USA) were 
anesthetized via intraperitoneal injection of a drug cocktail containing ketamine (95 mg/kg, Fort 
Dodge Animal Health, Fort Dodge, IA), buprenorphine (0.059 mg/kg, Bedford Laboratories, 
Bedford, OH), and xylazine (9.5 mg/kg, Lloyd Laboratories, Shenandoah, IA). The injection site 
Table 6.1 – In Vitro Conditions and Cell Concentrations. bmMSC – bone marrow-derived mesenchymal
stem cells, HUVEC – human umbilical vein endothelial cells.
Table 6.1. In Vitro Conditions and Cell Concentrations
COL/FIB/HA Microbeads COL/FIB Hydrogel
Blank Acellular Acellular
Vasculo Acellular 3 × 105 bmMSC/ml + 3 × 105 HUVEC/ml
Osteo 1 × 106 bmMSC/ml Acellular
Osteo + Vasculo 1 × 106 bmMSC/ml 3 × 105 bmMSC/ml + 3 × 105 HUVEC/ml
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on the dorsal surface of the mouse was then shaved and sterilized with betadine (Thermo Fisher 
Scientific, Fremont, CA) and alcohol prior to injection. Microbeads were added into the gel 
mixture at a ratio of 1:1 bead mixture:gel mixture and the total cell concentration was increased 
relative to the in vitro studies to 10.0 × 106 cells/ml for the bmMSC-HUVEC co-culture 
conditions (Osteo + Vasculo and Vasculo). A higher cell concentration was used in this phase of 
the study in order to be comparable to previous in vivo studies that have demonstrated the 
presence of transplanted perfused human vasculature [21, 22]. Table 6.2 shows a summary of the 
cell concentrations used with each condition. Two hydrogels were injected per animal with a 
final gel solution of 300 µl; mice were kept stationary for 2 minutes after injection and then 
placed in fresh cages. 
 
 
Laser Doppler Perfusion Imaging 
 Blood flow through the implant was imaged non-invasively using laser Doppler perfusion 
imaging (LDPI; Perimed AB, Sweden) [21]. After sedation as previously described, mice were 
imaged in triplicate. A region of interest (ROI) was drawn over the implant area and the mean 
perfusion through each implant was calculated. Results are represented as fold change from 
perfusion values before implantation (baseline).  
 
 
Table 6.2 – In Vivo Conditions and Cell Concentrations. bmMSC – bone marrow-derived mesenchymal stem
cells, HUVEC – human umbilical vein endothelial cells.
Table 6.2. In Vivo Conditions and Cell Concentrations
COL/FIB/HA Microbeads COL/FIB Hydrogel
Blank Acellular Acellular
Vasculo Acellular 5 × 106 bmMSC/ml + 5 × 106 HUVEC/ml
Osteo 1 × 106 bmMSC/ml Acellular
Osteo + Vasculo 1 × 106 bmMSC/ml 5 × 106 bmMSC/ml + 5 × 106 HUVEC/ml
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Micro-Computed Tomography (µCT) Imaging 
 Ectopic bone formation was measured using Micro-Computed Tomography imaging (µCT; 
µCT100 Scanco Medical, Bassersdorf, Switzerland). Explanted tissues were first embedded in 
1% agarose and placed in a 34 mm diameter tube and scanned over the entire length of the 
specimen. Scan settings were set to voxel size 15 µm, 55 kVp, 109 µA, 0.5 mm AL filter, and 
integration time 500 ms. Analysis of the bone volume (BV) and tissue mineral density (TMD) of 
each sample was performed using the manufacturer’s software, and a fixed global threshold of 
16% (160 on a grayscale of 0–1000) was used to segment bone from non-bone. 
 
Histology 
 Harvested samples were paraffin embedded, sectioned, and stained with hematoxylin and 
eosin (H&E) and Von Kossa at the Histology Core Facility at the University of Michigan Dental 
School. Human cell staining was performed using a human UEA-1 staining kit per 
manufacturer’s instructions (Vector Laboratories). Total vessel density was quantified by 
manually quantifying representative images of each sample in five distinct areas of the implant. 
Vessels were defined as structures with lumens containing erythrocytes.    
 
Statistical Analysis 
 All values are presented as mean +/- standard deviation. N = 5 samples for in vivo samples. 
Statistical significance was set to p < 0.05 and was determined by a one-way analysis of variance 






Dispersion of Microbeads within COL/FIB Hydrogels 
 Figure 6.2 shows acellular COL/FIB/HA microbeads in suspension (Figure 6.2A) and 
fluorescently-labeled acellular COL/FIB/HA microbeads dispersed within COL/FIB hydrogels. 
A maximum projection reconstruction of sequential confocal images over 100 µm showed 
homogenous distribution of microbeads in the XY-plane without aggregation over the imaged 
area (Figure 6.2B). A 3D reconstruction of the corresponding Z-stack also showed distribution of 
microbeads in the Z-axis (Figure 6.2C).   
 
Formation of Endothelial Networks around Microbeads In Vitro 
 The generation of vessel-like structures at Day 14 around COL/FIB/HA microbeads 
embedded in COL/FIB hydrogels is shown in Figure 6.3. The locations of microbeads are 
indicated by “MB” in the image. Ulex Europaeus Agglutinin I (UEA-1), a human endothelial cell 
marker, was used to stain vessel networks. Phalloidin served to label the actin cytoskeleton of 
both the bmMSC and HUVEC, and DAPI showed the nuclei of all cells. Both the Vasculo and 
Osteo + Vasculo conditions treatments showed clear evidence of the formation of vessel-like 
structures after two weeks in culture, as evidenced by positive UEA-1 staining. Co-localization 
Figure 6.2 – Acellular COL/FIB/HA microbeads and COL/FIB/HA microbeads embedded within a
COL/FIB hydrogel. Microbeads remained homogenously dispersed within the outer hydrogel after
gelation. Light micrograph (A) and fluorescent images (B,C) of acellular COL/FIB/HA microbeads.









of bmMSC and HUVEC was observed in both of these conditions (positive staining for actin and 
UEA-1 indicates HUVEC, whereas positive actin stain not associated with UEA-1 indicates 
bmMSC). The co-localization of the two cell types in vitro suggests peri-endothelial interaction 
between the two cell types in the composite hydrogel. Neither the Blank (acellular) nor the Osteo 
condition exhibited positive UEA-1 staining or vessel-like structures. 
 
Figure 6.3 – Vessel- like structure formation around microbeads. Acellular (Blank,
Vasculo) and osteogenically differentiated bmMSC-seeded microbeads (Osteo, Osteo
+ Vasculo) were embedded within acellular (Blank, Osteo) or bmMSC-HUVEC
(Vasculo, Osteo + Vasculo) composite COL/FIB hydrogels and cultured for 14 days.
Vessel- like structure formation was observed in the conditions containing HUVEC.
The actin cytoskeleton of both cell types is labeled in green, human UEA-1, an
endothelial cell marker, is labeled in red, and cell nuclei are labeled blue. The
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Neovascularization of Osteogenic-Vasculogenic Constructs In Vivo 
 Subcutaneous injection of osteogenic microbeads suspended in vasculogenic matrix was used 
to evaluate the degree of both neovascularization and ectopic bone formation generated by 
implanted hydrogels. Laser Doppler perfusion imaging (LDPI) provided non-invasive 
measurements of blood flow throughout the implant over the 8 week time course (Figure 6.4). A 
baseline of vascular perfusion was taken before implantation and used to normalize all values at 
all time points. Perfusion was significantly higher (p < 0.05) in all conditions at both 1 and 4 
weeks post-implantation, compared to the pre-implant baseline. At 8 weeks post-implantation, 
perfusion values in all conditions except the Vasculo samples remained significantly higher than 
the baseline, indicating constant perfusion through the implant site. There were no significant 
differences in perfusion between any of the conditions at any of the time points except between 
the Vasculo and Osteo conditions at 8 weeks. 
 
Figure 6.4 – Laser Doppler Perfusion Imaging. There were no significant differences between any
of the conditions at 1 or 4 weeks. At 8 weeks, the Vasculo only group was not significantly different
than the baseline. Representative photographs of mice (A,B) and heat maps (C,D) corresponding to
perfusion through the implants at 8 weeks. (E) Quantification of mean perfusion normalized to
before implant. *Statistically significant (p<0.05) vs. perfusion before implantation. #Statistically










 Histological analysis of explanted tissues was also used to examine the degree of 
vascularization and neovessel formation. Vessel density was quantified at both 4 and 8 weeks 
and showed no significant differences between any of the conditions at either time point (Figure 
6.5). The transplantation of bmMSC-HUVEC co-cultures did not enhance the degree of 
vascularization compared to the control Blank (acellular) condition or to the Osteo alone group. 
Further, there was little evidence of positive staining for human UEA-1 in the Osteo + Vasculo 
and the Vasculo conditions at 4 weeks (Figure 6.6).  
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Figure 6.5 – Total vessel density quantification at 4 and 8 weeks post- implantation. Quantification of
erythrocyte containing vessels yielded no significant differences between any of the conditions at either














Figure 6.6 – Human UEA-1 Staining with serial H&E staining at 4 weeks. There
was no clear indication of positive UEA-1 staining suggesting a lack of human
endothelial cells after 4 weeks of implantation. Arrows indicate corresponding











Ectopic Bone Formation 
 Micro-Computed Tomography was used as a method to non-destructively image and 
quantify bone volume and tissue mineral density of explanted tissues (Figure 6.7). At 4 weeks, 
there were no significant differences between the bone volumes (BV) of the Blank, Vasculo, or 
Osteo + Vasculo conditions. However, the BV of the Osteo alone group was significantly higher 
compared to all other groups. At 8 weeks, both the Blank and Osteo conditions had significantly 
higher BV compared to the Vasculo and Osteo + Vasculo groups. Evaluation of tissue mineral 
density (TMD) showed no differences across treatments at the 4 week time point. At the 8 week 
time point the Blank treatment showed significantly higher TMD compared to the Vasculo or 
Osteo conditions. Histological analysis and Von Kossa staining confirmed the µCT data (Figure 
6.8), and showed the same trends. Positive mineral staining was evenly distributed throughout 
the implanted structures in amounts that correlated with the BV calculations. 
144 
 
Figure 6.7– Micro-computed tomography analysis of ectopic bone formation. The Osteo only
group demonstrated the highest bone volume at 4 weeks and both the Osteo and Blank groups had
the highest bone volume at 8 weeks. (A) Representative 3D volumetric images of newly formed
bone. (B) Bone volume. (C) Tissue mineral density. @Statistically significant (p<0.05) vs Blank.
#Statistically significant (p<0.05) vs Vasculo. $Statistically significant (p<0.05) vs Osteo.

















 The goal of this study was to evaluate a dual-phase microbead-hydrogel system for 
promoting bone formation. The osteogenic microbead phase consisted of pre-differentiated 
bmMSC that were embedded in microscale (50-250 µm diameter) COL/FIB/HA modules. The 
microbeads in turn were distributed within a 3D vasculogenic matrix consisting of a COL/FIB 
hydrogel containing a bmMSC-HUVEC co-culture. Our previous work has demonstrated that 
microbeads support osteogenic differentiation of bmMSC [18], and that populations of 
microbeads can be collected and injected through a needle without the loss of cell viability [17]. 
Figure 6.8 – Von Kossa Staining of distributed mineral within the
implant site at 4 and 8 weeks. Positive black staining indicating











Therefore microbeads can be maintained in culture and exposed to desired differentiation 
conditions, and can subsequently be collected and implanted without the need to disrupt the 
cellular microenvironment. Microbeads also can be combined with other types of biomaterials to 
create multiphase constructs [23]. In the present work, we homogeneously dispersed 
osteogenically pre-differentiated microbeads within a collagen/fibrin composite hydrogel 
containing a co-culture of bmMSC-HUVEC that we have previously shown to support 
vasculogenesis in vitro [19]. The rationale for combining these phases was to promote 
simultaneous cellular osteogenesis and neovascularization to enhance the formation of new bone. 
The overall objective of this work is to develop a minimally-invasive therapy for treating large 
and recalcitrant bone defects. 
 We first investigated vasculogenesis in 3D hydrogel constructs that contained either acellular 
or osteogenically-differentiated cell-seeded microbeads in vitro. Robust endothelial cell networks 
formed in the hydrogel in both conditions containing HUVEC (Osteo + Vasculo, Vasculo). 
Interestingly, we did not observe an inhibitory effect of including osteogenically differentiated 
cells into our system on in vitro vessel formation. Although there are contradictory reports in the 
literature [24], some studies have observed that the differentiated state of co-cultured bmMSC 
can influence vascular network formation by HUVEC [25]. In addition, we did not observe 
positive staining for endothelial cell markers in osteogenic microbeads when cultured alone, in 
contrast to reports that have suggested that mesenchymal stem cells can differentiate along both 
osteogenic and vasculogenic cell lineages [26-29]. Taken together, our in vitro data provided 
support that osteogenic microbeads could be used in combination with a vasculogenic outer 
matrix, without impeding vascular network formation. 
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 We then progressed to a subcutaneous implant model in the mouse to examine bone and 
blood vessel formation by both mono- and dual-phase constructs. The bmMSC in the osteogenic 
microbead component were pre-differentiated for two weeks prior to being combined with an 
outer hydrogel containing a combination of undifferentiated bmMSC and HUVEC immediately 
prior to injection. Previous studies have shown that the co-transplantation of undifferentiated 
bmMSC and HUVEC lead to vasculogenesis containing human cells within this animal model at 
1 and 2 weeks [21, 22].  The subcutaneous location of the implants also allows angiogenesis 
from surrounding fat and muscle tissue, allowing perfusion of the implant site. The animal model 
supported the implantation of two constructs per animal, and therefore facilitated contralateral 
comparisons in this proof-of-concept study. 
 Non-invasive Doppler imaging showed consistent, above-baseline levels of construct 
perfusion regardless of the treatment condition, with the exception the purely vasculogenic 
condition at 8 weeks, which showed a significant decline in perfusion. In addition, quantification 
of neovasculature using histology showed no significant differences between the conditions at 
either time point. These data suggest that while the constructs were well perfused, the inclusion 
of endothelial cells did not improve vascularization of the implant site. Although human 
endothelial cells were originally implanted in constructs and previous studies have shown they 
contribute to vasculature at earlier time points [21, 22], we observed little evidence of human 
UEA-1 staining in these explanted tissues at 4 weeks. The microbeads used in this study 
contained exogenous HA, the primary mineral component of bone, which has been shown to 
have an osteoinductive effect on bmMSC [30]. However, HA has also shown the ability to 
promote sprouting of HUVEC [31, 32], and induces the secretion of the angiogenic growth factor 
VEGF when presented to bmMSC [30, 33]. The HA contained within the microbeads may have 
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provided an angiogenic signal for the host vasculature to infiltrate the implant and support bone 
formation. Therefore, the exogenously supplied HUVEC may not have been needed to achieve 
perfusion of the implants. 
 The benefits of combining endothelial cells with mesenchymal stem cells to potentiate bone 
formation have been shown in a variety of ways. In vitro studies have confirmed that co-culture 
of these cell types can achieve reciprocal beneficial effects: endothelial cells can secrete BMP-2 
to serve as osteogenic signal for mesenchymal stem cells [13], which conversely can release 
VEGF to provide an angiogenic signal for endothelial cells [34]. Several studies have shown 
comparable [35] or increased bone formation [36, 37] with the transplantation of both cell types 
in orthotopic bone regeneration models. Ectopic models have yielded either increased [13, 16] or 
equivalent [38, 39] bone formation in the dual cell condition, compared to the osteogenic cell 
condition alone. In the present study, addition of undifferentiated bmMSC in combination with 
HUVEC exhibited a clear inhibitory effect on ectopic bone formation by osteogenically 
differentiated microbeads in vivo. The presence of undifferentiated bmMSC in dual-phase 
condition may have resulted in signals that inhibited bone formation. 
 We elected to use a subcutaneous ectopic model to examine proof-of-concept of our dual-
phase approach. However, in this model it is possible that exogenous cells are not required to 
achieve neovascularization of the implant. An orthotopic model, in which angiogenesis from 
surrounding tissue is reduced, may be more appropriate for demonstrating the potential of the 
dual-phase tissue approach. In particular, a dual-phase engineered tissue may be of most value in 
ischemic bone wounds, in which the host tissue does not have the ability to regenerate the 
vasculature needed to support bone regeneration. While there are no reliable small animal 
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models of ischemic bone repair, our approach may show benefit in large segmental defects, 
which typically result in non-union unless a therapeutic intervention is applied. 
 This study has demonstrated the use of an injectable, modular approach that applies 
COL/FIB/HA microbeads for orthopaedic applications. The microbead phase generated robust 
bone formation in an ectopic model. Contrary to our expectation, the addition of undifferentiated 
bmMSC and HUVEC as part of the vasculogenic phase had an inhibitory effect on bone 
formation in this model. The mechanism of inhibition is unclear, but may be related to the 
presence of undifferentiated bmMSC in proximity to the osteogenic phase. Testing of this 
approach in a non-union or ischemic model may illuminate whether endothelial cells and/or 
bmMSC can potentiate bone healing in recalcitrant wounds. This works provides insight into 
bone formation by implanted bmMSC, and may lead to improved methods for engineering 
vascularized bone tissue. Such injectable therapies would aid in the treatment of a variety of 
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Summary, Discussion, Conclusions and Future Directions  
7.1 Summary 
  In the first aim (Chapter 3), we explored whether collagen/fibrin (COL/FIB) and 
collagen/fibrin hydroxyapatite (COL/FIB/HA) microbeads could support the osteogenic 
differentiation of bone marrow-derived mesenchymal stem cells (bmMSC) and adipose-derived 
stem cells (AdSC) [1]. These cell types were chosen because both are commonly used in 
osteogenic studies and can be used as autologous cell sources. The inclusion of HA into these 
matrices produced an osteoinductive effect on the encapsulated bmMSC as alkaline phosphatase 
(ALP) activity significantly increased in both the growth (control) and osteogenic conditions 
compared to cells seeded within microbeads not containing HA. Further, these cells mineralized 
COL/FIB microbeads (without HA) after culture in osteogenic media for two weeks indicating 
that the cells were adopting the osteogenic phenotype. COL/FIB/HA microbeads containing 
bmMSC did not show an increase in mineral content, likely due to the presence of mineral within 
the microbeads.  AdSC also mineralized their respective microbeads, however, they did not 
demonstrate the same response to HA in terms of ALP activity. COL/FIB/HA microbeads were 
chosen as the support material for the osteogenic microbeads. We elected to continue subsequent 
aims using bmMSC as they satisfied both of our markers of osteogenesis in these studies.   
 In the first part of the second aim (Chapter 4), both cell ratio and matrix composition 
were varied in HUVEC and bmMSC co-cultures seeded within 3D COL/FIB composite 
hydrogels [2]. The bmMSC served as pericytes in this model and provided paracrine signals that 
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stimulated HUVEC to form vessel-like structures. Endothelial network formation increased with 
increasing fibrin content in the composite matrices although the 40/60 COL/FIB exhibited the 
same degree of vessel-like structure formation compared to pure fibrin. Mechanical property 
measurements showed an inverse correlation between matrix stiffness and network formation. 
We further investigated this by modulating both the total protein concentration and crosslinking 
the 40/60 COL/FIB matrices using glyoxal and again, network formation demonstrated a 
negative correlation with matrix stiffness. However, qualitative assessment of the matrix 
microarchitecture indicated that our alterations in mechanical properties also led to changes in 
the matrix structure. Although the mechanical properties could not be altered independently from 
other properties, the results from this sub-aim suggest that COL/FIB matrices are permissive to 
network formation by bmMSC-HUVEC co-cultures and that vessel-like structure generation can 
be modulated by matrix mechanics. From this sub-aim, we chose the 40/60 COL/FIB composite 
hydrogels with a 1:1 HUVEC:bmMSC cell ratio for our continued vasculogenic studies.      
 Hydroxyapatite was then systematically added to the 40/60 COL/FIB hydrogels in a 
dose-dependent manner to evaluate its effect of network formation in unconstrained hydrogels 
(Chapter 5). In an unconstrained environment, cell contractile forces induce compaction of 
COL/FIB composite hydrogels thereby leading to a loss of vessel-like structure generation. 
Network formation in unconstrained hydrogels was recovered in vitro using low concentrations 
of HA, while network formation remained reduced using high concentrations of HA compared to 
constrained hydrogels without particulate mineral. This phenomenon was then assessed in vivo in 
a SCID mouse subcutaneous model. After one week, histological analysis of implanted 
hydrogels demonstrated successful transplantation of human endothelial cells and the creation of 
erythrocyte-filled vessels. However, there were no significant differences in the number of 
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capillaries generated in the conditions containing the low concentration HA compared to those 
without mineral. Although this result did not match our in vitro findings that HA enhanced 
network formation in unconstrained hydrogels, it did indicate that any HA present within 
implanted matrices would not induce detrimental effects towards vasculogenesis. This is 
particularly relevant to the results provided from the first aim in which COL/FIB/HA microbeads 
were selected as support structures for the osteogenic differentiation of bmMSC.  
 In the final aim (Chapter 6), osteogenic microbeads were combined within the 
surrounding vasculogenic matrix. Endothelial networks were formed around the embedded 
microbeads in the conditions containing HUVEC in the outer COL/FIB hydrogel. A 
subcutaneous bone formation model was then utilized to measure both vasculogenesis and 
osteogenesis within implants at 4 and 8 weeks. Blood flow was not significantly different 
between any of the conditions at any time point, except at 8 weeks where the vasculogenic 
matrix alone was lower than all other groups. Ectopic bone formation measured by micro-
computed tomography demonstrated significantly higher bone volume in the osteogenic 
microbead condition at 4 weeks and the blank and osteogenic microbead conditions at 8 weeks, 
compared to the dual Osteo + Vasculo condition. Histological analysis of total vessel density 
within the implants showed no significant differences between the conditions at any time point. 
At 4 weeks, there was no clear indication of human endothelial cells by UEA-1 staining in either 
the dual osteogenic/vasculogenic or the vasculogenic alone conditions, suggesting transplanted 
cells/vasculature could have regressed and or have been remodeled within a month. Von Kossa 
staining confirmed the micro-computed tomography data, as mineralized tissue was present 
within the implants. These data suggest an inhibitory effect of the vasculogenic component on 
bone formation in the non-ischemic model. However, this work suggests the potential use of 
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microbeads in bone regeneration applications. Dual-phase implants may be more effective in 
ischemic orthotopic bone regeneration models, and these results demonstrate that such constructs 
can be designed, fabricated, and delivered for therapeutic use. 
 
7.2 Discussion 
 This work presents an incremental step in the engineering of vascularized bone and has 
touched upon the fields of modular tissue engineering, biomaterial synthesis, in vitro endothelial 
network formation, matrix mechanics, and in vivo vasculogenesis and osteogenesis. Previous 
work from our lab has fabricated microbeads from protein/polysaccharide composite matrices 
such as collagen/agarose [3, 4], chitosan/fibrin [5], and collagen/chitosan [6, 7]. Pure protein 
microbeads have been difficult to fabricate through the water-in-oil emulsion process used to 
create these microbeads as they are difficult to harvest from the oil phase and are fragile. We 
were able to generate composite collagen/fibrin microbeads by controlling the rate of gelation of 
the fibrin through increasing the thrombin concentration. Supplementation of these microbeads 
with hydroxyapatite increased the density of the modular structures which provided structural 
integrity and prevented the aggregation of microbeads when cultured over two weeks. The 
addition of HA also presented embedded mesenchymal stem cells with an osteoinductive signal 
[8]. The first Aim provided data that both confirmed findings within the current literature 
pertaining to stem cell differentiation [9-13] but also presented a novel approach that could be 
used to design and fabricate the next generation of modular tissue engineered constructs.    
 In vitro endothelial network formation has been a well-studied phenomenon within the 
literature through both angiogenesis and vasculogenesis models. Previous studies have shown 
beneficial effects on network formation when endothelial cells are co-cultured with a stromal cell 
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type such as bmMSC [14-16]. Others have also demonstrated a negative effect on in vitro 
vasculogenesis when fibrin matrices supplemented with collagen [17-19]. We performed a 
systematic set of studies and varied both cell ratio and matrix composition in an attempt to create 
an optimized model for in vitro endothelial network formation in collagen/fibrin matrices. We 
were able to identify a composite collagen/fibrin matrix that was comparable to pure fibrin in 
terms of vessel-like structure formation. Also, in accordance with other studies, we observed a 
negative correlation between network formation and matrix stiffness. We elected to further 
pursue this observation by modulating both total protein concentration and by crosslinking the 
collagen/fibrin matrices. Qualitative assessment of matrix architecture indicated that we could 
not alter matrix stiffness without affecting matrix microarchitecture. This finding is an important 
addition to the field in which many have attempted to change matrix mechanics without 
considering their effects on porosity, mass transport, ligand density, and other parameters. We 
were able to contribute data and suggest a method towards the design of biomaterials that are 
permissive to vasculogenesis. This strategy could extend beyond orthopedic applications.   
 In the next study, we attempted to provide a solution to one particular issue within the 
angiogenesis/vasculogenesis tissue engineering literature. In an unconstrained environment, cells 
are able to exert contractile forces on their surrounding microenvironments which can then lead 
to an inhibition of vessel-like structure formation [20-23]. We approached this problem by 
adding hydroxyapatite in a dose-dependent manner to the COL/FIB hydrogels containing a co-
culture of bmMSC and HUVEC examined in the previous study. We observed a recovery of 
endothelial network formation in unconstrained hydrogels containing low concentrations of 
hydroxyapatite. This finding corroborated current work that has shown increased vessel ingrowth 
in materials containing low concentrations of bioceramics such as Bioglass [24-28]. Investigation 
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of these COL/FIB/HA hydrogels in a mouse subcutaneous model showed that this beneficial 
effect did not occur in an in vivo environment. However, there was not an inhibitory effect by the 
hydroxyapatite on in vivo vasculogenesis. The inclusion of HA into these matrices was chosen 
due to its relation to this thesis as a whole, but it allowed us to attempt a different approach to the 
problem than currently used in the vasculogenesis field. Mineral within vasculature is usually 
observed in pathological conditions and is therefore viewed as a detrimental factor in the field 
[29]. We were able to provide insight towards the design of unconstrained biomaterials that 
could support in vitro vasculogenesis by utilizing a different methodology than typically used in 
the field. This approach could benefit the vascular tissue engineering field by offering a method 
to create pre-vascularized structures in vitro which can then be implanted for rapid inosculation 
with host vasculature. 
 In the final Aim, we combined the results from the previous study to create a dual-phase 
osteogenic and vasculogenic tissue. Current work in vascularized bone tissue engineering has 
probed whether the co-implantation of endothelial cells and mesenchymal stem cells can form 
vascularized bone in vivo [30, 31]. Typically these studies used undifferentiated cells, but the 
microbead technology developed in the first Aim allowed for pre-differentiation of embedded 
stem cells prior to implantation. In a related study, a combinatorial osteogenic and vasulogenic 
tissue was created by first osteogenically differentiated bmMSC on a solid scaffold prior to 
combination with a hydrogel containing a bmMSC-HUVEC co-culture [32]. Although we 
employ a similar method to generate a dual-phase tissue, our construct was purely hydrogel-
based and can therefore be injected into the defect site in a minimally invasive manner. Our 
system was able to form ectopic bone in both the acellular control and Osteo conditions 
indicating that the material combination chosen for microbeads throughout the thesis might be 
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sufficient to generate vascularized bone in vivo. The study as a whole demonstrated the further 
need to understand the interplay between bmMSC and HUVEC as well as the implications of 
transplanting both undifferentiated and osteogenically differentiated bmMSC.    
 In the first chapter, we identified bone fractures that led to non-unions as one clinical 
problem that could be addressed by the findings of this thesis. We initially chose biomaterials 
that have been approved for both bone and vascular indications in an attempt to expedite clinical 
use. The combinatorial approach developed throughout this dissertation could be delivered into 
non-load bearing fractures or those that have been fixated with metal rods and plates. Moreover, 
our biomaterial could be used in other bone-related diseases such as avascular necrosis in which 
vascularized bone grafts have been commonly used [33]. In this condition, necrosis, or cell 
death, of bone tissue is caused due to an interruption of the blood supply. The necrotic tissue is 
removed by both macrophages and osteoclasts and this remodeling can lead to a collapse of the 
subchondral bone layer in joints such as the hip. In patients with these complications, our dual-
phase tissue could serve as a space-filling material and provide the necessary osteogenic and 
angiogenic signals to regenerate bone tissue potentially delaying or completely avoiding total hip 
replacement. Taken together, this thesis has provided a potential minimally-invasive injectable 
strategy for vascularized bone tissue engineering applications.   
 
7.3 Conclusions 
Aim 1: Formation of osteogenic microbeads 
 Collagen/fibrin/hydroxyapatite composite microbeads could be utilized as materials to 
direct human bone marrow-derived mesenchymal stem cells differentiation towards the 
osteogenic lineage.  
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Aim 2: Generation of a vasculogenic matrix 
 COL/FIB composite hydrogels were found to be permissive to endothelial network 
formation of human umbilical vein endothelial cells when co-cultured with bmMSC and the 
obtained results demonstrated a negative correlation with the mechanical properties of the 
COL/FIB composite matrices. The addition of hydroxyapatite to these constructs enhanced 
network formation in unconstrained hydrogels in vitro, but did not increase vasculogenesis in 
vivo.    
Aim 3: Dual-Phase Engineered Tissue for Enhanced Bone Formation  
 Our dual phase engineered tissue consisting of osteogenic microbeads embedded within a 
vasculogenic matrix did not demonstrate enhanced bone formation compared to the acellular 
control at either 4 or 8 weeks post-implantation. Osteogenic microbeads alone demonstrated the 
highest amount of ectopic bone at 4 weeks. At 8 weeks, both the acellular control and the Osteo 
groups formed increased bone volume compared to the Vaculo conditions indicating an 
inhibitory effect on ectopic bone formation with the inclusion of a bmMSC and HUVEC co-
culture.   
 
7.4 Future Directions 
 The results of this work demonstrate the feasibility of delivering cell-seeded hydrogel 
microenvironments in vivo within a vasculogenic matrix towards the goal of the forming ectopic 
bone. Clinical translation of this work will require continued studies to develop a dual-phase 




1. Optimizing the dual-phase tissue in vitro and performing subsequent in vivo studies to 
validate improvement in bone formation with the addition of a co-culture of bmMSC and 
HUVEC 
2. Studying the osteogenic/vasculogenic construct in an orthotopic bone regeneration model 
3. Generating pre-vascularized microbeads that could inosculate with host vasculature 
immediately after implantation 
4. Investigating alternate cell sources to facilitate clinical translation 
 
In the final study, we combined the results from the Aim 1 and 2 to form a dual-phase 
osteogenic-vasculogenic system. However, we did not validate this tissue’s potential to induce 
both a vasculogenic and osteogenic response in vitro nor optimize parameters within this tissue 
for the most robust response. Future work using the current system could include varying the 
microbead to matrix ratio and total cell concentration as well as investigating whether pre-
differentiation of bmMSC in the microbeads or in the vasculogenic matrix will enhance the final 
tissue properties. In vitro studies could be conducted to improve the system and assays such as 
quantification of endothelial network formation around embedded microbeads, cell proliferation, 
gene expression of both osteogenic (ALP, BMP-2, osteopontin, osterix, bone sialoprotein, 
collagen I) and vasculogenic (VEGF, VE-Cadherin, CD31) markers, calcium deposition in the 
tissue, as well as protein secretion of late osteogenic markers (osteopontin and osteocalcin) could 
serve to direct the final dual-phase tissue parameters. After these have been sufficiently studied, 
another ectopic bone formation experiment could be performed to validate the potential benefits 
of the dual-phase tissue in vivo. In the next ectopic study, earlier time points should be included 
in order to fully understand the system’s development in the in vivo environment. We did not 
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observe human endothelial cells in our current study but those cells presumably aid in vascular 
tissue formation at early (1-2 week) time points. The future study could include these samples as 
well as a 12 week time point to fully understand the dual-phase tissue’s development and 
progression.     
Further in vivo studies using orthotopic pre-clinical models are necessary to demonstrate 
bone regeneration induced by our dual-phase tissue. The subcutaneous mouse model employed 
in these studies provided proof-of-concept results that show promise in the use of pre-
differentiated cell-seeded microbeads as a cell-based therapy, but validation in orthotopic animal 
models such as cranial or femoral defect models are needed to demonstrate in vivo bone 
regeneration. Longer time points (up to 12 weeks), biomechanical testing, micro-computed 
tomography analysis, and histological confirmation of newly formed bone would all be required 
to indicate the tissue’s potential to generate vascularized bone prior to use in clinical practice.  
Another potential avenue of this work would be to create vasculogenic microbeads with 
pre-formed vessel-like structures in vitro that would later be combined with osteogenic 
microbeads prior to implantation. Current work has shown promise in creating sub-millimeter-
sized collagen gel cylinders, or modules, and coating the outer surface of these structures with 
endothelial cells to enhance vascularization in vivo [34-36]. In a similar vein to the work 
discussed in this thesis, collagen/fibrin composite materials can potentially be used to generate 
vessel-like structures in vitro by co-culturing bmMSC and HUVEC. Future work would focus on 
the fabrication of robust vasculogenic microbeads and validating their ability to inosculate with 
host tissue in vivo. These pre-formed vessels could presumably connect with host vasculature 
immediately after injection and transport blood throughout the transplanted area. 
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 Next, vasculogenic and osteogenic microbeads could be combined in vitro to study the 
tissue development and progression of this next-generation dual-phase tissue. As mentioned 
earlier, gene expression, protein expression, and calcium deposition could all be monitored in 
order to optimize vasculogenic to osteogenic microbead ratio. In vivo delivery of this system 
could be achieved by concentrating or patterning the microbeads into a paste and injecting them 
into both ectopic and orthotopic models. These studies would provide insight towards the goal of 
engineering pre-vascularized osteogenic structures for enhanced bone healing.    
One major hurdle in the translation of cell therapy strategies is in the use of the 
appropriate cell type that will be able to regenerate tissue while maintaining a proper 
immunological reaction. In this study, we used commercially available bmMSC and AdSC, yet, 
if autologous cell types were to be used, each donor cell type would need to be optimized and 
examined in vitro prior to use in order to overcome patient-to-patient variations. The use of stem 
cells from allogeneic sources is being explored, particularly due to their immunomodulatory 
properties. Different endothelial cell sources other than the ones used in work would need to be 
employed for translational purposes. HUVEC provide an excellent model cell type as they can be 
easily isolated from fresh umbilical cords yet they are limited in their clinical use. Other 
endothelial cell types such as microvascular endothelial cells or endothelial progenitor cells 
should be explored as potential candidates for cell therapy approaches to engineering 
vascularized bone tissue.  
 The fields of cell therapy and tissue engineering all provide cues towards the regeneration 
of long bone fractures. Designing combinatorial approaches to the concomitant formation of 
vasculature and bone tissue will aid in providing therapies for patients that suffer from non-
unions that prevent them from participating in normal activities. The results demonstrated 
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through the present work provide a step towards this goal and offer advances in stem cell 
differentiation, biomaterial synthesis, capillary morphogenesis, and ectopic bone generation, all 
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A.1 Collagen/Fibrin Composite Microbead Fabrication 
Materials 
• Collagen – Calf Skin Type I  
o MP Biomedicals, Product # 150026 
• Fibrinogen – Bovine Plasma 
o Sigma-Aldrich, Product # F8630  
• Thrombin – Bovine Plasma 
o Sigma-Aldrich, Product # T4648 or T6200 
• Sodium Hydroxide (NaOH) 
o Sigma-Aldrich, Product # S2770 
• Glyoxal 
o Sigma-Aldrich , Product # 128465 
• Fetal Bovine Serum (FBS) 
o Life Technologies, Product # 12662029 or 10437028 
• 1X and 5X Dulbecco’s Modified Eagle’s Medium (DMEM) 
o Fisher Scientific, Product # 50-003-PB 
• Phosphate buffered saline (PBS) 
o Life Technologies, Product # 21300-025 
• ε-amino caproic acid (ACA) 
o Sigma-Aldrich, Product # A7824 
• Pluronic L101 Surfactant 
o BASF 
• Polydimethyl siloxane (PDMS) 
o Dow Corning 
• 100 ml beaker 
• Double-bladed impeller 
• Impeller controller system 
• Water bath heater 
 
Cell Preparation 
• Trypsinize cells, count, and re-suspend in desired cell concentration 
• Centrifuge cells at 200 x g, aspirate media 
• Resuspend cells in media components  FBS, 5X DMEM, 1X DMEM 




Impeller and Oil Set-Up 
• Heat water bath to 37ºC 
o Make sure thermometer is placed into the water bath 
• Add 75 ml of PDMS into a 100 ml beaker 
o Place beaker in ice container and surround with ice 
• Connect impeller to system 
• Move beaker surrounded ice up to impeller 
 
Microbead Fabrication 
• Add components in the following order while mixing with a micropipette 
o Media Components 
 FBS, 5X DMEM, 1X DMEM 





• Collect gel mix into a 5 ml serological pipette 
• Start mixing impeller in PDMS bath at desired speed 
• Slowly add mixture into of PDMS pre-cooled to 0ºC (on ice) 
o Add at approximately 5 ml of gel mixture in 30 seconds 
• Turn vortexer on/off to break big clumps of mixture 
• Mix for 5 mins at 0ºC (on ice) 
• Transfer beaker (oil + microbeads) to a water bath pre-heated to 37ºC 
• Mix for 25 mins at 37ºC (water bath) 
 
Microbead Collection 
• Collect oil + microbeads into two 50 ml centrifuge tubes 
• Add 3 ml of PBS + L101 
• Invert tube slowly for 5 mins 
• Centrifuge at 200 x g for 5 mins 
• Remove oil, combine samples into one 15 ml centrifuge, fill with PBS + L101 
• Centrifuge at 200 x g for 5 mins 
• Wash samples in PBS + L101 for 5 mins/wash 
o Centrifuge at 200 x g between each wash 
 
Microbead Cell Culture 
• Culture microbeads with cells in 15 ml centrifuge tubes  
• Add 3-5 ml of media 
• Place on its side in the incubator 
o Use the top of a well-plate to keep tube angled 
• Loosen cap to allow for gas exchange 
• Change media every 2-3 days 
o Centrifuge at 200 x g 
o Aspirate media 
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o Re-suspend microbeads with a serological pipette 
 
Notes 
• Autoclave impeller, beakers and water bath container prior to use with cells 
• Changing oil viscosity changes bead size 
o Lower viscosity = bigger microbeads 
o Higher viscosity = smaller microbeads 
• Changing impeller speed changes bead size 
o Lower speed = bigger microbeads 
o Higher speed = smaller microbeads 
• Concentrations of components that have been used 
o Collagen/fibrin mass ratio 40/60 and 50/50 
o Collagen  1 – 1.25 mg/ml 
o Fibrin  1.25 – 1.5 mg/ml 
o Thrombin  1 UT/ml 
 Do NOT use 0.1 UT/ml, microbeads will not form 
o Glyoxal  0.5 – 1 mM 
o NaOH  0.1 N 
• Culture microbeads in media supplemented with 2 mg/ml ε-amino caproic acid (ACA) to 




A.2 Live/Dead Staining and Quantification 
Materials 
• LIVE/DEAD® Viability/Cytotoxicity Kit, for mammalian cells 
o Life Technologies, Product # L3224 
o Can buy Calcein AM separately 
 Fisher Scientific (Calbiochem), Product # 206700 
• Phosphate buffered saline (PBS) 
o Life Technologies, Product # 21300-025 
 
Protocol 
• Culture gels or cells until time point 
• Perform assay 2-3 hours before imaging 
• Transfer gels to a bigger plate 
• Wash gels 3x in PBS for 10 mins/wash 
• Add Live/Dead stain for 30-45 minutes at 37°C [1 ml/gel] 
o To prepare 5 ml 
• Calcein AM – 5 µl 
• Ethidium Homodimer – 10 µl 
o NOTE – all subsequent steps must be done in the dark! 
• Wash gels 3x in PBS for 10 mins/wash  
• Image using Confocal Microscope 
 
Cell Viability Calculations 
• Open “Merge” file in ImageJ 
• Image  Color  Split Channels 
• Image  Adjust  Threshold 
o Green (0, 112) 
o Red (0, 125) 
• Process  Binary  Watershed 
• Analyze  Analyze Particles  OK 
• Calculate Viability 
   
  % Viability =       Green x 100%     




A.3 Actin Cytoskeletal Staining 
Materials 
• Alexa Fluor® 488 Phalloidin 
o Life Technologies, Product # A12379 
• 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI) 
o Life Technologies, Product # D1306 
• Zinc-buffered formalin (Z-Fix) 
o Anatech Ltd., Product # 174 
• Triton X-100 
o Sigma-Aldrich, Product # T9284  
• Bovine Serum Albumin (BSA) 
o Sigma-Aldrich, Product # A1933 
• Phosphate buffered saline (PBS) 
o Life Technologies, Product # 21300-025 
 
Procedure 
• Wash cells 2x with PBS for 5 minutes 
• Fix cells in Z-fix at 4ºC for 10 minutes 
• Wash cells 2x for 5 minutes/wash  in PBS  
• Permeabilize cells with 0.5% Triton X-100 in PBS for 20 minutes at RT 
o 50 μl Triton X-100 in 10 ml of PBS 
• Wash cells 2x for 5 mins/wash minutes in PBS 
• Add Stain, incubate for 45 mins at RT [Cover in foil] 
o 1% BSA in PBS 
 100 mg in 10 mls of PBS 
o Phalloidin 1:40 dilution in PBS 
o DAPI  1:1,000 dilution in PBS 
o For 1 ml of Stain 
 10 mg of BSA  
 975 μl of PBS 
 25 μl Phalloidin dye 
 1 μl of DAPI 
• Wash cells 2x for 5 mins/wash minutes in PBS [Cover in foil] 
• Store at 4ºC until imaging 
174 
 
A.4 Osteogenic Supplements 
Beta-Glycerophosphate (β-GP)  Final concentration 10 mM 
• β-GP Catalog # G9422 
• Make stock β-GP at 1 M  
• Add 1.08 grams of β-GP to 5 ml of serum-free media 
• Add 10 μl/ml of osteogenic media 
 
Ascorbic 2-Phosphate (A2P)  Final concentration 50 μg/ml 
• Make stock A2P at 5 mg/ml 
• Add 25 mg of A2P to 5 ml of serum-free media 
• Add 10 μl/ml of osteogenic media 
 
Dexamethasone (DEX)  Final concentration 100 nM  
• Make stock DEX at 100 μM 
o Not  soluble in 10 mM stock 
• Add 1.9 mg of DEX to 50 ml of serum-free media 
• Add 1 μl/ml of osteogenic media 
 
NOTES 
• Store all osteogenic supplements in -80ºC freezer 
• Aliquots in 250 μl for β-GP and A2P 
o 25 μl for DEX 
• Add to media at every media change 
• A2P is light sensitive – prepare osteogenic media in the dark 
 
CELL TYPES 
Mesenchymal Stem Cells (MSC)  DMEM – Low Glucose or α-MEM (with ascorbic acid) 
• 10 mM β-GP 
• 50 μg/ml A2P 
• 100 nM DEX 
 
Adipose-Derived Stem Cells (ASC)  DMEM – Low Glucose or α-MEM (with ascorbic acid) 
• 10 mM β-GP 
• 50 μg/ml A2P 
• 100 nM DEX 
 
MC3T3 – Mouse Preosteoblasts  α-MEM  
• 10 mM β-GP 
• 50 μg/ml A2P 





A.5 Alkaline Phosphatase Activity (ALP) Assay 
Materials 
• P-Nitrophenol  
o Sigma-Aldrich, Product # N7660 
• 2-Amino-2-methyl-1-propanol 
o Sigma-Aldrich, Product # A65182 
• Phosphatase substrate 
o Sigma-Aldrich, Product # P4744 
• Collagenase Type I 
o Fisher Scientific (MP Biomedicals), Product # ICN1951091 
• Tris-HCl 
o Sigma-Aldrich, Product # T5941 
• IGEPAL 
o Sigma-Aldrich, Product # I8896 
• Phenylmethanesulfonyl fluoride 
o Sigma-Aldrich, Product # 78830 
• Sodium hydroxide (NaOH) 
o Sigma-Aldrich, Product # 221465 
 
Sample Collection and Lysis 
• Flash-freeze samples in liquid N2 and freeze in -80°C freezer until all samples are 
collected 
• Digest samples in Lysis Buffer for 1.5 hours at 37°C 
o Use tissue homogenizer to break up samples if not digested in 1 hour 
• Lysis Buffer (5 ml) 
o 10 mM Tris Buffer – pH 7.4 
o 0.6 mg/ml of Collagenase Type I 
 3 mg of Collagenase Type I 
o 0.2% IGEPAL 
 10 μl IGEPAL 
o 2 mM PMSF in Ethanol 
 200 mM Stock  Dissolve 348.4 mg in 10 ml Ethanol  
• Aliquot and freeze in -20ºC 
 Add 50 μl of stock PMSF 
• Freeze-Thaw samples 2X at room temperature and in -80°C freezer 
 
Prepare AMP Buffer (125 ml) 
• Solution A (62.5 ml) 
o 50 ml of MilliQ H2O 
o 6.25 ml of AMP 
o Adjust pH to 10 
o Add water to bring final volume to 62.5 ml 
• Solution B (62.5 ml) 
o 0.263 Phosphate substrate 
o 62.5 ml of MilliQ H2O 
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• 1 M MgCl2 
o 1.9 g MgCl2 
o 20 ml of MilliQ H2O 
• Combine Solution A and Solution B and add 1.25 ml of 1 M MgCl2 
• Prepare aliquots of 12 ml, store in -80°C freezer 
 
Standard Curve 
• Dilute p-nitrophenol stock solution 1:10 in water 
o 100 µl of p-nitrophenol 
o 900 µl of MilliQ H2O 
 
 nmol/well µl p-nitrophenol (1 mM) Lysis Buffer 
A 0 0 100 
B 2.5 12.5 87.5 
C 5 25 75 
D 7.5 37.5 62.5 
E 10 50 50 
F 12.5 62.5 37.5 
G 15 75 25 
H 20 100 0 
 
Assay 
• Add 5-20 µl of standard or sample in duplicate or triplicate  
• Add AMP buffer to bring the volume up to 100 µl 
• Incubate plates at 37°C for 5 – 20 mins 
o Reaction will cause wells to become yellow 
o Monitor and stop the reaction before the samples become darker than the highest 
standard 
o Record the time 
• Stop the reaction by adding 100 µl of 0.5 M NaOH 
• Read absorbance at 405 nm 
• Report values as nM/mg DNA/min 
 
Notes 
• Perform DNA assay or protein assay to normalize values 
• Cover aliquots of AMP buffer in foil 
• Do not use AMP buffer aliquots if they become yellow in the freezer 





A.6 Quant-iT™ PicoGreen® Assay for DNA Quantification 
Materials 
• Quant-iT™ PicoGreen® dsDNA Assay Kit 
o Life Technologies, Product # P7589 
• Collagenase Type I 
o Fisher Scientific (MP Biomedicals), Product # ICN1951091 
• Tris-HCl 
o Sigma-Aldrich, Product # T5941 
• IGEPAL 
o Sigma-Aldrich, Product # I8896 
• Phenylmethanesulfonyl fluoride 
o Sigma-Aldrich, Product # 78830 
 
Sample Collection and Lysis 
• Flash-freeze samples in liquid N2 and freeze in -80°C freezer until all samples are 
collected 
• Digest samples in Lysis Buffer for 1.5 hours at 37°C 
o Use tissue homogenizer to break up samples if not digested in 1 hour 
• Lysis Buffer (5 ml) 
o 10 mM Tris Buffer – pH 7.4 
o 0.6 mg/ml of Collagenase Type I 
 3 mg of Collagenase Type I 
o 0.2% IGEPAL 
 10 μl IGEPAL 
o 2 mM PMSF in Ethanol 
 200 mM Stock  Dissolve 348.4 mg in 10 ml Ethanol  
• Aliquot and freeze in -20ºC 
 Add 50 μl of stock PMSF 
• Freeze-Thaw samples 2X at room temperature and in -80°C freezer 
 
 
TE Buffer, DNA Stock Solution, and PicoGreen Dye 
• Dilute 20X TE buffer (in kit) to 1X  
o 1 ml of TE buffer, 19 ml of MilliQ H2O 
• DNA stock 100 µg/ml; diluted to 2 µg/ml in either TE or Tris Buffer  
o 10 µl stock + 490 µl buffer 
• Dilute PicoGreen Dye according to pico_procedure.xls file  
o 0.75 µl Pico Dye 













DNA (µl) Buffer (µl) 
A 0 0 600 
B 50 15 585 
C 100 30 570 
D 166.67 50 550 
E 250 75 525 
F 333.33 100 500 




• Dilute samples to ensure they are in linear range 
• 1:12.5 dilution  
o 40 µl sample + 460 µl TE Buffer 
• 1:25 dilution  
o 20 µl + 480 µl TE Buffer 
• 1:50 dilution  
o 10 µl + 490 µl TE Buffer 
• 1:10 dilution  
o 10 µl + 990 µl TE Buffer 
 
Assay 
• Add 50 µl standard/samples to each well in duplicates 
• Add 100 µl buffer into each well 
• Add 150 µl PicoGreen buffer into each well 
o Cover well plates with foil to avoid light exposure 
o Incubate for 2-3 mins 
• Read plates using fluorescent reader (498/518 nm) 
 
Notes 





A.7 OCPC Calcium Assay 
Materials 
• 1 N Acetic Acid 
o Sigma-Aldrich, Product # 318590 
• Calcium Chloride Dihydride (CaCl2 • 2 H2O)  
o Fisher Scientific, Product # C69-500 
• Ethanolamine 
o Sigma-Aldrich, Product # 398136 
• Boric Acid 
o Sigma-Aldrich, Product # B6768 
• Potassium Hydroxide (KOH) 
• o-Cresolphthalein Complexone 
o Sigma-Aldrich, Product # P5631 
• Hydroxyquinoline 
o Sigma-Aldrich, Product # H6878 
• 95% Ethanol 
• MilliQ H2O 
 
Sample preparation 
• Flash-freeze samples in liquid N2 and freeze in -80°C freezer until all samples are 
collected 
• Add 0.5 ml – 1 ml 1 N acetic acid to each sample 
• Shake overnight at room temperature 
 
Solutions 
• Calcium Standard 
  91.75 mg CaCl2 • 2 H2O in 25 ml MilliQ (Stock: 1 mg/ml) 
• Solution A: 14.8 M ethanolamine/boric acid buffer, pH = 11 (natural) 
  0.5 ml ethanolamine 
  1.0 ml MilliQ 
  0.36 g boric acid – mix 
  0.5 ml ethanolamine – mix til boric acid is dissolved 
  8 ml ethanolamine 
• Solution B: OCPC (natural) 
  166.7 µl 1 N KOH (2.81 g KOH in 50 ml MilliQ) 
  25 ml MilliQ 
  26.7 mg OCPC – mix and dissolve 
  166.7 µl 1 N Acetic Acid 
• Solution C: hydroxyquinoline (orange)  
  0.5 g 8-hydroxyquinoline 
  10 ml 95% ethanol 






A 100 µg/ml 100 µl Calcium Standard 900 µl acetic acid 
B 50 µg/ml 500 µl from A  500 µl acetic acid 
C 25 µg/ml 500 µl from B 500 µl acetic acid 
D 12.5 µg/ml 500 µl from C 500 µl acetic acid 
E 6.25 µg/ml 500 µl from D 500 µl acetic acid 
F 3.125 µg/ml 500 µl from E 500 µl acetic acid 
G 1.5625 µg/ml 500 µl from F 500 µl acetic acid 
H 0 µg/ml  1000 µl acetic acid 
 
Assay 
• 10 µl sample/standard into each well 
• 300 µl work solution to each well 
• Incubate 10 minutes at room temperature 





A.8 BCA Protein Assay 
Materials 
• Bicinchoninic acid (BCA) Protein Assay 
o Thermo Scientific, Product # PI-23227 
• Tris-HCl 
o Sigma-Aldrich, Product # T5941 
• IGEPAL 
o Sigma-Aldrich, Product # I8896 
• Phenylmethanesulfonyl fluoride 
o Sigma-Aldrich, Product # 78830 
 
Sample Collection and Lysis 
• Flash-freeze samples in liquid N2 and freeze in -80°C freezer until all samples are 
collected 
• Digest samples in Lysis Buffer for 1.5 hours at 37°C 
o Use tissue homogenizer to break up samples if not digested in 1 hour 
• Lysis Buffer (5 ml) 
o 10 mM Tris Buffer – pH 7.4 
o 0.2% IGEPAL 
 10 μl IGEPAL 
o 2 mM PMSF in Ethanol 
 200 mM Stock  Dissolve 348.4 mg in 10 ml Ethanol  
• Aliquot and freeze in -20ºC 
 Add 50 μl of stock PMSF 
• Freeze-Thaw samples 2X at room temperature and in -80°C freezer 
 
Standard Curve 
• Transfer 1 ampule of standard solution to a microcentrifuge tube 
o Stock solution  2.0 mg/ml 
 
A 2000 ng/µl 300 µl of Stock  
B 1500 ng/µl 375 µl of Stock 125 µl 0.2% Triton-X 100 
C 1000 ng/µl 325 µl of Stock 325 µl 0.2% Triton-X 100 
D 750 ng/µl 175 µl from B 175 µl 0.2% Triton-X 100 
E 500 ng/µl 325 µl from C 325 µl 0.2% Triton-X 100 
F 250 ng/µl 325 µl from E 325 µl 0.2% Triton-X 100 
G 125 ng/µl 325 µl from F 325 µl 0.2% Triton-X 100 
H 0 µg/ml  400 µl 0.2% Triton-X 100 
 
Work Solution 
• Add 25 ml Solution A to 0.5 ml of Solution B 
o Solutions in kit 





• 25 µl sample/standard into each well 
• 200 µl work solution to each well 
• Place on shaker for 30 seconds 
• Incubate 30 minutes at 37°C 




A.9 UEA-1 Human Endothelial Cell Staining 
Materials 
• Rhodamine labeled Ulex Europaeus Agglutinin I (UEA-I) 
o Vector Laboratories, Product # RL-1062 
• Zinc-buffered formalin (Z-Fix) 
o Anatech Ltd., Product # 174 
• Triton X-100 
o Sigma-Aldrich, Product # T9284  
• Bovine Serum Albumin (BSA) 
o Sigma-Aldrich, Product # A1933 
• Phosphate buffered saline (PBS) 
o Life Technologies, Product # 21300-025 
 
Procedure 
• Wash cells 2x with PBS for 5 minutes 
• Fix cells in Z-fix at 4ºC for 10 minutes 
• Wash cells 2x for 5 minutes/wash  in PBS  
• Permeabilize cells with 0.5% Triton X-100 in PBS for 20 minutes at RT 
o 50 μl Triton X-100 in 10 ml of PBS 
• Wash cells 2x for 5 mins/wash minutes in PBS 
• Add Stain, incubate for 45 mins at RT [Cover in foil] 
o 1% BSA in PBS 
o Rhodamine UEA-1 1:100 dilution in PBS 
o For 1 ml of Stain 
 10 mg of BSA  
 10 μl of PBS 
• Wash cells 2x for 5 mins/wash minutes in PBS [Cover in foil] 




A.10 Enzyme-Linked Immunoabsorbant Assay - BMP-2 
Materials 
• Human/Mouse/Rat BMP-2 Quantikine ELISA kit 
o R&D Systems, Product # DBP200 
o Included in the kit 
 BMP-2 Microplate 
 BMP-2 Standard 
 BMP-2 Conjugate 
 Assay Diluent RD1-9 
 Calibrator Diluent RD5P Concentrate 
 Wash Buffer Concentrate 
 Color Reagent A 
 Color Reagent B 
 Stop Solution 
 Plate Sealers 
 
Sample Collection and Lysis 
• Collect media at time points and flash-freeze in liquid N2  
• Freeze in -80°C freezer until all samples are collected 
 
Reagent Preparation 
• Wash buffer 
o Dilute 20 ml of Wash Buffer Concentrate into 480 ml diH2O   
• Substrate Solution 
o Add Color Reagents A and B together in equal volumes 15 minutes prior to use 
• Calibrator Diluent RD5P (1X) 
o Dilute 20 ml of Calibrator RD5P into  180 ml of diH2O, let sit for 15 mins prior to 
use 
• BMP-2 Standard 
o Reconstitute BMP-2 Standard in 1.0 ml of diH2O, let sit for 15 mins prior to use 
 
BMP-2 Standard Values 
A 4000 pg/ml 200 µl of OPN Standard 800 µl Calibrator Diluent RD5P 
B 2000 pg/ml 500 µl of A 500 µl Calibrator Diluent RD5P 
C 1000 pg/ml 500 µl of B 500 µl Calibrator Diluent RD5P 
D 500 pg/ml 500 µl of C 500 µl Calibrator Diluent RD5P 
E 250 pg/ml 500 µl of D 500 µl Calibrator Diluent RD5P 
F 125 pg/ml 500 µl of E 500 µl Calibrator Diluent RD5P 
G 62.5 pg/ml 500 µl of F 500 µl Calibrator Diluent RD5P 
H 0 pg/ml  500 µl Calibrator Diluent RD5P 
 
Procedure 
• Add 100 µl of Assay Diluent RD1-19 to each well 
• Add 50 µl of standard/sample to well. Add in duplicate 
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• Cover with adhesive strip and incubate at room temperature for 2 hours 
• Aspirate each well and wash 4X in Wash Buffer 
• Blot against clean paper towels after washing to remove excess liquid 
• Add 200 µl of BMP-2 Conjugate to each well 
• Cover with new adhesive strip and incubate at room temperature for 2 hours 
• Aspirate each well and wash 4X in Wash Buffer 
• Blot against clean paper towels after washing to remove excess liquid 
• Add 200 µl of Substrate Solution to each well (make solution 15 mins prior to use) 
• Cover with adhesive strip and incubate at room temperature for 30 mins. Cover from 
light. 
• Add 50 µl of Stop Solution to each well 




A.11 Enzyme-Linked Immunoabsorbant Assay - Osteopontin 
Materials 
• Human Osteopontin (OPN) Quantikine ELISA kit 
o R&D Systems, Product # DOST00 
o Included in the kit 
 OPN Microplate 
 OPN Standard 
 OPN Conjugate 
 Assay Diluent RD1-9 
 Calibrator Diluent RD5-24 Concentrate 
 Wash Buffer Concentrate 
 Color Reagent A 
 Color Reagent B 
 Stop Solution 
 Plate Sealers 
 
Sample Collection and Lysis 
• Collect media at time points and flash-freeze in liquid N2  
• Freeze in -80°C freezer until all samples are collected 
 
Reagent Preparation 
• Wash buffer 
o Dilute 20 ml of Wash Buffer Concentrate into 480 ml diH2O   
• Substrate Solution 
o Add Color Reagents A and B together in equal volumes 15 minutes prior to use 
• OPN Standard 
o Reconstitute OPN Standard in 1.0 ml of diH2O, let sit for 15 mins prior to use 
 
OPN Standard Values 
A 20 ng/ml 60 µl of OPN Standard 540 µl Calibrator Diluent RD5-24 
B 10 ng/ml 300 µl of A 300 µl Calibrator Diluent RD5-24 
C 5 ng/ml 300 µl of B 300 µl Calibrator Diluent RD5-24 
D 2.5 ng/ml 300 µl of C 300 µl Calibrator Diluent RD5-24 
E 1.25 ng/ml 300 µl of D 300 µl Calibrator Diluent RD5-24 
F 0.625 ng/ml 300 µl of E 300 µl Calibrator Diluent RD5-24 
G 0.312 ng/ml 300 µl of F 300 µl Calibrator Diluent RD5-24 





• Add 100 µl of Assay Diluent RD1-6 to each well 
• Add 50 µl of standard/sample to well. Add in duplicate 
• Cover with adhesive strip and incubate at room temperature for 2 hours 
• Aspirate each well and wash 4X in Wash Buffer 
• Blot against clean paper towels after washing to remove excess liquid 
• Add 200 µl of OPN Conjugate to each well 
• Cover with new adhesive strip and incubate at room temperature for 2 hours 
• Aspirate each well and wash 4X in Wash Buffer 
• Blot against clean paper towels after washing to remove excess liquid 
• Add 200 µl of Substrate Solution to each well (make solution 15 mins prior to use) 
• Cover with adhesive strip and incubate at room temperature for 30 mins. Cover from 
light. 
• Add 50 µl of Stop Solution to each well 









o Fisher Scientific, Product # T324 
• 100% Ethanol (EtOH) 
o Sigma-Aldrich, Product #459844 
• Scientific Device Laboratory Aqua Hold Pap Pen 
o Fisher Scientific, Product # 23-769-300 
• Thermo Scientific *Lab Vision* Mayer's Hematoxylin 
o Fisher Scientific, Product # TA-125-MH 
• Ammonium hydroxide 
o Sigma-Aldrich, Product # 320145 
• Eosin Y Stain 
o Fisher Scientific, Product # 2845-32 
• Fisher HealthCare *Xylene* Mounting Media 
o Fisher Scientific, Product # 23-245-691 
 
Rehydration of Slides 
• Place slides in toluene for 5 mins 
• Repeat in new toluene for 5 mins 
• Place slides in 100% EtOH for 3 mins 
• Repeat in 100% EtOH for 3 mins 
• Place slides in 95% EtOH for 3 mins 
• Repeat in 95% EtOH for 3 mins 
• Place in ddH2O for > 30 secs 
 
H&E Staining 
• Use PAP pen to mark around tissue section (make a box around each section, don’t have 
to get that close to each tissue) 
• Place slides in hematoxylin bath for 10 mins at room temperature 
• Rinse gently in ddH2O bath 
• Dip slides 10X in 0.037 M ammonium  
• Rinse slides in ddH2O bath for 5 mins 
• Place slides in 95% EtOH for 30 secs 
• Place slides in eosin for 30-60 secs 
Dehydration of Slides 
• Place slides 95% EtOH for 1 min 
• Repeat in new 95% EtOH for 1 min 
• Place slides in 100% EtOH for 2 mins 
• Repeat in new 100% EtOH for 2 mins 
• Place slides in toluene for 2 mins 
• Repeat in new toluene for 2 mins 
• Apply mounting medium (Xylene-based) and place coverglass over samples 
• Remove bubbles with edge of forceps and allow to dry before imaging  
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o Fisher Scientific, Product # T324 
• 100% Ethanol (EtOH) 
o Sigma-Aldrich, Product #459844 
• Scientific Device Laboratory Aqua Hold Pap Pen 
o Fisher Scientific, Product # 23-769-300 
• Silver Nitrate 
o Sigma-Aldrich, Product #S6506 
• Sodium Thiosulfate 
o Sigma-Aldrich, Product #217263 
• Eosin Y Stain 
o Fisher Scientific, Product # 2845-32 
• Fisher HealthCare *Xylene* Mounting Media 
o Fisher Scientific, Product # 23-245-691 
 
Rehydration of Slides 
• Place slides in toluene for 5 mins 
• Repeat in new toluene for 5 mins 
• Place slides in 100% EtOH for 3 mins 
• Repeat in 100% EtOH for 3 mins 
• Place slides in 95% EtOH for 3 mins 
• Repeat in 95% EtOH for 3 mins 
• Place in ddH2O for > 30 secs 
 
VK Staining (Eosin Counterstain) 
• Use PAP pen to mark around tissue section (make a box around each section, don’t have 
to get that close to each tissue) 
• Place slides in 1% silver nitrate for 1 hour under UV 
o 1 gram of silver nitrate in 100 mls of ddH2O 
• Rinse gently in ddH2O bath 
• Place slides in 5% sodium thiosulfate for 5 mins 
o 5 grams of sodium thiosulfate in 100 mls of ddH2O 
• Rinse slides in ddH2O bath for 5 mins 
• Place slides in 95% EtOH for 30 secs 
• Place slides in eosin for 30-60 secs 
 
Dehydration of Slides 
• Place slides 95% EtOH for 1 min 
• Repeat in new 95% EtOH for 1 min 
• Place slides in 100% EtOH for 2 mins 
• Repeat in new 100% EtOH for 2 mins 
• Place slides in toluene for 2 mins 
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• Repeat in new toluene for 2 mins 
• Apply mounting medium (Xylene-based) and place coverglass over samples 








o Fisher Scientific, Product # T324 
• 100% Ethanol (EtOH) 
o Sigma-Aldrich, Product #459844 
• HRP Mouse (DAB+) EnVision Kit 
o Dako, Product #K4006 
o Kit includes 
 DAKO antigen retrieval solution 
 Peroxidase block 
 DAB+ Substrate Chromagen 
• Tris-Base 
o Fisher Scientific, Product #BP152-1  
• Sodium chloride (NaCl) 
o Fisher Scientific, Product #S640 
• Triton X-100 
o Sigma-Aldrich, Product # T9284  
• Scientific Device Laboratory Aqua Hold Pap Pen 
o Fisher Scientific, Product # 23-769-300 
• Monoclonal Mouse Anti-Human CD31, Endothelial Cell Antibody 
o Dako, Product #M0823 
• Thermo Scientific *Lab Vision* Mayer's Hematoxylin 
o Fisher Scientific, Product # TA-125-MH 
• Ammonium hydroxide 
o Sigma-Aldrich, Product # 320145 
• Eosin Y Stain 
o Fisher Scientific, Product # 2845-32 
• Fisher HealthCare *Xylene* Mounting Media 





Prepare stock solutions 
• Make 10X Tris-Buffered Saline (500 mls) 
o 44 g NaCl 
o 15.75 g Tris 
o 500 ml of ddH2O 
• Make 1X Tris-Buffered Saline + 0.1% Triton-X 100 (100 mls) 
o 10 mls 10X TBS 
o 1 ml Triton-X 100 





Rehydration of Slides 
• Place slides in toluene for 5 mins 
• Repeat in new toluene for 5 mins 
• Place slides in 100% EtOH for 3 mins 
• Repeat in 100% EtOH for 3 mins 
• Place slides in 95% EtOH for 3 mins 
• Repeat in 95% EtOH for 3 mins 
• Place in ddH2O for > 30 secs 
 
CD31 Staining (H&E Counterstain) 
• Add ddH2O to heating compartment of food steamer 
• Add DAKO antigen retrieval solution to slide cassette and insert slides 
• Place cassette in steamer and steam for 25 mins 
• Wash slides in TBST and remove moisture from around tissues  
• Use PAP pen to mark around tissue section (make a box around each section, don’t have 
to get that close to each tissue) 
• Apply peroxidase block (enough to cover the specimen) and incubate at RT for 5 mins 
• Wash gently with ddH2O wash bottle without focusing stream on sample 
• Place in TBST bath and remove moisture from around tissues 
• Add primary antibody and incubate overnight at 4ºC (cover samples in plastic trays with 
parafilm) 




CD31/UEA-1 Staining (H&E Counterstain) 
• Wash in TBST and remove excess moisture 
• Apply secondary antibody and incubate at RT for 30 mins 
• Apply liquid DAB+ substrate-chromagen and incubate for 10 mins at RT 
• Rinse gently with ddH2O wash bottle without focusing flow on the sample  
• Place slides in hematoxylin bath for 10 mins at RT 
• Rinse gently in ddH2O bath 
• Dip slides 10X in 0.037 M ammonium  
• Rinse slides in ddH2O bath for 5 mins 
• Place slides in 95% EtOH for 30 secs 
• Place slides in eosin for 30-60 secs 
 
 
Dehydration of Slides 
• Place slides 95% EtOH for 1 min 
• Repeat in new 95% EtOH for 1 min 
• Place slides in 100% EtOH for 2 mins 
• Repeat in new 100% EtOH for 2 mins 
• Place slides in toluene for 2 mins 
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• Repeat in new toluene for 2 mins 
• Apply mounting medium (Xylene-based) and place coverglass over samples 








o Fisher Scientific, Product # T324 
• 100% Ethanol (EtOH) 
o Sigma-Aldrich, Product #459844 
• Tris-Base 
o Fisher Scientific, Product #BP152-1  
• Sodium chloride (NaCl) 
o Fisher Scientific, Product #S640 
• Triton X-100 
o Sigma-Aldrich, Product # T9284  
• Scientific Device Laboratory Aqua Hold Pap Pen 
o Fisher Scientific, Product # 23-769-300 
• Antigen Unmasking Solution, Citric Acid Based 
o Vector Laboratories, Product # H-3300 
• Streptavidin/Biotin Blocking Kit 
o Vector Laboratories, Product # SP-2002 
• Carbo-Free Blocking Solution (10X Concentrate) 
o Vector Laboratories, Product # SP-5040 
• Biotinylated Ulex Europaeus Agglutinin I (UEA-1) Antibody 
o Vector Laboratories, Product # B-1065 
• ImmPACT DAB Peroxidase Substrate 
o Vector Laboratories, Product # SK-4105 
• Thermo Scientific *Lab Vision* Mayer's Hematoxylin 
o Fisher Scientific, Product # TA-125-MH 
• Ammonium hydroxide 
o Sigma-Aldrich, Product # 320145 
• Eosin Y Stain 
o Fisher Scientific, Product # 2845-32 
• Fisher HealthCare *Xylene* Mounting Media 
o Fisher Scientific, Product # 23-245-691 
 
Prepare stock solutions 
• Make 10X Tris-Buffered Saline (500 mls) 
o 44 g NaCl 
o 15.75 g Tris 
o 500 ml of ddH2O 
• Make 1X Tris-Buffered Saline + 0.1% Triton-X 100 (100 mls) 
o 10 mls 10X TBS 
o 1 ml Triton-X 100 
o Bring volume up to 100 mls with ddH2O 
• Make 1X Carbo-Free Blocking Solution 
o 1 ml of 10X Carbo-Free Blocking Solution (stock) 
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o 9 ml of ddH2O 
• Make VECTASTAIN Elite ABC Reagent 
o 5 mls of TBST 
o 2 drops of Reagent A (gray label) 
o 2 drops of Reagent B (gray label) 
o Allow to stand for 30 minutes prior to use 
• Make ImmPACT DAB Peroxidase Substrate 
o 1 ml of ImmPACT DAB Diluent 
o 1 drop of ImmPACT DAB Chromogen concentrate 
 
Rehydration of Slides 
• Place slides in toluene for 5 mins 
• Repeat in new toluene for 5 mins 
• Place slides in 100% EtOH for 3 mins 
• Repeat in 100% EtOH for 3 mins 
• Place slides in 95% EtOH for 3 mins 
• Repeat in 95% EtOH for 3 mins 
• Place in ddH2O for 5 minuites 
 
UEA-1 Staining (H&E Counterstain) 
• Add ddH2O to heating compartment of food steamer 
• Add Antigen Unmasking Solution to slide cassette and insert slides 
• Place cassette in steamer and steam for 25 mins 
• Wash slides in TBST and remove moisture from around tissues  
• Use PAP pen to mark around tissue section (make a box around each section, don’t have 
to get that close to each tissue) 
• Incubate sections with streptavidin solution for 15 mins 
• Rinse gently with ddH2O wash bottle without focusing flow on the sample  
• Incubate sections with biotin solution for 15 mins 
• Rinse gently with ddH2O wash bottle without focusing flow on the sample  
• Block non-specific binding by incubating sections in Carbo-Free Blocking Solution for 
30 mins at RT 
• Wash gently in TBST for 5 mins 
• Add UEA-1 primary antibody (2-20 µg/ml final concentration) and incubate for 30 
minutes at room temperature 
o Biotinylated Anti-UEA-1   1:100 dilution in PBS 
****Prepare VectaSTAIN Elite ABC Reagent**** 
• Wash in TBST for 5 mins at RT and remove excess moisture 
• Incubate sections in VECTASTAIN Elite ABC Reagent for 30 mins at RT 
• Wash in TBST for 5 mins at RT and remove excess moisture 
• Add ImmPACT DAB for 2-10 mins (until it develops) at RT 
• Wash in ddH2O for 5 mins at RT 
• Place slides in hematoxylin bath for 10 mins at RT 
• Rinse gently in ddH2O bath 
• Dip slides 10X in 0.037 M ammonium  
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• Rinse slides in ddH2O bath for 5 mins 
• Place slides in 95% EtOH for 30 secs 
• Place slides in eosin for 30-60 secs 
 
Dehydration of Slides 
• Place slides 95% EtOH for 1 min 
• Repeat in new 95% EtOH for 1 min 
• Place slides in 100% EtOH for 2 mins 
• Repeat in new 100% EtOH for 2 mins 
• Place slides in toluene for 2 mins 
• Repeat in new toluene for 2 mins 
• Apply mounting medium (Xylene-based) and place coverglass over samples 




A.16 AR-G2 Rheometer 
Set up 
• Turn on Air 
• Close the valve – push latch up to unlock 
• Turn on switch for the rheometer 
o WAIT until starts spinning before doing anything else 
• Unscrew black cover gently from the top – NEVER pull off screw from bottom 
• Change the stage by hitting the left most button on machine 
o Reconnect each component until it clicks 
o Order does not matter 
• Switch screws if necessary 
o Pull up slowly, do not touch sides 
o Do NOT add geometry until after configure inertia 
 
Calibration 
• Open AR Instrument Control Program 
• Options  Instrument  Inertia  Calibrate 
• Add geometry 
o Hand tighten from screw on top, NEVER from the bottom 
• Select plate (8 mm or 20 mm) in Plate Settings 
• Plate  Settings  Calibrate (sets geometry inertia)  
• Options Instrument  Miscellaneous  Calibrate  Apply 
• Lower stage by pushing down arrow on program, get close to bottom 
• Instrument  Gap  Zero gap  Continue 
• Instrument  Rotational Mapping  Set to 1 iteration  Perform Mapping 
o Takes about 5 minutes to complete 
• Load oscillatory procedure 
o Sets parameters to measure 
o If new, Instrument  Oscillatory Mapping  Perform New Mapping 
• Add sample 
• Set gap to 1000 microns 
o Make sure touches sample 
• Run Experiment 
 
Turning off 
• Close program 
• Switch back screw to 20 mm screw 
• Place foil over stage 
• Turn off rheometer 




A.17 Compressive Testing Machine 
Set up  Do 2 hours before testing 
• Screw adaptor into base 
• Turn on (in this order) 
o Computer 
o Control Module  black 
o Power Module  white 
 Switch to “ON” 
 Pull out emergency stop 
• Will max out piston to the top 
• Screw in platens 
o Bigger platen to bottom 
o Smaller platen to top 
• Double click “Start 1st 1220 800LM” 
o Opens Machine Calibration 
 Do NOT mess with 
• Double click “V2 Script Program” 
• File  Open  DMA Control 
• Machine Offline  Go online 
 
Machine Offset 
• Utilities  Offset Readout 
• 1 actuator 
• 3 channels 
o Encoder1  tells machine where to go 
o Load  cell, gives reliable value 
o LVDT  sensor that measures the position of the piston, gives a reliable value 
• Offset all values to 0  
o Encoder1, Load, LVDT 
 
Run Sample 
• Click “Switch On” 
o Green light on White Power Module turns on 
• Negative values in system move piston down 
• Values are in mm 
• Target point – where piston will move 
• Time – duration for movement 
• Click “DAQ” 
o Set to Manual 
o Need unique name for every sample 
 Only 8 characters, avoid spaces 
• Log Rate  200 Hz 





• Test  Monotomic 
• Target point – where to move to while testing 
• Time – how long during ramp to point 
o Ramp – Linear 
o Sine – Sine wave performed 
• Left Panel  triggers to make stop 
o Max displacement set to 5 mm 
• Notes 
o Rate at which compression occurs affects values  pick 1 number for settings 
and keep constant 
 Time to ramp – 0.5 to 2 seconds 
• Move start point to right above gel 
• DAQ  Set name  Close 
• Start Recording  Start Test  Stop Recording 
 
Dynamic Testing 
• Test  Dynamic 
• Mean – absolute position 
• End cycle count – absolute value 
• Start Recording  Start Test  Stop Recording 
 
Exporting Data 
• DAQ  Export  All Data  Export 
o Outputs Excel File 
o Do NOT touch anything until “Done” 
o Sheet 1 – first set of data 
• Excel File contains  
o LVDT – position where it is 
o Load – force in grams 
• Convert to stress and strain to calculate Apparent Young’s Modulus 
• Force = (Load/1000) x (9.8 m/s2) 
• Area = cross sectional area of top of gel 
o Measure with micrometer or from picture in ImageJ 
• Strain = calculate from LVDT values 
• Plot stress vs. strain curve 












• Turn DAQ system to “Switch Off” 
• Machine  “Go Offline” 
• File  Quit (Do not hit X Button) 
• Close the Machine Control Application 
• Take out platens 
o MAKE SURE THESE ARE REMOVED 
• Push Emergency Stop Button 
o Cuts Power from system 
o MAKE SURE PLATENS ARE REMOVED OR THEY WILL GET CRUSHED 
• Turn off Power Module – white 
• Turn off Control Module – black 










Fabrication and Delivery of 3D Cell-Seeded Hydrogel 
Microenvironments 
B.1 Introduction 
 In contrast to traditional tissue engineering techniques in which cells are seeded onto a 
scaffold, modular tissue engineering aims to fabricate engineered tissues through the assembly of 
cell-seeded biomimetic structures [1]. Tissue subunits, or “modules,” are utilized to generate 
larger tissue structures that have been employed for orthopedic, vascular, and numerous other 
applications. Methods such as micro-fabrication of cell-laden hydrogels [2, 3], cell printing [4, 
5], or the creation of cell sheets [6, 7] have been employed in modular tissue engineering 
applications. Current work in the formation of cell-seeded hydrogels includes creating collagen 
microspheres in small droplets and through water-in-oil emulsion techniques [8, 9]. Cheng et. al 
utilized two different types of microspheres fabricated in this method to assemble larger tissue 
structures with compartmentalized cell phenotypes [10].  
 Our lab has previously generated cellular microenvironments, or “microbeads,” by 
encapsulating stem cells directly within hydrogels composed of natural ECM proteins and 
polysaccharides such as collagen, fibrin, agarose and chitosan [11-16]. Multiple factors including 
soluble cues, cell-to-cell contacts, and mechanical cues can be modulated in these cellular niches 
as an attempt to control cell adhesion, proliferation, phenotype and differentiation. These robust 
cellular microenvironments have potential in matrix-enhanced cell delivery applications that can 
be applied numerous tissue engineering applications.   
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 In the present work, we describe the methodology behind fabricating protein and 
polysaccharide-based microbeads. Numerous bead formulations are described as well as the 
effect on microbead size and size distribution by varying oil viscosity and impeller speed. Cell 
viability after microbead fabrication and in long-term culture is assessed and delivery methods of 
microbeads are evaluated to demonstrate feasibility of using these microbeads in modular tissue 
engineering applications. 
 
B.2 Materials and Methods 
General Microbead Fabrication 
 The general process of microbead fabrication using a water-in-oil emulsion technique is 
summarized in Figure B.1. Extracellular matrix (ECM) proteins and polysaccharides were 
reconstituted from a lyophilized form into a liquid and then mixed with chemicals, enzymes, 
growth factors, and cross-linking agents to form 3D hydrogels microbeads. Cells were added 
directly into the pre-gelled mixture to allow for homogenous distribution of the cells upon 
gelation. The solution was then injected into a polydimethylsiloxane (PDMS; Xiameter, Dow 
Corning, Midland, MI) bath and stirred with a double-bladed impeller. The pH of the gel solution 
and/or the temperature of the PDMS bath were then changed to allow for gelation and formation 
of stable microbeads. The microbeads formed in the oil phase were collected by centrifuging the 
mixture at 200 x g and were washed in PBS containing a surfactant, Pluronic L101 (BASF, 







Figure B.1 – Microbead preparation process. (A) Schematic of microbead fabrication process.































 Numerous microbead compositions have been fabricated using different biomaterials and 
gelation initiators. Each formulation provides a matrix for a tissue-specific application.  
 Collagen microbeads were generated by mixing 5x concentrated Dulbecco’s Modified 
Eagle’s Medium (DMEM; Life Technologies, Carlsbad, CA), Fetal Bovine Serum (FBS; Life 
Technologies), 0.1 N sodium hydroxide (NaOH; Sigma Aldrich, St. Louis, MO), 6.0 mg/ml 
bovine type I collagen (MP Biomedicals, Solon, OH), and 1 mM glyoxal (Sigma) for a final 
concentration of 3.0 mg/ml collagen in the microbeads. The mixture was emulsified in PDMS 
and collagen polymerization was initiated by raising the temperature of the mixture to 37°C. 
After mixing for 25 minutes, microbeads were collected from the oil phase by centrifugation at 
200 x g.  
 Collagen/agarose composite microbeads were fabricated by mixing 5x concentrated 
DMEM, FBS, 0.1 N NaOH, 4.0 mg/ml bovine type I collagen and 2.0% agarose (Fisher 
Scientific, Pittsburgh, PA) in varying ratios [11, 12]. Collagen polymerization is both 
temperature (37°C) and pH (7) sensitive; therefore, maintaining a cold acidic state prevents 
premature gelation. Agarose, on the other hand, polymerizes in a cold state. Therefore, collagen 
was precooled to 4°C and the agarose was preheated to 60°C. All components were then injected 
into an emulsification bath containing PDMS kept at 37°C and mixed with an impeller for 6 
minutes to allow for even formation of ECM droplets. The mixture was then cooled on ice for 30 
minutes to form spherical beads. Collagen/agarose microbeads have beneficial properties for 
osteogenic applications.  
 Chitosan/fibrin microbeads were prepared by adding chitosan (2% wt/vol) and fibrin 
(stock solution 60 mg/ml) in a pre-cooled solution containing β-GP and 0.1 UT/ml thrombin 
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(Sigma) at various chitosan-fibrin ratios [13]. During the emulsification step, the solution was 
injected into a PDMS bath kept at 4°C. Thermal and enzymatic gelation occurred by raising the 
temperature to 37°C and mixing for 20 minutes. The emulsion temperature was then reduced to 
4°C to stabilize the microbeads. Microbeads were centrifuged out of the oil phase at 200 x g.  
 Collagen/chitosan microbeads have been prepared in two methods. In the first method, 5 
mg/ml of high molecular weight chitosan (Sigma) was dissolved in 0.02 N acetic acid and was 
crosslinked with 7.5% genipin (Wako Chemicals USA, Richmond, VA) for 15 mins at 37°C. 
The solution was then cooled for 5 mins at 25°C. Type I collagen (4 mg/ml) and 15% gelatin 
Type A at 50°C and 4°C, respectively, were then added to the chitosan solution. A 0.1 N NaOH 
solution at 4°C was quickly added to the matrix mixture to neutralize the pH.  
In the second method, 2% wt/vol chitosan (FMC BioPolymer, Philadelphia, PA) 
dissolved in 0.1 N acetic acid and collagen (stock solution 4 mg/ml) were added together with 
physical and chemical crosslinkers, beta-glycerophosphate (β-GP; Sigma) and 1 mM glyoxal, 
respectively [14, 15]. The mixture was injected into a PDMS bath kept on ice and co-
polymerization was conducted by increasing the temperature of the bath to 37°C. Microbeads 
were then collected from the oil phase by centrifuging the mixture at 200 x g.  
 Collagen/hydroxyapatite (HA) microbeads have been formulated through the addition of 
particulate nano-HA (<200 nm; Sigma) to the pre-gelled mixture. A cold mixture of collagen 
(final concentration 3 mg/ml), nano-HA (final concentration 10 mg/ml), 1x DMEM, 5x DMEM, 
FBS, and 0.1 M NaOH then injected into the PDMS phase kept on ice. After 5 minutes of 
emulsification, the temperature was raised to 37°C and rotated for another 25 minutes to allow 
for collagen gelation. Collagen-HA beads were collected through centrifugation at 200 x g. The 
206 
 
addition of HA particles increased the density of the microbeads and facilitated separation from 
the oil phase.  
 Collagen/fibrin composite microbeads have been fabricated by mixing collagen (final 
concentration 1.25 mg/ml) and fibrin (final concentration 1.25 mg/ml) with 5x DMEM, 1x 
DMEM, FBS, 0.1 M NaOH, and thrombin (final concentration 1 UT/ml). The gel mixture was 
injected into PDMS and kept on ice for 5 minutes [16]. The temperature was then raised to 37°C 
and mixed for 25 minutes to allow for gelation of collagen and fibrin. Microbeads were collected 
through centrifugation at 200 x g.  
 All of the microbead formulations listed above were stained with EZBlue reagent 
(Sigma) to allow for visualization of the protein content within microbeads.  
 
Effect of Viscosity and Impeller Speed on Microbead Diameter and Size Distribution 
 The effect of oil viscosity was examined on collagen/chitosan microbeads. The dynamic 
viscosity of the PDMS oil was varied from 20 centistokes (CS), 50 CS, and 100 CS to determine 
its effect on microbead size and size distribution. Microbeads were collected and visualized 
under a light microscope and microbead diameter was analyzed using ImageJ software (National 
Institute of Health, Bethesda, MD).  
 The effect of impeller speed was investigated on collagen/HA microbeads. The impeller 
speed was varied from 600 to 1200 revolutions per minute (RPM) in increments of 200 RPM. 






Cell Viability Assessment 
 MC3T3-E1 Subclone 14 (generously provided by Dr. R.T. Franchesci, University of 
Michigan) [17] were cultured in Minimum Essential Medium (αMEM) alpha (Life 
Technologies) supplemented with 10% mesenchymal stem cell-qualified FBS and 1% PS. At 
passage 8, MC3T3 (1.0 X 106 cells/ml) were added directly in to the gel mix at to allow for 
homogenous distribution within microbeads. Collagen/fibrin (mass ratio 50/50) composite 
microbeads were fabricated in 100 CS PDMS using an impeller speed of 600 RPM. Microbeads 
were cultured statically in 15 ml centrifuge tubes. Cell viability and cell morphology were 
assessed at days 1 and 7 using a vital stain kit (Live/Dead®, Life Technologies). Microbeads 
were washed three times in sterile PBS for 5 mins/wash and then incubated at 37°C for 45 min in 
a solution containing 4.0 µm calcein-AM and 4.0 µm ethidium homodimer-1 in PBS. After three 
subsequent PBS washes, microbeads were imaged using a laser scanning confocal microscope 
(Olympus America Inc., Center Valley, PA).  
   
Cell Morphology (Actin, Nucleus) 
 To assess cell morphology, the actin cytoskeleton was stained with either Texas-red 
phalloidin or FITC phalloidin (Life Technologies). The cell nucleus was visualized using a DAPI 
stain (Life Technologies). Cells, gels, and microbeads to be stained and imaged were first 
washed twice in PBS for five minutes at room temperature. They were then subsequently fixed 
using Z-fix (buffered zinc formalin fixative, Anatech Ltd, Battle Creek, MI) for ten minutes at 
4°C. After fixation, the samples were washed twice in PBS at room temperature. To 
permeabilize the cell membranes and allow for infiltration of staining, the samples were 
permeabilized with 0.5% Triton X-100 (Sigma) for twenty minutes at room temperature. The 
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samples were then washed twice in PBS for five minutes and stored in PBS until staining was 
performed. The stain was created by mixing Bovine Serum Albumin (Sigma) at 10 mg/mL of 
stain, labeled phalloidin at 25 µL/mL, DAPI at 1 µL/mL, and 974 µL/mL of PBS. Stain was 
added to the samples for 45 minutes at room temperature in the dark. The samples were then 
washed in PBS for 5 minutes, and stored in PBS at 4°C in the dark until imaging. Imaging was 
performed using a laser scanning confocal microscope (Nikon A-1, Nikon Instruments, Melville, 
USA) at the MIL center in the NCRC.  
 
Visualization of Microbeads  
 In order to visualize the structure of the microbeads, Collagen-Fibrin microbeads were 
created using FITC-fibrinogen (Life Technologies). FITC-fibrinogen was added at 9 µg/mL to 
the filtered fibrinogen mixture in the dark. Collagen-Fibrin microbeads were then created as 
previously described, in the dark, using human mesenchymal stem cells at 250,000 cells/mL of 
bead mixture. The microbeads were cultured for seven days, and then subsequently imaged in 
fibrin gels.  
 
Microbead construct creation and visualization 
 A potential delivery method for microbeads is the creation of constructs for implant. 
Using a previously described method [14], centrifuged constructs were created using collagen-
chitosan beads with embedded human dermal fibroblasts and human mesenchymal stem cells at 
a concentration of 1,000,000 cells/mL of bead mixture. Disk constructs were created on top of 
filter paper, removed, and placed into culture dishes for seven days. At the one and seven day 
mark, the samples were fixed, permeabilized, and stained with FITC-phalloidin and DAPI for 
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morphological visualization. Live/Dead staining was also performed at the day one and day 
seven mark to observe cell viability. 
 
Injectable Delivery of Microbeads 
 Microbeads were delivered two ways. The first method involved the delivery of FITC 
collagen fibrin microbeads cultured for 7 days through a 25 ½ gauge needle in a fibrin gel. 500 
µL of beads, at a concentration of 1 mL of bead preparation/ mL of media, were centrifuged in a 
microcentrifuge tube at 200 g for five minutes. The media was then aspirated off the beads. In 
order to create the fibrin gel for delivery, bmMSC FBS (Gibco, Grand Island, NY) at 10%, 1x 
DMEM at 22.5%, fibrinogen at a  final concentration of 2.5 mg/mL, and thrombin at a final 
concentration of 1 UT/mL were sequentially added to the bead mixture, and then aspirated using 
a syringe with attached needle. This mixture was then injected into a microscope imaging plate 
and allowed to set for 40 minutes, after which the samples were stained for their actin 
cytoskeleton and nuclei.  
 The second method of delivery involved the delivery of a microbead paste into a cartilage 
defect in a bovine knee. A bovine knee was acquired from Dunbar Meats (Milan, MI), and a 
layer of cartilage was removed from the knee joint. A plug of microbeads was prepared using 
centrifugation as previously described by Caldwell et al [14] with blue particles for visualization, 
and placed into the defect. Using a microspatula, the microbeads were fit to the defect. The joint 






B.3 Results  
Microbead Size and Morphology 
 Microbeads collected from the oil phase are shown in Figures B.2, B.3, and B.4. 
Microbead size varied inversely with both oil viscosity (Figure B.2) and impeller speed (Figure 
B.3). Average microbead size decreased from 505.6 µm at 20 CS to 247.5 µm at 100 CS. 
Furthermore, the size distribution became less variable with increasing oil viscosity as indicated 
by the decrease in standard deviation values. Similarly, microbead size decreased from 195.8 µm 





Figure B.2 – Effect of viscosity on microbead size and size distribution. Microbead size







Figure B.3 – Effect of impeller speed on microbead size and size distribution. Microbead size




 All composite microbead formulations depicted spherical morphology (Figure B.4). 
Homogenous blue staining in chitosan/collagen and collagen/HA microbeads implied an even 
distribution of the protein component within these microbead formulations. However, 
chitosan/fibrin microbeads exhibited a phase separation in their morphology with the chitosan 
forming a shell around the inner fibrin core. Collagen/HA microbeads exhibited homogenous 
dispersion of the nano-HA crystals throughout the microbeads as indicated by the darker images 
obtained through light microscopy.  
 
Cell Viability and Matrix Architecture within Microbeads 









 MC3T3 cells embedded within 50/50 collagen/fibrin microbeads demonstrated high 
viability (approximately 75% on day 1, and 90% on day 7) over seven days in culture, as shown 
in Figure B.5. Cells spread and proliferated over this time period within the microbeads. The 
collagen/fibrin fibrillar structure within microbeads was observed in the confocal reflectance 
images in Figure B.5. After seven days in culture, the microbeads with seeded MC3T3 cells 






 50/50 collagen/fibrin microbeads with bmMSC cultured for seven days and embedded in 
a fibrin gel demonstrated spreading and proliferation within and on the surface of the microbead 
(Figure B.6). A maximum intensity projection of a population of microbeads demonstrated that 
Figure B.5 – Cell viability of MC3T3 cells seeded within 50/50 collagen/fibrin composite
microbeads. Embedded cells remained viable after 1 and 7 days post-microbead fabrication.
Green staining indicates live cells, red staining indicates dead cells. Dashed areas depict areas of
microbeads. Scale bar = 200 µm. Confocal reflectance images of collagen/fibrin composite
microbeads demonstrated the matrix architecture throughout the culture period.
Day 7Day 1
200 µm 200 µm








microbeads could be visualized using FITC-fibrinogen, along with the actin cytoskeleton and 
nucleus of the human mesenchymal stem cells. A 3D reconstruction of a Z-Stack (Figure B.6) 
obtained of a singular microbead with embedded cells illustrated that the cytoskeleton spread 



























Figure B.6 – Cell spreading within COL/FIB microbeads. Actin (red) /DAPI (blue) Staining in
FITC (green) COL/FIB Microbeads after 7 days in microbead culture. Maximum intensity




 Collagen/fibrin microbeads were placed into a fibrin gel mixture and injected into a 
microscope well plate through a 25 ½ gauge needle, as shown in Figure B.7. The microbead and 
gel mixture was loaded through the needle into the syringe before gelation occurred, and a 
bubble-free gel was produced after needle injection. Collagen/fibrin microbeads with embedded 
bmMSC cultured for 7 days were able to be injected through a 25 ½ gauge needle in a fibrin gel 
with no apparent microbead or cell deformation, as seen by the microbead structure and 





 Collagen/chitosan microbeads with embedded bmMSC were successfully vacuumed into 
cohesive constructs that were removed from filter paper, transferred to a 24 well plate, and 























Figure B.7 – Delivery of Fibrin Gel with embedded Microbeads. Neither microbead shape or cell
morphology were altered after injection of microbeads through a needle. Actin Staining (red) in
FITC COL/FIB Microbeads after 7 days in microbead culture.
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over 7 days in culture. Additionally, confocal imaging of constructs indicated cell proliferation, 
































Figure B.8 – Vacuum molding of Constructs. Day 1 and Day 7 Live/Dead images of MSC
collagen seeded constructs. Green staining indicates live cells, red straining indicates dead cells.
Day 1 and Day 7 Actin/DAPI maximum intensity projection Images of MSC seeded constructs.
Green staining indicates actin cytoskeleton, blue staining indicates cell nuclei.
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Delivery into Cow Knee 
 Centrifuged collagen/fibrin microbeads were successfully delivered into an osteochondral 
defect in a bovine knee through a plastic tube and push rod (Figure B.9). The deposited 
microbeads were formed to fit the defect through the use of a spatula, subsequently producing an 
adhered microbead paste. This microbead paste demonstrated the ability to resist shear and 














Figure B.9 – Delivery of microbeads into Cow Knee. Left to right, top to bottom - Delivery of
centrifuged microbeads, Microbeads in defect, Spreading of microbead paste, Mechanical articulation of




 In the current work, we have described methods to generate 3D cell-seeded hydrogel 
microenvironments, or “microbeads,” through a water-in-oil emulsion process. We have 
described two parameters, oil viscosity and impeller speed, which have a significant effect on the 
control of both the size and size distribution of the microbeads. These microbeads can be created 
in a batch fabrication process which allow for large volumes of cell-seeded microenvironments 
to be generated at once. Direct encapsulation of MC3T3 inside these 3D hydrogel 
microenvironments can be achieved at the time of fabrication and cell viability remained high for 
a week in culture. This format is advantageous in that cells can be cultured in small volumes of 
physiologically relevant matrices, and then injected into a wound site. 
 Cell-seeded hydrogel microenvironments demonstrate the ability to support cell 
spreading after a week in culture with the use of human mesenchymal stem cells embedded 
within collagen/chitosan microbeads. The spreading of cells within and on beads demonstrates 
the potential for these microenvironments as cell culture and delivery vehicles. The microbeads 
are amenable to delivery as a construct, through a needle in a fibrin gel, or as an adhesive paste 
to a wound site. The microbeads formed into a construct support cell spreading, indicating that 
the microbeads are able to successfully maintain cell viability despite dehydration via 
vacuuming, packing of the microbeads within the constructs, and shear stress due to fluid flow 
during vacuuming. Vacuumed constructs indicate potential for implantation of precultured and 
predifferentiated cell combinations, cell co-culture studies, and cell patterning. The ability of the 
microbeads to maintain cell morphology after needle injection demonstrates the robustness and 
potential for the use of microbeads as a deliverable carrier for cell based therapies. An adhesive 
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microbead paste attached to a mock defect site created within a cow joint and demonstration of 
resistance to deformation under mechanical articulation of the joint.  
 Cell-seeded hydrogel microenvironments have been previously utilized as cell delivery 
vehicles for orthopedic applications. There is a need for better bone repair strategies for healing 
of complex fractures, non-unions, tumor resected sites, and periodontal defects, which together 
constitute over 4 million procedures per year worldwide [18].  Kim et. al developed biomimetic 
collagen-apatite microspheres through a water-in-oil emulsion technique that served as 
microcarriers for rat bone marrow derived stem cells [19]. Although these structures did not 
encapsulate cells directly, they demonstrated favorable adhesion properties for cells and 
upregulation of alkaline phosphatase activity, an osteogenic marker, as well as gene expression 
for osteogenic genes such as osteocalcin. Other work has utilized RGD-modified alginate 
microspheres to deliver a co-culture of human bone marrow stromal cells with endothelial cells 
into mouse femoral defect model [20]. The implantation of these hydrogel microspheres 
demonstrated bone regeneration and promoted mineralization of delivered cells.  In our lab, we 
have generated collagen/agarose [12], collagen/chitosan [15], and collagen/fibrin microbeads 
[16] that have all demonstrated the ability to support osteogenic differentiation of embedded 
stem cells. Protein-based microbeads have supported osteogenic differentiation and remain 
viable post-injection. However, due to the relatively weak mechanical properties of the 
microbeads, they would not serve as favorable scaffolds for load bearing applications such as 
long bone defects. These systems could serve as cell delivery conduits for avascular necrosis, 
tumor resection areas, and oral-maxillofacial injuries and defects.  
 Hydrogel microenvironments could also be beneficial to deliver engineered vasculature 
into ischemic areas where blood supply to an organ is compromised. The lack of blood in 
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ischemic areas leads a decrease in oxygen, glucose, and nutrients as well as an increase in waste 
products. Extensive work has shown promise in creating sub-millimeter-sized collagen gel 
cylinders, or modules, and coating the outer surface of these structures with endothelial cells to 
enhance vascularization in vivo [21-23]. Collagen/fibrin composite materials are of particular 
interest for vasculogenic applications due to their roles in the wound healing response. 
Microbeads formed from these materials could be employed to generate vessel-like structures in 
vitro by co-culturing bmMSC and endothelial cells. The microbeads could be then concentrated 
into a paste and then injected into an ischemic site. These pre-formed vessels could presumably 
connect with host vasculature and transport blood throughout the transplanted area. Yet, these 
structures are difficult to form within microbeads due to the cell-generated forces which cause 
protein hydrogel structures to compact [24-26]. This dynamic process induces changes in the 
total protein density and cell cytoskeletal structure, thereby reducing the necessary cell tractional 
forces necessary to generate vessel-like structures [27]. Vascularization could also offer benefits 
in creating large tissue-engineered constructs by aiding in overcome to the diffusion limit 150-
200 µm [28].  Delivering vasculogenic microbeads could serve as key regulators in maintaining 
tissue viability post-implantation [29].  
 Further studies are underway to augment cell-seeded microbeads in an attempt to direct 
cell phenotype and stem cell differentiation. Currently, we culture cell-seeded microbeads 
statically in suspension, yet the use of bioreactors and spinner flask culture methods can also be 
employed to allow for constant agitation of the microenvironments, potentially inducing changes 
in cell phenotype [30, 31]. Moreover, we have begun investigating the incorporation of 
polymeric microspheres (2-5 µm diameter) into microbeads for controlled drug and growth 
factor release.  Gelatin microspheres have been fabricated in a similar emulsification process as 
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microbeads and have shown promise their ability to demonstrate controlled release of bone 
morphogenic protein-2 (BMP-2) [32].  Other alterations such as mineralizing microbeads 
through incubation in a modified culture media are underway in efforts to mechanically enhance 
the microbead structures.  
 Future work with cell-seeded microbeads involves the assembly of muti-phase constructs 
from different microbead formulations. One potential multi-phase construct, an osteochondral 
interface, has been manufactured with a continuous gradient between the bone-like and cartilage-
like structures using collagen/chitosan and collagen/chitosan/HA microbeads, respectively. Our 
future goals are to develop dual-phase constructs consisting of both osteogenic and vasculogenic 
microbeads for bone regeneration applications. Bone is a highly metabolic tissue requiring a 
large vascular supply throughout its structure. By providing both endothelial cells and bmMSC 
to bone defect sites, we aim to develop a dual-phase cell therapy system that mimics that natural 
microenvironment within bone [33].  Although we have described specific applications for cell-
seeded microbeads, these modules are amenable to any tissue/organ application such as islet 
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Exogenous Mineralization of Cell-Seeded and Unseeded  
Collagen-Chitosan Hydrogels using Modified Culture Medium 
C.1 Introduction 
There is a clear need for materials and methods to improve bone healing outcomes, particularly 
in cases of large defects and non-unions. The natural healing response is often not adequate to 
obtain full repair, and in such cases strategies to augment bone regeneration can be applied. 
Autografts and allografts are currently used clinically, but are hampered by issues of tissue 
availability and consistency [1]. The generic tissue engineering approach is to combine cells, 
biomaterials, and growth factors in a controlled fashion to create living materials that can replace 
damaged tissue and/or enhance regeneration. In the case of bone tissue, a wide range of 
strategies have been employed, using a variety of cell types, materials, and biochemical factors 
[2].  
 One strategy for potentiating the bone healing response is to use materials that have been 
exogenously mineralized using defined ionic solutions. Simulated body fluid (SBF) is a solution 
formulated with ion concentrations similar to blood plasma, which mineralizes the surfaces and 
pore walls of both natural [3-7] and synthetic [8-10] scaffolds if thermodynamic conditions are 
appropriate. Kokubo et. al [11] first described that soaking a biomaterial in SBF leads to the ex 
vivo formation of a bone-like apatite coating, and later studies showed that such coatings can be 
both osteoconductive [10] and osteoinductive [13], and can facilitate the regeneration of bone 
[12, 14]. SBF-induced mineralization has been further examined as a method for controlling 
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osteoconductivity [5, 9, 15], as well as for protein [13, 16] and gene delivery [17, 18]. Taken 
together, this body of work has shown that SBF can be a useful tool to modify biomaterials for 
bone tissue engineering applications. 
 Previous studies using SBF to modify material scaffolds have been performed in the absence 
of cells, since the high ionic concentrations and lack of nutrients in SBF are not conducive to the 
maintenance of cell growth. However, cell-seeded materials have been proposed for a number of 
orthopaedic applications. Natural biomaterial hydrogels are of interest in such cases due to their 
ability to mimic the natural extracellular matrix [19] and provide tissue-specific cues to enhance 
cell attachment and stem cell differentiation [20]. Direct encapsulation of cells during gel 
formation can be used to facilitate homogenous cell distribution in hydrogels. Numerous natural 
polymers including collagen [3], chitosan [21], and composite matrices [22-25] have been 
employed to engineer tissues and have shown promise in bone regeneration [26]. A drawback of 
natural hydrogel materials is that they often lack mechanical strength and represent only the 
protein component of the native bone tissue. Mineralization of such matrices has been pursued as 
a strategy to improve their mechanical properties and more closely mimic the native matrix [6], 
however the cellular component is typically not included during the mineralization process. 
 In the present study, we mineralized 3D hydrogels using a modified culture medium that 
combined the ionic constituents of SBF with the nutrients, vitamins, and amino acids needed to 
maintain cell viability. The model tissue constructs consisted of fibroblast cells embedded in 
collagen-chitosan hydrogel matrices developed previously in our laboratory [24, 26]. Fibroblasts 
were used as a model cell type to examine the feasibility of mineralization in the presence of 
cells, since this non-mineralizing cell type allowed us to isolate the effects of mineralization to 
the medium alone. Both unseeded and fibroblast-seeded hydrogels were exposed to mineralizing 
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solutions that were formulated to induce biomineralization while also supporting cell growth, 
and the effects of such treatment on mineral content, mechanical properties, and cellular viability 
were determined. Our primary goal was to demonstrate that mineralization of protein-based 
hydrogels is possible in the presence of cells. The ability to mineralize cell-seeded protein 
matrices could be useful in creating mechanically stable and osteogenic tissue constructs, as well 
as in studying the process of biomineralization. 
 
C.2 Materials and Methods 
Media formulations 
 The composition of the mineralization medium was based on previously studied simulated 
body fluid (SBF) formulations, with modifications to enhance both mineralization and the ability 
to support cell growth. The base medium was Dulbecco’s modified Eagle medium (DMEM; high 
glucose, Invitrogen, Carlsbad, CA, Catalog No. 12100), which was supplemented with ionic 
salts. Table C.1 shows the ion concentrations of relevant biological fluids and mineralizing 
media. The main augmentation to the modified medium formulation was a 4-fold increase in 
calcium (Ca2+) and phosphate (PO43-) in order to promote biomineralization, and an increased 
carbonate (HCO3-) level to provide buffering capacity. These modifications are further discussed 
in the Results and Discussion section. Liquid high glucose DMEM (Invitrogen, Catalog No. 




 The modified medium (mDMEM) formulation was prepared by adding salts directly to 
DMEM to achieve final concentrations of 141 mM NaCl, 5.3 mM KCl, 6.2 mM CaCl2·H2O, 1.0 
mM MgCl2, 8.4 mM NaHCO3, 0.8 mM MgSO4, and 2.5 mM KH2PO4. This resulted in final 
concentrations of 149 mM sodium (Na+), 7.8 mM potassium (K+), 8.0 mM calcium (Ca2+), 1.8 
mM magnesium (Mg2+), 8.4 mM carbonate (HCO3-), 0.8 mM sulfate (SO42-), and 3.45 mM 
phosphate (HPO42-). The medium was prepared at 25°C and titrated to a pH of 7.4. In 
experiments examining the effect of serum, mDMEM  and control DMEM were supplemented 
with varying concentrations of fetal bovine serum (FBS; Invitrogen) and 1% 
penicillin/streptomycin (P/S; Invitrogen). As per previous protocols, mDMEM was changed 
every 12 hours to avoid precipitation in the culture solution and DMEM was changed every 3 
days. In subsequent mineralization experiments using cells, the mineralization medium (MM) 
used was mDMEM supplemented with 2% FBS. The control medium (DM) was DMEM 
supplemented with 10% FBS. 
Table C.1 – Ionic composition of biological fluids and media formulations.
Table B.1. Media Formulation Ion Concentrations (mM)
Na+ K+ Ca2+ Mg2+ HCO3- SO42- HPO42- pH
Blood 
Plasma


















Collagen-chitosan Gel Fabrication 
 Collagen-chitosan gel composites were formed through a β-GP induced mechanism as 
previously described [24]. Briefly, 4.0 mg/ml bovine Type I collagen (MP Biomedicals, Solon, 
OH) was dissolved in 0.02 N acetic acid (Sigma) and was mixed with 2.0 wt% chitosan (93% 
DDA; Biosyntech, Quebec, Canada) dissolved in 0.1 N acetic acid at a mass ratio of 50/50 
collagen/chitosan. Beta-glycerophosphate (β-GP) and glyoxal were added as physical and 
chemical cross-linkers, respectively, at concentrations of 7.0 wt% β-GP and 0.5 mM glyoxal. A 
400 µl aliquot of the pre-gelled mixture was injected into a well of a 24-well plate to create a 
disk-shaped construct with diameter of 1.5 cm. Gelation was then initiated by incubation of the 
mixture at 37°C for 30 min. Gels were washed three times in phosphate buffered saline (PBS; 
Invitrogen) for 10 min to remove excess β-GP prior to use.  
 
Calcium Quantification 
 Calcium deposition on acellular gels after 3 days incubation in either modified medium or 
DMEM containing 0, 2, 5, 10% FBS was quantified using an orthocresolphthalein complex-one 
(OCPC) method as previously described [27]. Briefly, collagen-chitosan gels were washed three 
times in PBS for 10 minutes and frozen at days 0, 1, and 3. Samples were then digested in 0.5 ml 
of 1.0 N acetic acid overnight. Ten microliters of the dissolved solution was then incubated at 10 
min at 25°C with 300 µl of a working solution consisting of 0.05 mg/ml of OCPC solution and 
ethanolamine/boric acid/8-hydroxyquinoline buffer (Sigma). Samples were read 
spectrophotometrically at 575 nm. Calcium values were quantified via a standard curve prepared 




Gel Morphology and Von Kossa staining 
 Acellular gel morphology was examined 3 days after incubation in mineralization medium 
(MM = mDMEM + 2% FBS) and in control medium (DM = DMEM + 10% FBS). Gels were 
washed three times in PBS for 10 min each and then transferred to a 12-well plate for imaging 
using a standard CCD camera in manual mode with a constant exposure setting. 
 For von Kossa staining, acellular gels were washed three times in PBS for 10 min and then 
placed in zinc-buffered formalin (Anatech LTD, Battle Creek, MI) for 30 minutes, followed by 
immersion in 70% ethanol (Fisher Scientific, Pittsburgh, PA). Samples were cryosectioned into 
the top, middle (300 µm from the top face), and bottom face at the Histology Core Facility at the 
University of Michigan Dental School. Gels were stained with von Kossa reagent, embedded in 
paraffin and then mounted on slides. Images were taken at 4X magnification using an Olympus 
IX15 Microscope system (Olympus America, Center Valley, PA) and stitched together using 
Metamorph Premier software (Molecular Devices, Sunnyvale, CA). Images were quantified 
using ImageJ software (National Institute of Health, Bethesda, MD) using thresholding and color 
discrimination to define positive staining. The ratio of the stained to unstained area was used to 
determine the fraction of the sample that was positively stained in each sample.  
 
Gel Rheology 
 Acellular collagen-chitosan constructs incubated in MM or DM for 3 days were washed three 
times in PBS for 10 min each and then evaluated by gel rheometry using an AR-G2 rheometer 
(TA Instruments, New Castle, DE). Gels were loaded on to a Peltier stage preheated to 37°C. A 8 
mm steel parallel plate was used with a gap height of 1500 microns. A strain sweep was 
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performed over the course of 45 minutes with strain rates from 0.1 to 100% and a constant 
frequency of 1 radian/second. Reported values were taken over the linear range of the samples.  
 
Cell Culture and Assays 
 Prior to gel fabrication, human neonatal dermal fibroblasts (hFb; Lonza Inc., Walkersville, 
MD) were cultured in DMEM containing 10% FBS and 1% PS. For cell assays, hFb were used at 
passage 7-9 and placed directly into the solution of collagen and chitosan at a concentration of 
1.0 x 106 cells/ml prior to gelation, to allow for homogenous encapsulation within formed gels. 
Previous studies have shown that cells survive the encapsulation process [24, 26], and hFB were 
used in this study as a model cell type to isolate the effects of mineralization to the modified 





 Cell-seeded constructs in the MM condition were cultured for 1 day in DM, 3 days in MM, 
and then 7 days in DM for a recovery period. Samples were collected at days 0, 1, 2, 4, 5, 7, 11 
corresponding to initial conditions, 1 day in DM, 1 day in MM, 3 days in MM, 1 day recovery in 
DM, 3 days recovery in DM, and 7 days recovery in DM (Figure C.1). Gels were washed three 
times in PBS for 10 min when switching between culture medium. Cell-seeded gels cultured in 
DM only were used as controls and samples were collected at corresponding time points. 
 To evaluate toxicity of the MM media, cell viability was examined using a vital stain kit 
(Live/Dead®, Molecular Probes, Eugene, OR). Constructs were washed three times in sterile 
PBS and incubated at 37°C for 45 min in a solution containing 4.0 µm calcein-AM and 4.0 µm 
Figure C.1 – Experimental protocol showing timing of control cultures in standard DMEM (DM)
and mineralizing cultures in modified DMEM (MM). All cell-seeded hydrogels were cultured in
DM for 1 day. Mineralizing constructs were then incubated in MM for 3 days, followed by a 7
day recovery period in DM. Control constructs were incubated in DM for 11 days. Arrows on
time scale indicate points at which constructs were sampled and analyzed.
0 1 542 7 11
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ethidium homodimer-1 in PBS. Gels were then washed again in PBS and imaged using a laser 
scanning confocal microscope (Olympus FluoView 500 Laser Scanning Confocal Microscope, 
Olympus). Image scans were captured at a horizontal plane 150 µm above the bottom surface of 
the gel and quantified using ImageJ software.  
 To quantify cell number during the mineralization period, DNA was extracted in 4.0 M 
guanidine hydrochloride solution and measured using a commercially available DNA assay 
(PicoGreen kit, Invitrogen). Calcium deposited on the constructs during the mineralization 
period was also measured using the OCPC assay described above.  
 
Statistical Analysis 
 One-way ANOVA testing with Tukey's post hoc analysis was used to analyze the effect of 
FBS concentration over time on calcium deposition in acellular hydrogels. Student's T-test was 
used to assess the significance of the fractional area of von Kossa staining, rheological data, cell 
viability, DNA content, and calcium deposition in cell-seeded hydrogels treated with 
mineralizing medium, compared to control medium. One-way ANOVA with Tukey's post hoc 
analysis was used to analyze the effect of medium type over time on DNA content in cellular 
hydrogels. Statistical significance was set at p < 0.05. Numerical values are presented as mean 
+/- standard error of the mean (SEM). N = 4 for each assay, and error bars on graphs represent 
the standard error of the mean. 
C.3 Results and Discussion 
Rationale for media formulations 
 This work demonstrated the ability to mineralize protein biomaterials and change their 
properties both in the presence and absence of embedded cells. Mineralization techniques 
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typically employ simulated body fluid (SBF), however, the lack of nutrients, vitamins, amino 
acids, and glucose prevent these media from being used for cell culture. DMEM is a commonly 
used medium for cell culture that can lead to the precipitation of mineral nodules on 
hydroxyapatite and tricalcium phosphate scaffolds in normal cell culture environments [28]. 
Therefore we used DMEM as a base medium and supplemented it with the specific salts to 
enhance the mineralization process. Table B.1 shows the ion concentrations of SBF, DMEM, and 
mDMEM, as well as blood plasma for reference. The mineralizing DMEM (mDMEM) used in 
this study was formulated to have specific ionic concentrations aimed at maximizing mineral 
deposition [28]. mDMEM contained concentrations of sodium (Na+), magnesium (Mg2+), and 
sulfate (SO42-) similar to conventional SBF. Calcium (Ca2+) and phosphate (PO43-) are the 
primary ions required for biomineralization, and were therefore added at concentrations 
approximately 4-fold higher than conventional SBF to promote rapid mineralization of 
substrates. The carbonate (HCO3-) level was maximized to serve as a pH buffer in the media to 
allow culture in a CO2 incubator, though this anion may be associated with decreased 
mineralization. Each of these solutions was adjusted to physiological pH to provide an 
appropriate environment for cell culture. 
 
Effect of serum on calcium deposition 
 Serum is a necessary supplement in cell culture medium because it contains growth factors 
that maintain cell viability and growth [28, 29]. However, in some systems serum proteins can 
detrimentally effect mineralization by delaying or inhibiting deposition [13, 30, 31]. To 
investigate the effect of serum on calcium deposition in collagen-chitosan materials,  acellular 
hydrogel constructs were exposed to mineralizing DMEM supplemented with 0, 2, 5, and 10% 
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FBS. Gels incubated in control DMEM with 0, 2, 5, 10% FBS served as controls. 
Figure C.2 shows that calcium deposition increased significantly (p<0.01) from day 0 in all 
samples incubated in mineralizing DMEM by day 1, and that mineralization continued to 
increase to day 3 in culture. In contrast, samples exposed to control DMEM showed no evidence 
of calcium deposition regardless of serum content or time point. In mDMEM samples, the 
presence of serum had no effect on the degree of calcium deposition at the day 1 time point, but 
by day 3 serum-supplemented samples showed decreased mineral deposition, relative to the 
sample with no serum (p<0.01). There was no significant difference between 2, 5 and 10% 
serum. These data show that FBS had an inhibitory effect on calcium deposition, but that 
Figure C.2 – Calcium deposition in collagen-chitosan gels through incubation in mineralizing
DMEM (mDMEM). Incubation in mineralizing media led to a significant increase in calcium
content compared to control media (DMEM) after 3 days of culture. (*) denotes p < 0.05 from the
groups containing FBS. Values are mean +/- standard error, n = 4.
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mineralization did occur in the presence of serum proteins. Because of the need for at least a low 
level of serum for cell maintenance, mineralization studies conducted with cells were performed 
using mDMEM supplemented with 2% FBS as the mineralization medium (MM). The control 
medium (DM) was standard DMEM supplemented with 10% FBS, which is widely used for cell 
culture.  
 
Mineralization of collagen-chitosan materials 
 Figure C.3 shows data on mineralization and mechanical properties of acellular collagen-
chitosan matrices incubated in MM and DM for three days. Histological evaluation of Von 
Kossa stained sections taken at the top, middle, and bottom of the constructs showed clear 
differences in degree of phosphate deposition between mineralizing and control conditions (Fig. 
C.3A). After three days in incubation, constructs in DM remained translucent, whereas those in 
MM were opaque, and dark staining for calcium was more prominent in MM samples (Fig. C.3A 
inset). Quantification of relative phosphate staining showed that hydrogels in MM exhibited 
significantly higher phosphate levels at the top and middle of the constructs, though staining in 
the bottom section was not statistically different compared to constructs in DM. These results 
support the finding that MM induces mineralization, but show that mineral deposition was not 
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evenly distributed through the material. 
 
 Figure C.3B shows the storage (G’) and loss (G’’) modulus from acellular collagen-chitosan 
gels exposed to DM or MM for three days. Relative to control gels, mineralized gels exhibited a 
Figure C.3 – Regional calcium deposition, representative histological sections, and rheological
characterization. Mineralization was distributed in the top and middle sections of constructs.
Storage modulus measurements indicated a significant increase in mechanical properties after
incubation in mDMEM. A) Quantification of calcium deposition in different regions of collagen-
chitosan constructs using histological staining for calcium (n=4 at each location). Inset shows
control and mineralized collagen-constructs (top row, scale bar = 1 mm) and representative
histology sections (bottom row, scale bar = 500 µm). B) Storage (G’) and loss (G”) moduli for
control and mineralized collagen-chitosan constructs after three days of culture (n=4, * denotes p

























3-fold increase in stiffness as reflected by the storage modulus (p<0.05). The loss modulus also 
increased significantly (p<0.001) in the MM condition, as compared to the DM condition. These 
data show that the mechanical properties of hydrogel constructs can be augmented by 
mineralization even over relatively short time periods. SBF treatment can affect the properties of 
scaffolds, though the effects can vary depending on the distribution of the mineral throughout the 
scaffolding material [8, 18]. Increasing the stiffness and toughness of protein hydrogel materials 
is desirable in order to allow implantation of constructs, particularly in load-bearing applications. 
A stiffer matrix may also attenuate the cell-mediated matrix remodeling that occurs in 3D protein 
hydrogels [32], and may direct the phenotype of progenitor cells toward an osteogenic phenotype 
[33]. 
 
Effect of mineralization on cell function 
 Viability data for hFb embedded in 3D collagen-chitosan materials are shown in Figure C.4 
and Figure C.5A. Green staining indicates the cytoplasm of living cells, whereas red-stained 
nuclei identify dead cells. The culture protocol is shown schematically by the arrows in Figure 
C.4. Control constructs were cultured in DM for 11 days, whereas mineralized constructs were 
cultured in DM for one day, followed by three days of incubation in MM, and then 7 days of 
culture recovery in DM. All samples were imaged and assayed for cell function at days 1, 2, 4, 5, 
7, and 11. After one day of culture in DM, cells began to spread through the collagen-chitosan 
matrix (Fig. C.4A, C.4B) and exhibited very high viability (>90%). Constructs subsequently 
exposed to MM showed significantly decreased viability (p<0.05) over the incubation period in 
MM (days 2 through 4, Fig. C.4D, C.4F), but viability was still high (~80%). The morphology of 
cells incubated in MM was more rounded than the control cells, which were highly stellate and 
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exhibited viability over 90% (Fig. C.4C, C.4E). Upon reintroduction into standard medium, cells 
in the mineralized constructs recovered a spread morphology (Fig. C.4H, C.4J, C.4L) and 




 The DNA content of hydrogel constructs was used as a measure of cell number and is shown 
in Figure C.5B. Cell number increased steadily and significantly (p<0.001) over time in the DM 
Figure C.4 – Live/Dead imaging of mineralized cell-seeded matrices. Cell viability remained
high in control media, while viability decreased through culture in mineralizing media. Confocal
micrographs of fibroblast-seeded collagen-chitosan gels cultured in control medium (A, C, E, G,
I, K) or under mineralizing conditions (B, D, F, H, J, L). Cells are stained so that the cytoplasm of
living cells is green and the nuclei of dead cells are red. Arrows at sides show culture protocol.





















condition, resulting in an approximately 5-fold increase by day 11. Constructs in the 
mineralization group showed an initial rise in DNA content, which subsequently dropped 
significantly upon incubation in MM from days 2 through 4 (p<0.0001). Similar to cell viability, 
cell number in mineralized constructs recovered after transfer to DM, although the DNA content 
did not recover to the same levels as controls. The cell viability and cell number data provide 
different but complementary information on cell “health” in the constructs. A lack of cell 
proliferation would lead to a decrease in overall cell number over time, though viability observed 
as a snapshot at any given time can still be high, as observed in MM at the day 1 and 2 time 
points. Cell death is suggested by the data at the day 4 and 5 time points, since both viability and 
cell number were decreased. In contrast, when cells are proliferating then cell number will 
increase and viability can also be high. This corresponds to the trends observed in DM. Taken 
together these data suggest that incubation in mineralizing medium significantly reduces, and 
perhaps completely inhibits, the proliferation of the embedded cells while cell viability is also 




Figure C.5 – Quantification of cell viability, DNA content, and calcium deposition in cell-seeded
mineralized constructs. Cell viability and DNA content both decreased while culturing cell-
seeded hydrogels in mineralizing media, but could be recovered after switching to control media.
Calcium content significantly increased in constructs cultured in mDMEM compared to control
media. A) Cell viability (n=4), B) DNA content (n=4), and C) calcium content (n=4) of collagen-
chitosan constructs cultured in control and mineralizing medium. (# denotes statistical
significance from day 0 controls; * denotes statistical significance from DM controls; ^ denotes
statistical significance from day 7).
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 Figure C.5C shows calcium deposition in cell-seeded constructs over the time course of the 
experiment. Upon transfer to MM at day 2, constructs in the mineralizing group showed a sharp 
and significant increase in calcium content and reached a level approximately 140-fold higher 
that controls after three days of incubation in MM (p<0.001). The calcium levels remained 
similarly high after transfer to recovery medium for the remainder of the experimental period. In 
contrast, constructs cultured in control medium (DM), showed very little calcium deposition, 
though a statistically significant increase over day 0 was observed at days 7 and 11 in DM 
(p<0.001). 
 Fibroblasts were used as a model cell type in this study in order to isolate the effects of the 
modified medium. Unlike bone marrow stromal cells and osteoblasts, fibroblasts are a non-
mineralizing cell type and therefore increases in mineral content of the matrices can be attributed 
purely to the effect of the medium, and not cellular action. Preliminary studies showed that hFb 
could survive three days incubation in MM, though longer culture periods lead to increased cell 
death (data not shown). In 3D collagen-chitosan hydrogels, cell viability and proliferation rate 
decreased over three days of incubation in MM, but the cell population remained over 75% 
viable. These effects can be attributed to the hypertonic nature of MM, which is required to 
induce mineralization but can also modify cell function. Importantly, both the viability and 
proliferative capacity of fibroblasts recovered when collagen-chitosan constructs were cultured 
in standard DMEM after mineralization. These results suggest that the medium and protocol 
employed were sufficient to mineralize 3D protein constructs in the presence of living 
fibroblasts, and it is likely that similar results would be observed with other cell types. 
 A number of further questions remain to be answered in future studies. The specific structure 
and type of mineral being deposited is of interest because it has relevance to creating biomimetic 
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materials. In addition, it is known that the presence of mineral, either as a substrate or in 
solution, can affect differentiation of progenitor and stem cells. The influence of material 
stiffness on cell phenotype is of great interest in the field of tissue engineering, and mineralized 
matrices may provide a tool to examine such effects. While the biochemical and mechanical 
effects of matrix mineralization can be difficult to decouple, the ability to mineralize 3D protein-
based materials may be another tool to study the effects of the tissue microenvironment on cell 
function. In addition, creating mineralized matrices in the presence of cells may be used to direct 
progenitor cell differentiation and/or to create more mechanically stable biomimetic constructs 
for orthopaedic and other applications. 
 
C.4 Conclusions 
 This study represents an initial step in the development of techniques to mineralize 3D 
protein constructs in the presence of living cells. A modified culture medium and protocol were 
developed to achieve mineralization of collagen-chitosan matrices at physiological pH and 
temperature. Typically used SBF formulations do not support cell viability and growth and 
therefore are limited in their utility in the presence of cells. The modified medium used in this 
study contained a similar panel of mineralizing ions similar to SBF, though at modified 
concentrations, and also contained the nutrients and buffers needed to sustain cell function. It 
was shown that three day incubation of 3D collagen-chitosan materials resulted in mineral 
deposition and stiffening of the gels. Cell viability was reduced and cell number decreased 
during incubation in mineralizing medium, however a viable cell population was maintained and 
it was shown that viability and proliferation recovered after rescue in standard medium. These 
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results suggest that in vitro mineralization in defined media can be used to modulate the 
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Noninvasive, Quantitative, Spatiotemporal Characterization of 
Mineralization in 3D Collagen Hydrogels Using High Resolution 
Spectral Ultrasound Imaging 
D.1 Introduction 
Comprehensive and objective characterization of engineered tissues is a challenge in the 
development of new products that apply the tissue engineering approach of combining 
biomaterials, cells, and growth factors to generate living tissues [1]. Such engineered tissues are 
typically assessed using biochemical and histological assays that provide information about cell 
function and tissue development, but many of these assays require complex and destructive 
sample processing. In addition, relatively few assays provide true 3D spatial resolution of 
biochemical events and physical properties in developing tissues, and most are not suitable for 
longitudinal monitoring of the same constructs over time because of their invasive and often 
destructive nature. Nondestructive imaging and tissue characterization techniques are therefore 
highly attractive both for tissue engineering research and for translation of well-defined products 
to the clinic. Such techniques can help speed the development of tissue engineered technologies, 
reduce the cost of production, and improve the level of quality assurance. 
 Ultrasound imaging has shown promise for rapid and nondestructive imaging in tissue 
engineering. In particular, conventional ultrasound has been used to characterize the evolution of 
tissue components and corresponding changes in tissue properties in a variety of systems, as 
253 
 
summarized in Table D.1. For example, attenuation of gray scale (B-mode) ultrasound signals 
over time has been shown to correlate with matrix deposition and differentiation of adipose stem 
cells on synthetic scaffolds [2]. Similarly, gray scale signals have been used to assess collagen 
production by myofibroblasts in 3D fibrin matrices over time [3], as well as proliferation of bone 
marrow stromal cells in β-tricalcium phosphate scaffolds [4]. Acoustic parameters have also 
been correlated to the mechanical properties and cartilage matrix evolution by chondrocytes in 
polyethylene glycol hydrogels [5] and have been used characterize the mechanical properties of 
agarose hydrogels as they develop over time [6].  
 
 Conventional B-mode ultrasound imaging is based purely on gray scale values and is able 
to provide spatial and temporal information about sample morphology. However it provides little 
direct information about sample composition. A key drawback of purely gray scale analysis is 
that the image signal is dependent on a variety of factors including ultrasound transducer 
Table D.1 – Summary of reported studies using ultrasound to characterize engineered tissue
constructs.
 Construct used Type of study Parameter measured or estimated 
Ultrasound 
parameter used 
Fite et al 
(ref. [2]) 
PLGA scaffold with 
adipose stem cells 
Tissue 
development 





intensity (in dB) 
Kreitz et al 
(ref. [3]) 




over 35 days 
Hydroxyproline content 
(collagen) Mean grayscale 
Oe et al 
(ref. [4]) 
Bone marrow stromal 
cell/β-tricalcium 
phosphate scaffold 
Fresh gels Number of cells Amplitude 
Rice et al 
(ref. [5]) 








Speed of sound, 
slope of 
attenuation 
Lizzi et al 
(ref. [6]) Agarose hydrogel Fresh gels 
Mechanical properties 
(Young’s modulus) Speed of sound 
Ghudur et al 
(this study) 
Collagen hydrogel doped 
with HA mineral or 
mineralized using SBF 
Fresh gels; tissue 
development 
over 21 days 







response and image post-processing. The results are therefore operator- and system-dependent, 
and it is difficult to compare data taken on different imaging systems or at different times in an 
objective and meaningful fashion. 
In contrast, spectral ultrasound imaging (SUSI) utilizes unprocessed, raw backscattered 
radiofrequency (RF) signals. In this approach, the power spectra of the RF signals from a region 
of interest are computed and calibrated to remove system input and output effects. Because the 
resulting spectra are often quasi-linear over the bandwidth used in typical ultrasound imaging, 
linear regression can be performed to obtain a relatively small set of parameters from the 
calibrated spectra. These parameters include the slope and intercept of the regression line, as well 
as the midband fit (MBF), which is the value of the linear function at the midpoint of the usable 
bandwidth. This analysis produces instrument-independent parameters that can greatly facilitate 
comparison of data between studies and time points, and which permit tissue characterization in 
an absolute and standardized manner [7]. It has been shown theoretically that these spectral 
parameters are related to tissue microstructural properties [8]. In particular, the slope provides 
information on the effective size of acoustic scatterers, and the MBF provides information on the 
concentration, size, and relative acoustic impedances of scattering particles in the sample. These 
parameters have also proven to be effective for identifying changes in tissue state for prostate, 
breast and other cancer tissues [9-12] as well as intravascular plaque [13,14]. In a similar 
manner, spectral analysis may therefore have utility in more fully characterizing the composition 
of engineered tissues. 
In the present study, high resolution spectral ultrasound imaging was applied to a model 
engineered construct that mimics a mineralized tissue. We evaluated the ability of SUSI to 
determine the distribution of mineral in a 3D collagen gel that was loaded with hydroxyapatite 
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particles, to discriminate between different grades of hydroxyapatite, and to quantify particle 
distribution in the protein hydrogels. We also induced exogenous mineralization of pure collagen 
gels to assess the ability of SUSI to monitor changes in the constructs over time, and correlated 
spectral parameters with the concentration of mineral in the constructs. Our goal was to evaluate 
the utility of spectral ultrasound techniques for non-invasively imaging and characterizing 
mineral-containing protein materials, which may be relevant to orthopaedic and other tissue 
engineering applications. 
 
D.2 Materials and Methods 
3D Collagen Hydrogel Fabrication 
 3D collagen hydrogels were generated as previously described [15]. Briefly, collagen 
type I (MP Biomedicals, Solon OH) was dissolved at 4.0 mg/ml in cold 0.02 N acetic acid 
overnight. Constructs were created by mixing 10% fetal bovine serum (FBS; Invitrogen, 
Carlsbad CA), 10% Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen), 20% 5X-
concentrated DMEM, 10% 0.1 N NaOH (Sigma Aldrich, St. Louis MO) and 50% collagen stock 
solution at 4°C for a final collagen concentration of 2.0 mg/ml. The mixture (500 µl) was then 
injected into a 24 well plate and allowed to gel at 37°C for 45 min.  
 
Addition of Hydroxyapatite to 3D Hydrogels 
 Composite collagen-hydroxyapatite (HA) hydrogels were fabricated by adding particulate 
HA directly to the gel mixture. Three types of hydroxyapatite were used, each with a different 
average particle size: reagent-grade (HA-R; Sigma) with a particle size of 590 µm, micro-grade 
(HA-M; Plasma Biotal Ltd., North Derbyshire, UK) with a particle size of 5 µm, and nano-grade 
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(HA-N; Sigma), with a particle size of <200 nm. A stock HA solution of 200 mg/ml HA in 
DMEM was prepared and autoclaved at 120°C for 20 minutes maintain to achieve sterility. 
Collagen-HA hydrogels were fabricated at 10.0 mg/ml by mixing cold 5% HA stock solution, 
5% DMEM, 10% FBS, 20% 5X concentrated DMEM, 10% 0.1 N NaOH, and 50% collagen 
stock, and then initiating gelation by raising the temperature to 37°C. Constructs with higher and 
lower concentrations of HA (5.0 mg/mL and 20.0 mg/mL) were prepared by correspondingly 
changing the amount of HA stock solution used. 
 For dispersion studies, HA stock solution and DMEM (10% of final gel) were mixed at 4 
°C and placed in a sonication water bath (Branson Ultrasonics, Danbury, CT) for 1 h to disrupt 
particle aggregates. The HA-DMEM mixture was then added immediately to the collagen pre-gel 
mixture and gelation was initiated as previously described. 
 
Mineralization in Simulated Body Fluid 
 Simulated body fluid (SBF) was prepared as previously described [16]. The standard 
(1X) mineralizing solution has final ion concentrations of 141 mM NaCl, 4.0 mM KCl, 2.5 mM 
CaCl2H2O, 1.0 mM MgCl2, 4.2 mM NaHCO3, 0.5 mM MgSO4, and 1.0 mM KH2PO4 (Sigma). 
For this study, SBF solutions of higher-fold concentrations (2.5X and 5X) were prepared by 
increasing the concentrations of each reagent by the appropriate factor. Collagen hydrogels were 
fabricated as described above and were incubated at 37°C in 3.0 ml of either phosphate buffered 
saline (PBS), 2.5X SBF, or 5X SBF. The medium was replenished with fresh stock twice a day. 
Samples were imaged at days 3, 7, 10, 14, and 21. 
 




 Figure D.1 shows a schematic diagram of the imaging setup that included a 90 mm 
diameter Petri dish filled with PBS at room temperature. Collagen constructs were placed on top 
of an agar gel pad, which reduced signal reflection from the bottom of the dish. Ultrasound 
imaging was performed with a Vevo 770 instrument (VisualSonics Inc., Toronto, Canada) using 
an RMV 708 imaging probe with a nominal 55 MHz center frequency, 20-75 MHz bandwidth 
(−6 dB), 4.5 mm focal distance, and 1.5 mm depth of focus (−6 dB). 3D backscattered RF data 
from the tissue construct were collected at either 100% or 10% scanner power and 420 MS/s by 
performing multiple B-mode scans using an automatic 3D translational controller. The interval 
between adjacent A-lines and B-mode scans were 31 μm and 64 μm, respectively. After each RF 
acquisition of a construct, a reference RF acquisition of the setup without the construct was 
collected. This approach allowed the acquisition of operator-independent data and provided 
objective measures of each parameter. 
 
Ultrasound Data Analysis 
 1) Grayscale (GS): Each A-line signal acquired as 3D RF data was Hilbert transformed to 
obtain the complex analytic signal p(y,z). The conventional B-scan image is generally 




constructed using the logarithmic amplitude envelope of this signal, log10|p(y,z)|. For quantitative 
analysis, the GS parameter (in mV) used in this study was the absolute value of the complex 
analytic signal, while the logarithm of the absolute value was used to create GS images: 
 ( )10( , ) ( , ) log ( , )GS y z p y z or p y z=  (1) 
The time of travel of the ultrasound pulse to the construct’s top surface ( )topt , bottom surface 
( )bottomt and to the agar gel pad ( )constructpadt was determined based on grayscale thresholding using 
an automated algorithm. The time of travel to the agar gel pad without the construct ( )refpadt  was 
also determined as the reference. Using the known sound speed in the surrounding fluid medium
( )fC , the thickness of the construct was determined as:  
                                    ( ) ( )
ref construct
f bottom top pad padThickness C t t t t = − + −   (2)                                          
 2) Spectral parameters and parametric images: The power spectrum of each RF A-scan 
signal was calculated by taking the Fast Fourier Transform (FFT) of the data gated by a series of 
sliding Hamming windows of 0.2 μs, each offset by 0.1 μs. To remove artifacts associated with 
the transfer function of the ultrasound system, a calibrated power spectrum was generated by 
dividing the tissue power spectrum by the calibration spectrum, which was the power spectrum 
of the RF signal from the reflection of the imaging pulse from the interface of deionized water 
and phenylated silicone oil (Dow Corning 710, Midland MI) [17]. The calibrated power 
spectrum was processed by linear regression to find the spectral parameters, i.e. the slope and the 
MBF of the −15 dB bandwidth. 
To better represent the spatial distribution of spectral features of the construct on the GS 
B-mode images, we constructed parametric images by marking each pixel with a color that 
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corresponded to the values of the spectral parameter. The density of each of the analysis 








where X is either GS or spectral parameters evaluated for a selected volume (V) of the tissue 
construct. Ultrasound backscattering from pure collagen constructs (without mineral) was very 
low and its mean GS value within a 0.1 μs time window was very close to that of liquid medium 
alone, as expected. A threshold GS value based on pure collagen constructs was used to assist in 
identifying regions of the constructs that lacked mineral. 
 
Calcium Quantification 
 The amount of calcium deposited in collagen hydrogels after incubation in PBS, 2.5X 
SBF, and 5X SBF was quantified at days 3, 7, 10, 14, and 21 using an orthocresolphthalein 
complex-one (OCPC) method [18]. Calcium content correlates to mineral deposition. Collagen 
gels were washed in PBS and digested in 0.5 ml of 1.0 N acetic acid overnight. 10.0 µl of the 
dissolved solution was then incubated for 10 minutes at room temperature with 300 µl of a 
working solution consisting of 0.05 mg/ml of OCPC solution and ethanolamine/boric acid/8-
hydroxyquinoline buffer (Sigma). Samples were read spectrophotometrically at 575 nm. Calcium 
values were quantified by comparison to a standard curve prepared over a range of 0 – 100 
µg/ml. Samples were diluted 100-fold or as necessary to obtain readings within the linear portion 







 Four separate constructs were used for each biochemical and imaging assay. Aggregated 
SUSI data were collected from a 0.5 mm x 5.0 mm x thickness (~2 mm) volume of each 
construct and the data are presented as mean ± standard deviation. Statistical comparisons 
between parameters were made using Student’s t-test for paired samples and the differences were 




 The setup used in this study allowed rapid and noninvasive 3D imaging of collagen 
constructs while still in incubating culture medium. Image acquisition was completed in a few 
seconds at a frame rate of 45 Hz, and saving of the raw RF data required 2-3 minutes. In the 
present study, construct boundaries were determined manually based on GS thresholding, though 
this process could be automated and accelerated in the future. Overall, analysis of each construct 




Figure D.2 shows a representative example of ultrasound imaging and analysis output 
from a collagen hydrogel containing HA-N mineral (Fig D.2A-D.2F), as well as a “control” 
construct of pure collagen (Fig D.2G-D.2L). The photographs of the construct (Fig. D.2A, D.2G) 
show a top view (xy-plane) and the region that was imaged is indicated by the dotted rectangle. 
The 3D volume-rendered ultrasound images (Fig. D.2B, D.2H) show the overall dimension and 
morphology of the construct. This digital reconstruction can be rotated and/or sectioned to 
provide any desired viewing prospective. Figure D.2C is an image in the xy-plane at a defined 
depth (known as a C-scan) of the 3D of the HA-N construct, and shows homogeneous speckles 
Figure D.2 – Virtual histology of 3D collagen constructs. Panels A-F show a collagen construct
with added HA-N mineral, and panels G-L show corresponding images of a pure collagen control
construct. (A, G) Color images of the top view of constructs. (B, H) 3D ultrasound rendered
image of the section represented by white dotted box in A and G. (C, I) Ultrasound C-scans a
transverse xy-plane. (D, J) Grayscale (GS), (E, K) mid-band fit (MBF) and (F, L) slope images of
one section in the xz-plane.
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indicative of uniform spatial distribution of mineral in the construct. Similarly, a GS image in an 
xz-plane of the HA-N construct (Fig. D.2D) shows a mainly homogeneous distribution of 
mineral in the lateral (x) and depth (z) directions, as well as evidence of mineral settling at the 
bottom of the construct. The corresponding MBF image of the calibrated RF power spectrum 
(Fig. D.2E), which is related to scatterer radius and concentration in the construct, shows an 
increasing concentration of scatterer toward the bottom of the HA-N construct. In contrast, the 
slope parameter (Fig. C.2F), which varies inversely with scatterer radius, is relatively 
homogeneous in the bulk of the HA-N construct but decreases near the bottom of the construct, 
indicating settling of larger particles or cluster formation by the mineral. The corresponding 
rendered and RF spectrum images for the control construct (Fig D.2H-D.2L) show very little 
signal, demonstrating that SUSI can discriminate between mineral-containing and pure collagen 
materials. 
 
Imaging and Analysis of Hydroxyapatite Content, Characteristics, and Spatial Distribution   
 To further demonstrate the ability of spectral ultrasound to determine mineral distribution 
and particle size in engineered tissues, three different types of HA mineral were added to 
collagen hydrogels at a concentration of 10.0 mg/ml. In addition, duplicate sets of each gel type 
were fabricated in which the HA was first sonicated to improve dispersion in the constructs. 
Figure D.3 shows images of constructs made with each type of HA under both unsonicated 
(upper panels in each group) and sonicated (lower panels) conditions. The 3D rendered images in 
the first column of images in Figure D.3 clearly show the morphology of each construct. The 
second and third columns include the sectional GS images with the MBF and slope values 
mapped over the right half of the images, to show specific information on each construct type. In 
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unsonicated HA-R samples, significant settling of the mineral component was suggested by the 
very high GS signal near the bottom of the constructs. In addition, the MBF signal was mostly 
absent in the bulk of HA-R constructs except toward the lower bottom of the construct, since the 
settled mineral was not included in the MBF analysis because it produced a saturated signal. 
Sonication clearly improved dispersion of the HA-R mineral. Settling was also observable 
though less pronounced in the HA-M samples, and to a lesser extent in HA-N samples. The slope 
values showed the expected size difference between HA-R and HA-M (lower slope values 
correspond to larger particles), though the difference between HA-M and HA-N was not 
detected, possibly due to the resolution of the imaging system at this frequency. The effect of 
sonication on HA-M and HA-N was also less marked, though dispersion was improved by 




Figure D.3 – Parametric images of collagen-HA constructs made with three different HA grades:
reagent (R), micro (M), and nano (N). Constructs were made either without sonication (top row of
panels in each set) or with sonication (bottom row of panels in each set). First Column: 3D
rendered image of the construct. Second Column: images of GS (left half of image) and MBF
(right half of image) in a representative cross-section. Third Column: images of GS (left half of




 To more systematically quantify the effects of HA type and sonication on mineral 
dispersion in collagen constructs, a 3D volume of 0.5 mm ×  5.0 mm ×  thickness (~2 mm) was 
analyzed for each treatment. This provided assessment of data from a larger volume of the 
constructs (as opposed to a single section, as in Fig. D.3). The GS, MBF and slope parameters 
are plotted as histograms in Figure D.4 and the means and standard deviations of the histogram 
data are shown in Table D.2. The first column of histograms in Figure D.4 shows a comparison 
of the HA types using the unsonicated samples, and subsequent columns compare the 
unsonicated to the sonicated sample for each HA type. Since all constructs contained the same 
mass of HA mineral, the higher area under the curve and the higher mean of the GS and MBF 
data are indicative of more homogeneous distribution of the mineral in the construct, since 
settled HA was not included in the analysis. The lower mean of the slope for HA-R reflects the 
larger particle size, though the difference between HA-M and HA-N was not clearly 
discriminated. Sonication improved the distribution of HA-R significantly and the histogram data 
Table D.2 – Mean and standard deviation of ultrasound parameters correspondence of HA
mineral.
Process Parameter  
HA mineral type 
R (µ ± σ) M (µ ± σ) N (µ ± σ) 
Unsonicated 
GS (dB) 1.24 ± 0.33 1.45 ± 0.32 1.59 ± 0.39 
MBF (dB) -72.2 ± 6.1 -69.8 ± 4.2 -67.4 ± 5.5 
Slope (dB/MHz) 0.20 ± 0.18  0.33 ± 0.16  0.37 ± 0.17  
Sonicated 
GS (dB) 1.68 ± 0.38 1.61 ± 0.37 1.73 ± 0.36 
MBF (dB) -66.0 ± 5.1 -67.1 ± 5.6 -65.0 ± 4.9 




suggested better dispersion of HA-M and HA-N as well. The parametric data in Table D.2 also 
reflect and quantify the observations made from the histogram data. 
 
 As a further validation of the ability of spectral ultrasound to characterize mineral in 3D 
collagen gels, a set of constructs with increasing HA concentration (5.0, 10.0 and 20.0 mg/ml) 
were created. HA-N was used with sonication since these constructs showed the most uniform 
HA distribution in previous studies. Figure D.5 shows 3D renderings as well as GS, MBF and 
slope data for these constructs. The intensity of both the GS and MBF signals reflect the 
increasing HA content, while the slope values remain essentially unchanged. These data reflect 
Figure D.4 – Histogram distributions of spectral parameters for unsonicated (U) and sonicated
(S) collagen-HA constructs made with reagent (R), micro (M), or nano (N) grade HA. Top row
shows gray scale values, middle row shows MBF values, and bottom row shows slope values.
First column compares parameters between unsonicated samples. Subsequent columns compare
unsonicated and sonicated constructs made with each HA type.
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that while the amount of HA in the constructs increased, the size of the HA particles remained 
the same. Figure D.6 shows correlations between the density of the GS, MBF, and slope 
parameters and the amount of HA added to the constructs. These data show a strong linear 
correlation between HA content and both the GS and MBF parameters. In contrast, the slope 
parameter was minimally affected by the concentration of HA, as would be expected when the 
particle size remains constant. The linear regression has a slight negative slope (-0.4°), possibly 
due to aggregation of mineral particles at higher concentration. 
 
Figure D.5 – Ultrasound imaging of collagen-HA constructs made with three different
concentrations of HA-N with sonication. First column shows 3D rendered images, second column
shows GS and superimposed MBF, third column shows GS and superimposed slope. Rows show




Imaging and Analysis of Mineral Deposition over Time 
 As an alternative to incorporating a mineral phase at the time of construct fabrication, we 
also promoted progressive mineral deposition over time by incubating constructs in simulated 
body fluid (SBF). Pure collagen constructs incubated in either PBS (control), 2.5X SBF, or 5X 
SBF for a period of 21 days were imaged at different days and the resulting spectral ultrasound 
data at day 21 are shown in Figure D.7. Constructs incubated in PBS showed low signal levels, 
Figure D.6 – Correlation of sonicated HA-N mineral density with GS density, MBF density and
Slope density. Nearly flat correlation for slope density is a correspondence of very close mineral
sizes. (n=4 for each sample type; error bars represent standard deviation).
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indicative of minimal mineral deposition. Constructs incubated in 2.5X SBF showed some 
mineralization on the surface, although the interior of the material was largely free of mineral. In 
contrast, the 5X SBF constructs showed robust mineralization and a marked compaction to form 
a dense and mineral-rich material. The MBF values show the spatial location and the amount of 
mineral in the constructs, whereas the decreased values of the slope parameter in the 5X 
constructs suggest that the mineral phase in these constructs was composed of larger particles. 
 
 Figure D.8 shows a temporal analysis of mineral deposition, using the 5X SBF constructs 
as an example because they demonstrated the most robust mineralization. The 3D renderings, GS 
images and MBF images show the pattern of mineral deposition, which clearly was initiated at 
the construct surface as early as day 3, and then extended progressively into the interior of the 
construct. Ultrasound imaging also shows the morphology of the construct as a whole, and in 
particular the marked compaction in the z-direction that occurred between day 7 and day 10. The 
slope decreased over time, indicating increased particle size, as would be expected for a mineral 
deposition process. 
Figure D.7 – Collagen constructs exposed to mineralizing solution imaged at day 21 of
incubation. First column shows 3D rendered images, second column shows GS and superimposed




 Thresholding on ultrasound images was used to automatically determine construct 
thickness using Eqn. (2), by averaging the values in a 5.0 mm × 0.5 mm section. This method 
takes into account changes in construct shape, and therefore can provide an accurate measure of 
the relevant dimensions at any specific location and time. Figure D.9 shows that constructs in 
PBS compacted 17.4 ± 6.2 % (n = 4, p<0.05) over the first week but recovered over time at days 
14 and 21. Constructs in 2.5X SBF did not compact significantly (1.8±2.8 % at day 7 with p = 
0.35) over 21 days of incubation and had similar thickness as the constructs in PBS at day 21. 
Constructs in 5X SBF compacted markedly to less than a third of their original thickness (1.75 ± 
Figure D.8 – Collagen constructs mineralized in 5X SBF and imaged over time. First column
shows 3D rendered images, second column shows GS and superimposed MBF, third column
shows GS and superimposed slope. Rows show the time point of imaging.
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0.06 mm, n = 4 with p<0.001) after day 7, and their dimensions remained relatively constant for 
the remainder of the incubation period. 
 
 The density of the MBF signal over a 0.5 mm x 5.0 mm x thickness volume of each 
construct determined using Eqn. (3) was compared with the extent of mineral deposition as 
measured by calcium content using the OCPC assay. Figure D.10 shows both MBF density and 
calcium density in constructs over time. Overall, the MBF density matched the measured 
calcium concentration very closely in all constructs (R2>0.95 in all cases). In PBS, there was 
essentially no exogenous mineral deposition and the calcium concentration remained below 2 
µg/mL. In 2.5X SBF the calcium content remained low and statistically unchanged over the first 
14 days of incubation, but then climbed to ~35 µg/mL by day 21, with a corresponding increase 
in MBF density. The 5X SBF constructs were robustly mineralized and the calcium content 
increased linearly over the incubation period to a final value above 6000 µg/mL at day 21. 
Figure D.9 – Plot of thickness over time of constructs incubated in PBS, 2.5X SBF, or 5X SBF.





Spectral ultrasound imaging rapidly generated objective and quantitative information 
about the morphology and composition of 3D collagen constructs. Importantly, the imaging 
method was noninvasive and could be performed while constructs remained bathed in incubating 
medium. Since the assay was non-destructive, the same samples could be imaged over time to 
monitor their development. In addition, 3D imaging allowed sub-volume analysis and 
comparison of different regions of the imaged constructs through simple processing of the digital 
data. The use of high frequency ultrasound imaging (≈50 MHz) provided a spatial resolution of 
approximately 25 µm, which is suitable for characterization of engineered tissue constructs. High 
frequency imaging resulted in a lower penetration depth than other modalities, but still allowed 
characterization of the 2 mm thick engineered constructs used in this study. We imaged volumes 
on the order of 0.5 cm3, but larger volumes can easily be imaged by increasing the lateral scan 
dimension. Importantly, the wide bandwidth available at higher frequencies is beneficial for 
spectral analysis because it provides richer information about the composition of the constructs, 
relative to conventional gray scale imaging. Taken together, these features make ultrasound 
Figure D.10 – Calcium density and calculated MBF density over time in constructs incubated in
PBS, 2.5X SBF, and 5X SBF. (n=4 for each sample type; error bars represent standard deviation).
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imaging very attractive for biomaterials and tissue engineering research, and potentially for 
quality assurance purposes as engineered tissues approach the market.  
  In this study, we focused on mineral-containing materials because of our interest in 
developing mineralized orthopaedic tissues [19, 20]. Analysis of 3D collagen gels supplemented 
with different types of hydroxyapatite showed that spectral ultrasound can characterize the 
concentration, degree of dispersion, and spatial location of the mineral phase in 3D. In particular, 
3D ultrasound imaging showed clearly the ability of sonication to enhance dispersion of the 
larger HA-R particles as well as the much smaller HA-M and HA-N particles. Mineral 
distribution was best analyzed using the GS and MBF parameters, since both depend primarily 
on the concentration of scatterers in the sample. The settling and dispersion effects could be 
assessed by color-coding the parametric images, and could be further quantitatively characterized 
using histogram analysis. In addition, the relative concentration of samples supplemented with 
different levels of HA were characterized using ultrasound imaging results, which correlated 
well with the initial loading level. Achieving good dispersion of hydroxyapatite particles 
throughout scaffolds and hydrogels is a well-studied problem in developing biomimetic matrices 
[21], and assessment of dispersion has been a challenge. Our results show that ultrasound 
imaging has the ability to both qualitatively and quantitatively characterize dispersion in 3D 
samples, and can be used to compare treatments designed to enhance dispersion. 
 In the analysis of HA distribution, the GS and MBF data provided similar information. 
However a key distinction between these parameters is that MBF is independent of both the 
imaging system used and the scanning power of the ultrasound probe, whereas the GS data is 
dependent on these factors. Therefore MBF data generated by different users on different 
systems is comparable, whereas GS data is not. In addition, SUSI uses raw spectral data and no 
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manual thresholding is required. These features are important advantages of the method, since 
the ability to generate objective operator- and instrument-independent data makes the method 
more broadly applicable and appropriate for inter-study comparisons.  
 The slope parameter is reflective of particle size. In this study, the slope parameter was 
able to differentiate between HA-R particles (590 µm diameter) and the smaller HA-M (5 µm) 
and HA-N (<200 nm) particles. However the smaller particle sizes could not be differentiated 
from each other because of the resolution of the probe used (approximately 25 µm). While the 
MBF parameter varied with added HA content as the concentration increased, the slope 
parameter remained relatively constant, as would be expected from adding more particles of the 
same size. The slope parameter is extracted from the raw RF spectrum and therefore is also 
instrument-independent. 
Simulated body fluid (SBF) was used as way to exogenously mineralize 3D collagen 
matrices, to observe and characterize the evolution of a mineral phase in constructs over time. 
SBF treatment has been developed and validated as a method to deposit a bone-like apatite 
mineral coating throughout scaffolds and hydrogels [22, 23]. Ultrasound imaging revealed the 
pattern, degree and temporal progression of mineral deposition. There was a clear dose-
dependent effect of SBF concentration on mineral development, which was initiated at the 
surface of the constructs. In the most concentrated SBF solution (5X), the formation of a mineral 
“shell” around the construct was followed by a dramatic compaction of the material after a week 
of incubation. Both the mineralization and the compaction processes were tracked over time 
using ultrasound imaging, which are not possible using current histological techniques. The 
spectral parameters were used to quantify the degree of mineral deposition and these results 
correlated well with corresponding data from a destructive calcium quantification assay. The 
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reason for the marked volume change in highly mineralized constructs is not clear, but may have 
been due to changes in osmotic pressures caused by the mineral shell or the weight of the 
mineral deposits. Mineralization by SBF is a crystallization process that proceeds exponentially 
as new surface area and nucleation sites for crystal growth are provided. The much higher 
mineral content in the 5X SBF constructs was therefore expected based on the higher ion content 
in the mineralizing solution and the corresponding exponentially greater mineral deposition. 
We have validated SUSI as a method to characterize a developing mineral phase in 
protein-based hydrogels. This technique therefore can be used to complement existing tissue 
imaging and characterization methods, and may provide additional information that cannot be 
obtained using current techniques. Microcomputed tomography (microCT) has been used widely 
in orthopaedic tissue engineering [24, 25], but is most suited to highly mineralized samples with 
strong radiographic contrast. Ultrasound is more applicable to soft tissues, and as we have shown 
it can distinguish mineral phases in such tissues. SUSI offers relatively rapid image acquisition 
(seconds to minutes for cm sized samples) whereas microCT imaging typically takes much 
longer. In addition, SUSI can be performed with a small and easily transported probe whereas 
microCT requires inserting the sample into a larger scanner. 
 The SUSI technique has other possible extensions and applications in addition to those 
addressed in this study. More detailed analysis of spectral data from multi-component samples 
may allow discrimination between material phases, e.g. between different protein types in 
hydrogels and/or between different types of mineral components. In addition, SUSI may be 
extended to in vivo characterization of mineralization. Spectral analysis already is performed 
clinically to assess intravascular plaque formation [26], and is being developed for virtual 
histological examination of cancerous tissue. Such extensions will be part of future work in the 
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Noninvasive Quantification of In Vitro Osteoblastic Differentiation in 
3D Engineered Tissue Constructs using Spectral Ultrasound Imaging 
E.1 Introduction 
 Bone tissue engineering approaches combine cells, biomaterials, and growth factors to 
recreate native bone tissue [1]. Traditionally, biochemical and histological assays are performed 
to monitor cell function and development in these engineered tissues. However, these techniques 
require sample processing and are destructive in nature, and therefore do not allow for an 
individual sample to be tracked as it develops. For example, traditional methods for 
characterizing cell number include manual counting chambers, automated cell counters, 
spectrophotometers, and flow cytometers [2-4]. These methods require a variety of sample 
processing steps including disruption of the tissue construct into constituents for counting 
(destructive in nature) and sample dilution. In addition, they may require specialized equipment 
and reagents that can be expensive. Importantly, most currently used measurement techniques 
describe only single timepoint, aggregate characteristics of the sample, and do not provide three 
dimensional (3D) spatial and temporal information. 
 Non-destructive approaches based on confocal microscopic imaging to count cell nuclei 
have been used to provide 3D assessment of cell numbers [5]. However, such techniques require 
high quality microscopy images, are time consuming, and involve complex processing 
algorithms to acquire entire spatially registered 3D images of the construct. Magnetic resonance 
imaging (MRI) and micro-computed tomography (µCT) techniques have been used to estimate 
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bone mineral densities [6, 7]. However, these methods require the use of calibration phantoms 
and involve long data acquisition times [8]. Long exposures to X-ray may affect cell-seeded 
constructs in terms of the structure, viability, and cellular development of the constructs. 
Conventional MRI imaging systems do not provide the ability to study the microstructural details 
of 3D engineered tissue constructs due to their low resolution. Therefore there is a need for non-
destructive imaging and characterization modalities, capable of providing both spatial and 
temporal information of engineered tissues as they develop in vitro. Such methods would greatly 
facilitate the translation of tissue engineering products from the lab to the clinic. 
 Ultrasound imaging is a widely used non-invasive and non-destructive method that has 
the potential for quantitative evaluation of tissue development both in vitro and in vivo.  It has 
been reported recently that ultrasound can be used to quantify cell number in BMSC/β-TCP 
composites using a grayscale equivalent parameter [9]. Fite et al. used an ultrasound method to 
monitor the chondrogenic differentiation of equine adipose stem cells in 3D poly(lactide-co-
glycolide) scaffolds [10] by correlating signal attenuation measured through gray scale image 
analysis to extracellular matrix (ECM) deposition, which was considered to be a marker of cell 
differentiation. Kreitz et al. tracked collagen deposition by myofibroblasts in fibrin tissue 
constructs over an 18 day culture period [11]. Their quantitative analysis correlated observed 
gray scale values to ECM deposition as measured by hydroxyproline content. Ultrasound has 
also been used as a tool to measure the mechanical properties of agarose hydrogels as they 
develop over time [12], by correlating material properties such as elastic modulus with obtained 
acoustic properties. 
 Ultrasound propagation and acoustic scattering in a tissue volume depend on tissue 
microstructure, composition, and physical properties such as density and compressibility. 
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Therefore, backscattered ultrasound signals may be used to extract information about the 
structure and composition of the tissue under investigation, as well as its mechanical and 
physical properties. Although tissue properties such as speed of sound, acoustic attenuation and 
the tissue volume can be calculated directly from the backscattered radiofrequency (RF) data, 
tissue microstructural details are not apparent from the raw RF signals. Tunis et al. [13] studied 
the envelope statistics of ultrasound backscatter signals from cisplatin-treated aggregated acute 
myeloid leukemia (AML) cells and evaluated the applicability of various statistical distribution 
functions to model the envelope histograms. They reported that shape parameters of the 
generalized gamma distribution function were sensitive to structural changes within cells 
induced by the drug. 
 Quantitative ultrasound imaging methods using spectral analysis of the RF signals have 
been developed to extract additional parameters for enhanced tissue characterization. The power 
spectrum of the backscattered RF data includes information about tissue microstructure, and the 
spectral regression parameters can be related to scatterer properties such as effective sizes, 
concentrations and acoustic impedances [14, 15]. Spectral slope has been shown to depend on 
the scatterer size, whereas mid-band fit (MBF) relates to the size, concentration and relative 
acoustic impedances of the scattering elements [14]. Spectral analysis has been used in various 
applications, including characterization of plaque composition by intravascular ultrasound 
(IVUS) [16, 17], lesions induced by high intensity focused ultrasound (HIFU) [18, 19] and RF 
ablation [20]. Spectral parameters have also shown the ability to identify changes in tissue state 
for prostate, breast, pancreas, lymph node, and other cancer types [21-27]. Oelze et al. [22] 
developed methods to differentiate and characterize rat mammary fibroadenomas and 4T1 mouse 
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carcinomas by estimating scatterer properties from backscatter RF signals in the spectral domain 
with a Gaussian form factor model [28].  
 The use of high frequency (20 – 60 MHz) ultrasound imaging has provided higher spatial 
resolution than conventional ultrasound imaging (5 – 15 MHz) in diagnostic radiology [23]. 
Kolios et al. have developed spectral analysis technique to characterize the properties of cell 
aggregates that were used as simplified models of tumors [23, 29], to detect cellular changes 
with high spatial resolution and sensitivity after exposure to chemotherapy drug treatments [30]. 
They found that ultrasound backscatter intensity and spectral slope increased due to treatment, 
which was interpreted as a consequence of the decrease in effective scatterer size of cell 
aggregates. The use of higher ultrasound frequency imaging, with corresponding ultrasound 
wavelengths in the order of 100 μm, permits sensing of changes in cell nuclei and cell structure.  
In order to achieve non-invasive and quantitative assessment of engineered tissue constructs with 
high spatial resolution, we have implemented a high frequency spectral ultrasound imaging 
(SUSI) technique, and have validated its use to characterize the composition and structure 
engineered tissue constructs. In previous work, we used the spectral MBF and slope parameters 
to measure the quantity and spatial distribution of particulate hydroxyapatite in acellular collagen 
hydrogels [31]. We observed a strong correlation between MBF and mineral concentration, and 
between the spectral slope and particle size. The amount of mineral deposited from simulated 
body fluid on acellular collagen constructs over a period of 3 weeks was also studied using 
spectral parameters, and showed strong correlation with MBF.  
 The work presented here extends our previous study using high resolution SUSI to 
quantitatively characterize the osteogenic differentiation of MC3T3 mouse pre-osteoblast cells 
seeded within 3D collagen-based engineered tissues. MC3T3 cells are a well characterized 
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mineralizing cell type that can be induced towards the osteogenic lineage with the addition of a 
defined set of supplements in the culture medium [32]. Collagen is a widely used biomaterial in 
orthopaedic tissue engineering due to its ability to support cell attachment and proliferation, as 
well as to serve as an osteoconductive and osteoinductive matrix [33]. In this study we non-
destructively quantified the bulk properties of the hydrogels, including speed of sound, acoustic 
attenuation and volume compaction, and tracked these parameters over time. Microstructural 
properties of the cell-seeded constructs, including cell size, cell number, and cell differentiation, 
were also assessed using spectral ultrasound and were compared to data generated by traditional 
biochemical assays and confocal fluorescence imaging. This study demonstrates that SUSI can 
be used to non-destructively characterize cell-seeded engineered tissue constructs longitudinally 
over time with high spatial resolution. 
 
E.2 Materials and Methods 
Cell Culture 
Mouse pre-osteoblast MC3T3-E1 (generously provided by Dr. R.T. Franchesci, 
University of Michigan) were cultured in α-MEM without ascorbic acid (Life Technologies, 
Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Life Technologies) and 1% 
penicillin and streptomycin (PS: Life Technologies) and used at passage 8. Media was changed 
every other day. 
 
Collagen Hydrogel Synthesis 
 Three-dimensional (3D) collagen hydrogels were created as previously described [31]. 
Briefly, collagen type I (MP Biomedicals, Solon, OH) was prepared at 4.0 mg/ml in 0.02 N 
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acetic acid. Collagen hydrogels (2.0 mg/ml final concentration) were formed by mixing 10% 
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies), 10% FBS, 20% 5X-
concentrated DMEM (stock concentration), 10% 0.1 N NaOH (Sigma Aldrich, St. Louis, MO), 
and 50% collagen stock solution.  500 μL of the mixture was then pipetted into a 24-well plate 
and allowed to gel for 30 mins at 37°C. Cells were encapsulated within the hydrogels at the time 
of gelation at a concentration of 1.0 x 106 cells/ml.   
After gelation, hydrogels were moved into a 6-well culture plate containing α-MEM 
supplemented with 10% FBS and 1% PS to allow cells to compact their matrices. After 24 hours, 
the media was changed with either a control media or osteogenic media containing 10 mM beta-
glycero phosphate (β-GP; Sigma) and 50 μg/ml ascorbic acid 2-phosphate (Sigma).  
 
Cell Viability 
 Cell viability was visualized and quantified as previously described [34]. At days 1 and 
21, cell-seeded hydrogels were washed 3X in phosphate buffered saline (PBS; Life 
Technologies) for 5 mins and then incubated in 4 μM calcein-AM (EMD Millipore, Billerica, 
MA) and 4 μM ethidium homodimer-1 (Sigma) in PBS for 45 mins. Constructs were washed 3X 
in PBS prior to imaging on a Nikon A1 Confocal Microscope (Nikon Instruments, Melville, 




 At days 1 and 21, cells were stained for their actin cytoskeleton and nuclei. Hydrogels 
were washed 2X in PBS for 5 mins/wash and then fixed in zinc-buffered formalin (Z-Fix; Battle 
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Creek, MI) for 10 mins at 4°C. Gels were washed another 2X in PBS and then permeabilized 
using 0.5% Triton-X 100 (Sigma) in PBS for 20 mins at room temperature. Constructs were 
washed again 2X, and then incubated in a solution containing 165 nM AlexaFluor 488 phalloidin 
(Life Technologies) and 10 nM fluorescent DAPI (Life Technologies) in 1% bovine serum 
albumin (BSA; Sigma) in PBS for 45 mins. Hydrogels were washed again prior to imaging.  
 
Biochemical Assays 
 Cellular DNA content and calcium were quantified as previously described [35]. For 
DNA quantification, hydrogels were collected and degraded overnight in 10 mM Tris-HCl 
(Sigma) containing 0.6 mg/mL collagenase type I (MP Biomedicals), 0.2% IGEPAL (Sigma), 
and 2 mM phenylmethanesulfonylfluoride (Sigma). DNA was then measured using the 
PicoGreen DNA assay (Life Technologies). Calcium secretion was assayed by first dissolving 
the constructs in 1 N acetic acid (Sigma) overnight. The cell-hydrogel lysate was then assayed 
using the ortho-cresolphthalein (OCPC) method [31]. 
 
Phantom Studies 
 Agar phantoms embedded with Polybead® microspheres (Polysciences, Inc., Warrington, 
PA) of different diameters at various concentrations were used to validate the size and 
concentration estimation from SUSI. Polybeads were added to the 2% agar solution at 450 C and 
thoroughly mixed to disperse them uniformly throughout the phantom. Four polybead diameters 
of interest were chosen: 6, 10, 16 and 25 µm. For each polybead size, phantoms with four 
different concentrations of polybeads were made. Each phantom was approximately 2000 mm3 




Ultrasound Imaging and Backscattered Signal Acquisition 
 
 Figure 1 shows a schematic diagram of the ultrasound imaging setup. A gel slab with 8% 
agarose (Sigma) was placed at the bottom of a 60 mm Petri dish to reduce ultrasound reflection 
from the bottom of the dish. The dish was then filled with α-MEM at room temperature and the 
constructs were placed on top of the agarose gel pad. Ultrasound imaging was performed using a 
Vevo 770 (VisualSonics Inc., Toronto, Canada) and an RMV 708 imaging probe with a nominal 
55 MHz center frequency, 20 - 75 MHz bandwidth (−6 dB), 4.5 mm focal distance, and 1.5 mm 
depth of focus (− 6 dB). Ultrasound B-mode imaging was performed with the ultrasound beam 
focus placed 0.5 mm below the top surface of each sample. The interval between adjacent A-
lines in the B-scans was set at 31 μm. 3D imaging of the construct was performed by acquiring a 
series of B-scans with 200 μm interval between adjacent scans across the tissue construct using a 
computer-controlled automatic translational stage. The 3D image data were used to estimate the 
volume of the construct. The backscattered radiofrequency (RF) signals of all ultrasound images 
were acquired at a sampling rate of 420 million samples/s. For estimating the speed of sound and 
acoustic attenuation of the construct, backscattered RF data with ultrasound focus placed at the 















Ultrasound Imaging Analysis 
1) Construct Volume: A semi-automated segmentation procedure and edge detection 
algorithm from the Vevo 770 system were used to detect the contour of the construct in a B-
image. The volume of the construct was then calculated as the volume within the contours 
defined from each of B-mode images separated by 200 μm in 3D image data. 
2) Speed of Sound in Construct: A grayscale parameter [31] was computed from the RF 
data of a B-scan. The time of travel of the ultrasound pulse from the imaging transducer to the 
construct top surface ( )topt , bottom surface ( )bottomt , and the agar gel pad surface ( )constructpadt was 
determined based on grayscale thresholding using an automated algorithm. The time of travel to 
the agar gel pad without the construct ( )refpadt  was also determined and used as the reference. 
Assuming the speed of sound in the surrounding fluid medium ( )fC to be 1480 m/s, the thickness 
of the construct (L) was determined as 
 ( ) ( )0.5 ref constructf bottom top pad padL C t t t t = − + −  , (1) 










3) Attenuation: Frequency dependent attenuation in dB/cm was calculated as: 






α =  (3) 
where |A(f)| and |A0(f)| are the spectral magnitudes of the RF signal from the gel pad surface with 
and without (reference) the presence of construct respectively. The slope of α against f was 
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estimated by a linear fit between 20 - 55 MHz to yield the attenuation coefficient in the construct 
in dB/(cm-MHz). 
                                         
SUSI analysis 
 1) Scatterer Size: The calibrated power spectrum of the RF signals for each A-line was 
obtained using linear regression to find the spectral parameters, i.e., the slope (m’) and the mid-
band fit (MBF’) within a − 9 dB bandwidth [31]. The spectral parameters were corrected for the 
attenuation (α, dB/(cm-MHz)) of the tissue construct as m=m’+2αz and MBF=MBF’+2αzfc 
where z is the ultrasound propagation distance in the tissue construct. Ultrasonic spectral 
parameters have been related to the system factors and the physical properties of effective 
acoustic scatterers in tissue [14]. As described previously [14], spectral slope represents a 
parameter associated with scatterer radius (a), its geometry (n) and the center frequency of the 
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2) Acoustic Concentration: The spectral MBF depends on an additional parameter, the 
acoustic concentration (CQ2), 
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where C is the number concentration of the acoustic scatterers (/mm3), Q is the relative acoustic 
impedance, and E is a shape-dependent parameter. Eq. (6) can be rearranged to obtain C as 












= . (7) 
The relative acoustic impedance, Q, of MC3T3 cells was estimated from a known number 
concentration, C, of cells in constructs.   
 3) Deposited calcium by cells: Differentiation of MC3T3 cells was assessed by detecting 
and quantifying the mass of the calcium deposited [36]. The mass of calcium at day 21 was 
calculated by comparing the relative acoustic impedance of the scatterers at day 0 to day 21. The 
relative acoustic impedance is defined as  






= , (8) 
where ρ and ρi are the mass densities of the ECM and scatterers on the ith day, c and ci are the 
speed of sound in the ECM and scatterers on ith day respectively. On day 21, the presence of 
deposited calcium around the cells will increase relative acoustic impedance of the scatterer. 
With known relative acoustic impedance of the scatterer on day 0 (cell alone without calcium) 
and day i (cell and calcium), the mass of secreted calcium can be calculated as (derivation in 
Appendix) 
  ( ) ( )0 0
0
1 1cal ii i i
i









where Ni is the total number of cells on day i and Vi is the volume of the net scatterer on day i 
and is approximately 4
3
𝜋𝑎𝑖3. 
 4) SUSI Parametric Images: The spatial distribution of scatterer features (scatter size and 
calcium concentration) within a construct was represented as parametric images where each pixel 
within a B-mode image was marked with a color that corresponded to the values of the scatterer 
size or calcium concentration. 
 
Statistical Analysis 
 Analysis of the scatterer size and concentration was carried out in an element volume 
with dimensions of 0.6 mm x 5.0 mm x thickness (~1 mm) throughout the construct. Results are 
presented as mean ± standard deviation. Statistical comparisons between any two parameters 
were performed using Student’s t-test for paired samples and the differences were considered 
significant at a level of p < 0.05. 
 
E.3 Results 
Validation of SUSI Estimation of Scatterer Size and Concentration 
Verification of SUSI technique was performed using agarose phantoms embedded with 
polystyrene microspheres of known size and concentration. As shown in Supplemental Table 
SE.1, experiments were performed on phantoms with 4 different concentrations of Polybead® 
polystyrene microsphere (Polysciences Inc.) of different sizes (6, 10, 16 and 25 µm diameter). 
The SUSI method was able to detect the scatterer (polystyrene spheres) size and concentration in 
these phantoms, validating the SUSI estimation protocol. Additional validation of SUSI for 
estimation of cell size was performed using MC3T3-seeded engineered tissue constructs on day 
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0 with four known concentrations of cells (Supplemental Figure SE.1). Constructs with a known 
concentration of cells (2x106 cells/ml) were used to estimate the relative acoustic impedance of 
the MC3T3 cells via SUSI analysis, providing a value of approximately 0.6. SUSI was also used 
to estimate cell size, and the estimated cell diameter was approximately 14 µm (n = 9, range = 
≈13.5-15.5 µm). The estimated diameter decreased slightly with increasing cell concentration 
(Figure S1E), possibly due to increased compaction of the constructs at higher cell concentration. 
The estimated relative acoustic impedance was then used to estimate the cell concentration of 
other constructs with prepared at different cell concentration (0.5, 1 and 5x106 cells/ml) at day 0. 
These data are shown in Figures SE.1E, F, and show a good linear fit between the estimated 
concentration and the true concentration (R2 = 0.92). These data confirmed the ability of SUSI to 
detect particle size and concentration in hydrogel constructs. 
 
Virtual Histology for Longitudinal Monitoring of Tissue Constructs 
 Imaging using the Vevo 770 system at 55 MHz achieved rapid and non-invasive 3D 
ultrasound imaging of MC3T3-seeded collagen constructs. During ultrasound imaging, the 
constructs in α–MEM media were removed from the incubator for less than 20 minutes. Figure 2 
shows an example of non-destructive longitudinal monitoring of the progression and 
development of cell seeded collagen constructs incubated in control and osteogenic media. The 
3D rendered ultrasound images at different time-points (day 1, 7, 14 and 21) clearly show a 
reduction in the volume of the constructs over time (“gel compaction”) in both control and 
osteogenic media. Constructs adopted a symmetrical concave shape from day 1, which is a 
typical result of cell-mediated gel compaction. In addition, constructs in osteogenic medium 
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became more echogenic than those in control medium, indicating changes occurring during 
development in osteogenic medium. 
 
 Cell viability in the constructs with and without ultrasound imaging was compared to 
assess possible effects of ultrasound imaging. As shown in Figure 3, viability was greater than 
90% at day 1 in all of the samples and greater than 70% in all samples at day 21. There were no 
statistical differences between the samples with and without ultrasound imaging at either time 




















A B C D
Figure E.2 – Longitudinal monitoring of MC3T3 cells seeded in collagen constructs. 3D rendered
ultrasound backscattered images of the constructs in (A) control and (B) osteogenic media on day
1, 7, 14 and 21 of the development process. Brightfield images of corresponding constructs are





Measurement of Construct Volume, Speed of Sound, and Acoustic Attenuation 
 As shown in Figure 4, a significant decrease in construct volume to about 25-30% of the 
original volume occurred between days 1 and 7, and the construct volume then stabilized 
between days 7 and 21. No statistically significant differences in construct volumes were 














Figure E.3 – Comparison of cell viability at day 1 and 21 of MC3T3 cells seeded in collagen
constructs. Constructs in (A) were not imaged using ultrasound, while those in (B) were imaged
using ultrasound. Bar plot in (C) shows quantification of cell viability calculated from the
images. Scale bar = 200 µm.
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increase and then plateau in the speed of sound over development time for constructs in both 
control and osteogenic media. The acoustic attenuation parameter increased almost linearly over 
development time in culture, with no significant differences between constructs in control and 
osteogenic media. Since the acoustic attenuation is typically an indicator of increased acoustic 
impedance and/or scatterer concentration, this increase may indicate cell proliferation and/or 
mineral deposition. These results of construct volume, speed of sound, and acoustic attenuation 
were used in further analysis of the constructs including estimation of spectral parameters and 




SUSI analysis of Size of Cells or Scatterers in Constructs  
Figure 5A-D shows the seeded MC3T3 cells in the collagen hydrogels with the F-actin 
filaments stained in green and cell nuclei stained in blue. From these images, diameters of the 




Figure E.4 – Backscatter analysis of MC3T3-seeded constructs in control and osteogenic media
over time in culture. Quantification of (A) construct volume, (B) speed of sound, and (C)
attenuation at each time-point.
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1 and 7.6 ± 1.9 µm (n = 4) on day 21; these values are not statistically different. The effective 
size of the cells over the three week period was also estimated using the slope parameter 
obtained from SUSI analysis (Figure 5E). The average diameter for the cells, was approximately 
14 µm with a range from about 12-15 µm, and remained essentially unchanged during the three 
week culture period for constructs in both control and osteogenic media. The significantly higher 
estimate value for scatterer diameter from SUSI compared to nucleus diameter measurement 
from DAPI stain suggest that the entire cell may have involved in the scattering of ultrasound, 




Acoustic Concentration and Calcium Deposition in Constructs 
 The total amount of DNA in a construct was measured biochemically and converted to 
the total number of cells by determining the average amount of DNA per cell on a construct at 
day 0, when the number of cells was known (0.5x106 cells/construct). As shown in Figure 6A, 
the number of cells decreased by about 60% from day 1 to day 7 in constructs in both the control 
and osteogenic groups, indicating probable cell death or migration out of the constructs. 













Figure E.5 – Developmental changes in sizes of MC3T3 cells seeded in collagen constructs. (A)-
(D) Fluorescence staining of MC3T3 cells embedded in collagen constructs in control and
osteogenic media on day 1 and day 21 (actin cytoskeleton is stained green, nuclei are stained blue).
(E) Estimated diameter of cells from SUSI analysis over time in culture. Scale bar = 50 µm.
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differences between or within media groups. These cell numbers correlated well with the 
equivalent number of acoustic scatterers, which is the acoustic concentration (CQ2) estimated by 
SUSI analysis multiplied by the construct volume, with the exception of the day 21 measurement 
in the osteogenic group (Figure 6B). The acoustic concentration from SUSI depends on both the 
relative acoustic impedance of the scatterers (Q) and the actual number of scatterers (C). Thus 
assuming the actual number of scatterers or cells remained constant, the increased equivalent 
number of acoustic scatterers (or increased acoustic concentration) can be attributed to an 
increase of the relative acoustic impedance of the scatterers during the last days of incubation of 
the constructs (Figure 6C). The significantly increased acoustic impedance on day 21 may 
therefore be indicative of changes due to the differentiation process in the constructs. Since 
acoustic impedance depends on the mass density and the speed of sound in scatterers, the 
increased acoustic impedance may reflect an increase in mass density due to calcium deposition 
associated with cell differentiation. As calcium is much denser than water, its presence is 




As a quantitative marker to identify the extent of osteogenic differentiation of seeded 
MC3T3 cells [36], we estimated the calcium content using both standard biochemical assays 




Figure E.6 – Quantified development of MC3T3 cells seeded in collagen constructs (A) Total
number of cells as assessed by DNA quantification of MC3T3-seeded collagen constructs in
control and osteogenic media over time in culture. (B) Equivalent number of acoustic scatterers as
estimated from SUSI analysis. (C) Relative acoustic impedance estimated from (A) and (B).
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± 11.4 µg/ml (n = 9) and was comparable with the measured values of 38.7 ± 16.7 µg/ml (n = 
10) from the OCPC method. No statistically significant difference in calcium deposition at day 
21 was detected in constructs subjected to ultrasound imaging and those without ultrasound 
imaging performed (Figure 7B).  
 
Spatiotemporal Evolution of Constructs by Parametric Ultrasound Imaging 
 The estimated microstructural properties (acoustic scatterer size and secreted calcium 
concentration) from SUSI analysis were used to generate parametric, color coded images 
overlaid on B-mode images, allowing visual assessment of the spatiotemporal evolution of 
constructs during development. As an example, Figure 8 shows the estimated microstructural 
parameters in a representative region of interest for constructs in control and osteogenic groups 
throughout the 21 day culture period. Scatterer diameter was uniform within the construct, and 
did not vary significantly during the development process for constructs in either control or 
osteogenic medium (Figure 8A). The estimated calcium concentration was relatively constant at 
low values at all time-points to day 14, but exhibited a significantly higher value in the 
A B
Figure E.7 – Amount of calcium mineral secreted by MC3T3-seeded collagen constructs in
control and osteogenic media. (A) Calcium content as determined by OCPC assay and SUSI
estimation. (B) Comparison of calcium content between constructs cultured in control and
osteogenic media with and without exposure to ultrasound imaging.
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constructs in osteogentic medium on day 21. The increase in calcium content is indicative of 
osteogenic differentiation of MC3T3 cells in the constructs. 
 
E.4 Discussion 
In this study, we demonstrated that high resolution ultrasound imaging provided non-destructive 
monitoring of MC3T3-seeded collagen constructs over 3 weeks. Physical parameters including 
the volume of each individual construct, speed of sound and acoustic attenuation in the 
constructs were obtained from simple analysis of the ultrasound RF signals. Notably, SUSI 
analysis provided estimation and assessment of key microstructural characteristics of the 
constructs, beyond what can be generated by conventional ultrasound images. These parameters 
included cell size, acoustic scatterer concentration, cell number, and mineral deposition. Since 
system-dependent factors are removed from SUSI analysis by calibration, the parameters 
provided are objective and instrument-independent. Therefore such data have broad utility and 
are particularly useful for inter-study comparisons. These features make ultrasound imaging and 
particularly SUSI a very attractive tool for biomaterials and tissue engineering research, and as a 
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Figure E.8 – Overlaid B-mode (grayscale) and color maps of SUSI parameters. (A) Cell diameter,




tool in quality assurance as engineered tissues approach the market. Below we discuss 
implications of our results and limitation of this study. 
When embedded in 3D collagen hydrogels, many cell types including fibroblasts, smooth 
muscle cells, cardiomyocytes and osteoblasts, will remodel the collagen by exerting contractile 
forces that can align and compact the matrix [37].  These forces are significantly higher than the 
forces required for cell locomotion and it has been proposed that this force generation is targeted 
at matrix remodeling, rather than cell migration [38, 39]. This morphogenic phenomenon has 
been studied widely, and the mechanisms are still not fully understood. Assessment of tissue 
construct morphology in 3D in a non-invasive method is important to study these changes, and to 
quantitatively characterize the degree of remodeling. In this study, we showed that high 
resolution 3D ultrasound imaging could be used to noninvasively track morphological changes in 
tissue constructs longitudinally, revealing the significant compaction of unconstrained MC3T3-
seeded constructs from day 1 to day 7. 
We showed that ultrasound imaging provides non-destructive monitoring without 
affecting the structure or function of the constructs. Cell diameter as determined by SUSI was in 
the range of 12.5-15.5 µm, which matched the size determined by parallel fluorescent confocal 
imaging. SUSI analysis also revealed that the total number of acoustic scatterers in unconstrained 
MC3T3-seeded collagen constructs decreased by approximately 80% over the 21 day culture 
period in control medium. This result was in agreement with destructive biochemical DNA 
measurement performed in parallel. The decrease in cell number may have been a result of cell 
death or migration from the construct, possibly as a result of the decrease in construct volume 
that resulted from gel compaction. A similar pattern in cell number was observed in a previous 
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study of unconstrained constructs seeded with undifferentiated mesenchymal stem cells (MSC) 
[40].  
The acoustic concentration is defined as CQ2, where C is the number concentration of the 
scatterers and Q the acoustic impedance of the scatterers. The parameter Q depends on the 
physical and acoustic properties of the scatterer, particularly the mass density and speed of 
sound. Therefore assessment of the total number of acoustic scatterers (CQ2 multiplied by 
construct volume) can provide information regarding changes in the construct microstructure. 
MC3T3 cells secrete mineral into the surrounding matrix as they undergo osteogenic 
differentiation [36]. They thereby modify the properties of the acoustic scatterers in the construct 
by increasing their mass density and thus the relative acoustic impedance. Therefore, relative 
acoustic impedance can be used as an indicator of changes in cellular state during osteogenic 
differentiation. In the current study, we qualitatively characterized the differentiation process by 
monitoring changes in the relative acoustic impedance, and also generated quantitative values of 
the mass of calcium deposited based on the relative acoustic impedance values. These data 
matched well with parallel measurement from conventional destructive biochemical tests for 
calcium content. We therefore have demonstrated that ultrasound imaging can be used to 
estimate the mass of calcium mineral in 3D collagen constructs as MC3T3 cells differentiate in 
osteogenic medium.  
The current study highlights the advantages of high frequency ultrasound imaging for 
monitoring of tissue construct development. The use of a high frequency in our study provided 
high spatial resolution, which allowed detailed characterization of the constructs in vitro. 
However, most in vivo and eventual clinical applications will require the use of lower frequency 
imaging (e.g. 10 MHz) to allow deeper tissue penetration, which will reduce the resolution of the 
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images. Another limitation of our current method is that our estimation of the relative acoustic 
impedance in this study required knowledge of the number of cells, which may not be readily 
available non-destructively. Relative changes to the acoustic concentration, a composite 
parameter that is obtained directly from SUSI analysis, can be used to noninvasively assess 
relative changes in the constructs. However, at this stage we are not able to use this parameter to 
generative an absolute quantitative estimation of calcium deposition without knowledge of the 
cell number. We assumed that cells and the calcium they deposited were a single scatterer, 
however future work will examine the ability to resolve different cell types and matrix 
components using SUSI. 
 
E.5 Supplemental Information, Figures and Tables 
The relative acoustic impedance (Q) of the scatterers in the construct on day i is  






=  (A1) 
where ρi and ρ are the densities of the scatterer and extracellular matrix (ECM), ci and c are the 
speed of sound in the scatterer and ECM respectively. Rewriting the expression for density of the 
net scatterer,  




ρρ = +  (A2) 
The density of the net scatterer can also be calculated from its total mass and volume. On any 
specific developmental time-point of the construct, the net scatterer is considered to be a cell 
along with any secreted calcium mineral. Thus, the total mass of the net scatterer on day i is the 
sum of the masses of a cell on day 0 and secreted mineral on day i.  
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ρρ +=  (A3) 
After rearranging the expression for mass of the mineral secreted by each cell, the total mass of 
calcium on day i can be obtained.  
  ( )0 0cal cali i i i i iM N m N V Vρ ρ= = −  (A4) 
  ( ) ( )0 0
0
1 1cal ii i i
i
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 (A5) 
where Ni is the total number of cells on day i and Vi is the volume of the net scatterer on day i 






Concentration (x104 beads/mm3) 
6 µm 10 µm 16 µm 25 µm 
True Est True Est True Est True Est True Est 
6 6.4 ± 0.2 7.1 6.2±0.2 1.4 1.1±0.2 0.6 0.4±0.1 0.22 0.13±0.04 
10 10.1 ± 0.6 9.7 9.4±0.4 2.7 2.5±0.4 0.8 0.7±0.2 0.40 0.36±0.08 
16 13.4± 1.1 15.4 16.6±0.8 3.9 4.4±0.8 1.5 1.6±0.3 0.52 0.56±0.11 
25 24.7 ± 0.2 21.9 23.1±1.4 5.0 5.5±1.1 2.3 2.5±0.5 0.62 0.71±0.15 
 
Supplemental Table E.1 – Tabular values of estimated Polybead® polystyrene microsphere
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Supplemental Figure E.1 – Experiment for estimation of relative acoustic impedance of MC3T3
cells on day 0 and validation of estimated cell concentration from SUSI analysis. (A)-(D)
Ultrasound B-mode (grayscale) images of MC3T3-seeded collagen constructs on Day 0 at 0.5, 1, 2
and 5 x106 cells/ml cell concentrations, respectively. (E) Cell diameter, and (F) cell concentration
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